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Obesity and obesity-related diseases have become major health concerns in 
industrialized countries.1 Excessive caloric intake and, at the same time, a more 
sedentary life style are the main factors contributing to the current obesity epidemic. 
This combination has been referred to as a patho-environment, stressing a cause of 
this pathology outside the patient. The problem is, however, much more complex, 
and involves an interplay between genetic, epigenetic, psychological, pedagogical, 
socio-economical and nutritional factors. Since a large variation in body weight exists 
within populations despite exposure to the same nutrient availability and to the same 
lifestyle factors, it is of great relevance to understand intrinsic factors contributing to 
the development of obesity. Moreover, broad advertisements ‘to eat less and exercise 
more’ did not prevent the dramatic increase in prevalence of obesity and there is an 
urgent need for new strategies for treatment and prevention. Consequently, it is pivotal 
to understand mechanisms involved in maintenance of energy balance and to define 
possible mechanisms contributing to the current increase in prevalence of obesity. 
The endocannabinoid system (ECS), recently defined as an important modulator of 
energy homeostasis, constitutes an interesting research field and a promising target for 
pharmaceutical intervention.2
The Endocannabinoid system
The endocannabinoid system is a signalling system with multiple functions. It is a 
phylogenetically old system found in most species, indicating an essential role in vital 
functions.3,4 The name “endocannabinoid” system is derived from “cannabis”. Among 
others, cannabinoid receptors have binding affinity for Δ9-tetrahydrocannabinol (THC), 
the major psychoactive component of cannabis.5-7 
 Medicinal properties of cannabis are known since ancient history but only recently, 
in 1988, receptors for cannabis were identified and in the early nineties endogenous 
ligands for these cannabinoid (CB) receptors were characterized.7-10 Since then, major 
progress has been made in understanding the role of the endocannabinoid system as 
an important modulator of energy homeostasis (Table 1).11,12





both G-protein coupled receptors.5,6,13 CB
1
-receptors are the most abundant G-protein 




outside the CNS among others in liver and fat tissue.14 CB
2
-receptors are primarily found 
in cells of the immune system.2,15 Several endogenous ligands for these cannabinoid 
receptors have been identified with arachidonoylethanolamide (anandamide) and 
2-arachydonoylglycerol (2-AG) being the most extensively investigated ones.12
Table 1. History of identifying components of the endocannabinoid system.
 Key findings First author
B.C. Therapeutic use of cannabis in Eastern medicine
19th century Introduction to Western Medicine reviewed by Abel 1975
1964 Identification of THC as major psychoactive 
component of cannabis
Gaoni and Mechoulam
1988 Identification of cannabinoid receptors Devane
1990 Cloning of cannabinoid receptors Matsuda
1992-1995 Isolation of endocannabinoids Devane, Mechoulam, Sugiura
1994 development of rimonabant Rinaldi-Carmona
1996 cloning of FAAH Cravatt
2002 recognizing the role of MAGL in the  
hydrolysis of 2-AG
Dinh
2003-2004 cloning of enzymes responsible for synthesis  
of anandamide and 2-AG 
Bisogno, Okamoto
 The endocannabinoids anandamide and 2-AG are eicosanoids, a class of lipids 
derived from arachidonic acid. The synthetic pathway of anandamide involves two 
major steps (Figure 1); 1) synthesis of N-arachidonyl-phosphatidylethanolamine 
(NAPE) from arachidonic acid and phosphatidylethanolamine catalyzed by the enzyme 
N-acyltransferase and 2) synthesis of anandamide and phosphatidic acid from NAPE via 
activity of N-arachidonyl-phosphatidylethanolamine phospholipase (NAPE-PLD). There 
are two pathways suggested for synthesis of 2-AG (Figure 1). In both pathways 2-AG is 
derived from phosphatidylinositol. These pathways either involve diacylglycerol lipase 
(DAGL) or phospholipase C.4
 In line with the fact that endocannabinoids are lipids, which makes intermediate 
storage in vesicles impossible, endocannabinoids are synthesized on demand. Synthesis 
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Figure 1. Schematic representation of the endocannabinoid system (ECS): The ECS comprises 
cannabinoid (CB) receptors, endogenous ligands for these receptors called endocannabinoids 
and enzymes responsible for synthesis and degradation of endocannabinoids. CB receptors 
can bind THC, the psychoactive component of cannabis. There are at least two different CB 
receptors, the CB
1
 and the CB
2
-receptor. Anandamide (AEA) and arachidonoylglycerol (2-
AG) are endocannabinoids. Both are derived from arachidonic acid (AA). N-arachidonyl-
phosphatidylethanolamine phospholipase (NAPE-PLD) and N-acyltransferase, and diacyl-
glycerol lipase (DAG-lipase) and phospholipase C are enzymes important in synthesis of 
respectively anandamide and 2-AG. Fatty acid amide hydrolase (FAAH) and monoacylglycerol 
lipase (MAG-lipase) are enzymes important in degradation of respectively anandamide and 
2-AG. Rimonabant is a synthetic inverse agonist-antagonist of the CB
1
-receptor.
 Endocannabinoids are thought to act either autocrine or paracrine. Because of 
their lipid characteristics they can move across the membrane of the producing cell 
and signal via CB receptors on the same cell. To reach CB receptors on (more distant) 





 Since endocannabinoids act as intercellular messengers, the magnitude of effect 
of endocannabinoids is not only determined by binding affinity for CB receptors and 
rate of synthesis and release, but also by rate of removal from the extracellular space 
and rate of intracellular degradation.11 Clearance of anandamide and 2-AG from the 
extracellular space is thought to be mediated by protein transporters.7,11 Intracellularly, 
fatty acid amide hydrolase (FAAH) is responsible for the degradation of anandamide, 
whereas monoacylglycerol lipase is involved in the degradation of 2-AG.11,16
 Thus, endocannabinoids are produced following an increase in intracellular Ca2+ or 
cAMP levels, and are inactivated when paracrine or autocrine cannabinoid activation is 
to be terminated via active transport mechanisms and intracellular degradation.12
 Activation of cannabinoid receptors is coupled to several intracellular signalling 
pathways including 1) inhibition of adenylate cyclase; 2) stimulation of mitogen-
activated protein kinases (MAPK); 3) inhibition of voltage-activated Ca2+ channels; 
4) stimulation of inwardly rectifying K+ channels. It depends on the agonist which 
transduction pathway is activated.17
Functions of the endocannabinoid system
Endocannabinoid signalling has been found to be involved in control of a variety of 
processes.17-19 In general, functions of endocannabinoid signalling concern repair of 
(local) homeostasis as stated by Di Marzo: “excessive neuronal activity, cell damage, 
exaggerated stimulation of inflammatory cytokine receptors and physiological 
perturbations of homeostasis (i.e., food deprivation) trigger endocannabinoid 
production, which, together with other homeostatic signalling systems, helps cells 
return to their steady state.”12
 Several characteristics of the endocannabinoid system perfectly suit a modulatory 
functions; 1) signal transduction via inhibition of voltage-activated Ca2+ channels; 2) 
stimulation of synthesis of endocannabinoids by increased intracellular Ca2+ and 
activation of other G-protein coupled receptors; and 3) presynaptic localization.17 
Predominantly presynaptic localization of CB
1
-receptors in the nervous system allows 
retrograde signalling. In this way activation of CB
1
-receptors results in modulation of 
release of several neurotransmitters including gamma-aminobutyric acid (GABA), 
dopamine, noradrenaline, glutamate and serotonin (5-HT). This process is called 
depolarization-induced suppression of inhibitory and excitatory neurotransmission.17 
In this manner, the endocannabinoid system is able to modulate a wide range of 
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physiological functions including neuroprotection; nociception; cardiovascular and 
respiratory effects (regulation of blood pressure, heart rate and bronchial functions); 
gastrointestinal functions; regulation of energy homeostasis; reproduction; cognitive 
functions; emotion; reward and addiction; modulation of movement and posture; 
modulation of immune and inflammatory responses; and bone formation.7,17
The endocannabinoid system as a modulator of energy balance
Research so far clearly indicates a crucial role for the endocannabinoid system in 
regulation of energy balance. Contribution of endocannabinoids to maintainance of 
energy balance involves regulation of both food intake (often referred to as “central 
effects”) and food-intake independent mechanisms (“peripheral mechanisms”).
Central regulation of energy balance by endocannabinoid signalling
Following the identification of cannabinoid receptors and endocannabinoids, it has 
been shown that these receptors and their endogenous ligands are present in areas 
in the central nervous system important for regulation of food intake. Administration 
of endocannabinoids, systemic as well as hypothalamically, stimulates food intake in 
animal species, consistent with earlier established effects of administration of cannabis 
or synthetic cannabinoids.15,20-23 
 Since regulation of feeding behaviour by endocannabinoids is acting in brain stem 
and in hypothalamic circuits regulating hunger/satiety as well as in the limbic forebrain 
circuitry (for control of consummatory and rewarding aspects of feeding behaviour), 
it is suggested that the endocannabinoid system is involved in both the homeostatic 
and hedonic aspects of feeding behaviour.4,24 Endocannabinoid control of homeostatic 
aspects of feeding either involves a direct route via activation of CB
1
-receptors in 
hypothalamic centres or involves activation of CB
1
-receptors at peripheral afferent 
nerves that project to the brain stem and hypothalamus.25 
 In general, food intake is influenced by a complex network of orexigenic (appetite-
promoting) and anorexigenic (appetite-inhibiting) pathways. Interconnections between 
endocannabinoids and these regulatory pathways are reviewed by Pacher et al.18 
Endocannabinoids have been found to interact with both orexigenic factors including 
NPY, orexins, ghrelin, and endogenous opioids and with anorexigenic factors such as 
α-melanocyte-stimulating hormone (α-MSH), corticotrophin-releasing hormone (CRH), 




Leptin, a key signal in the long-term regulation of food intake and energy balance, was 
also found to interact with endocannabinoid activity. Tonic inhibition of endocannabinoid 
levels by leptin was suggested based on observed elevated endocannabinoid levels 
in mouse models unable to produce leptin (ob/ob mice) and in animal models with 
dysfunctional leptin receptors (Zucker rats and db/db mice).26,28,29 On the other hand, 
endocannabinoids have been suggested to increase leptin levels, since mice with a 
genetic deletion of the CB
1
-receptor show decreased leptin levels and increased leptin 
sensitivity compared to wild type mice.30 
 Nutritional state contributes to observed orexigenic effects of CB
1
-activation 
with maximal effects in pre-satiated animals.22 Kirkham et al. directly measured brain 
endocannabinoid levels in response to fasting, feeding and satiation in rats. Fasting 
levels of anandamide and 2-AG were increased in the limbic forebrain and to a lesser 
extend in the hypothalamus while hypothalamic 2-AG levels declined during eating. No 
changes were detected in satiated rats. Endocannabinoid levels in the cerebellum, a 
control region not directly involved in regulation of feeding behaviour, were unaffected 
by nutritional state.24,31 Orexigenic effects of (endogenous) cannabinoids are prevented 
by administration of exogenous CB
1
-receptor antagonists (e.g., Rimonabant), confirming 




 A role of CB
1
-receptors in the endocannabinoid regulation of food intake was 




-/-). Di Marzo et al. showed that 
food intake in previously fasted CB
1
-/- mice was reduced compared to their wild type 
littermates and that food intake of CB
1
-/- was not affected by treatment with a CB
1
-




Peripheral effects of endocannabinoid regulation of energy homeostasis
Studies on effects of cannabis in humans showed that treatment with cannabis led to 
a transient increase in food intake in combination with a more sustained increase in 
body weight. Conversely, treatment with CB
1
-receptor antagonists in animal models 
and humans resulted in a sustained reduction in body weight despite merely a 
transient decrease in food intake, suggesting that endocannabinoids have food-intake 
independent effects on energy balance.30,32-34 
 By showing that CB
1
-/- mice have decreased body weight compared to pairfed wild 
type littermates Cota et al. clearly pointed out that there are food intake-independent 
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mechanisms contributing to endocannabinoid regulation of energy balance (Figure 2).20 
Several mechanisms and target organs were suggested to underlie peripheral effects. 
Presence of CB
1
-receptors and endocannabionoids has been described for most organs 
involved in energy homeostasis (i.e., liver, gastrointestinal tract, muscle, adipose tissue, 
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-/-) mice, as compared 
with pair-fed wild type (WT) mice show reduced body weight, indicating a food intake 
independent effect of CB
1
-ablation on energy balance besides an effect on food intake. B) 
Inhibition of CB
1
-signalling results in reduced body weight via central effects on intake, via 
peripheral effects on intake (gastrointestinal (GI) satiety signals) and via central and peripheral 




 In summary, the presumed role of endocannabinoid signalling in energy 
homeostasis is to facilitate energy storage, as stated by Woods; “the net effect of 
endocannabinoids is anabolic, facilitating increased energy intake, decreased energy 
expenditure, and increased accumulation of body fat.”4,35 The effect on food intake upon 
manipulating endocannabinoid signalling appears to be transient, whereas intervening 
with endocannabinoid signalling has a more persistent effect on body weight and body 
composition and pair feeding experiments confirmed that both central and peripheral 




























Figure 3. Metabolic effect of endocannabinoid receptor activation: So far, several mecha-
nisms, summarized in this figure, have been suggested for peripheral mechanisms by which 
endocannabinoid activation affects energy balance.
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The endocannabinoid system and implications for treatment of 
disturbance of energy balance
Since the endocannabinoid system has emerged as a crucial modulator in the regulation 
of energy homeostasis, it is recognized as a potential target for drug treatment in 
obesity and related disease, but also in (disease-associated) cachexia.36 
The endocannabinoid system and obesity
There are several findings to indicate that increased endocannabinoid tone might 
contribute to the development of obesity. First of all, compared to lean controls, obese 
rodents are more sensitive to the anti-obesity effects of treatment with CB
1
-receptor 
antagonists. Secondly, diet-induced obesity in animal models is accompanied by 
elevated levels of endocannabinoids and adipocytes of obese rats show a higher CB
1
-
receptor expression. Thirdly, CB
1
-/- mice are resistant to diet-induced obesity. Moreover, 
in obese humans significantly higher levels of endocannabinoids were observed in blood 
and visceral fat. Finally, plasma 2-AG levels, but not anandamide levels, are positively 
correlated to amount of intra-abdominal fat in humans.37-39 It has been suggested that 
obesity-related overactivity of the endocannabinoid system could be the consequence 
of a reduced degradation of endocannabinoids. Interesting in view of this is a reported 
association between obesity and a missense polymorphism in the Faah gene, since FAAH 
is responsible for the degradation of anandamide (explained in Figure 1).40 However, 
this finding was not confirmed by others.41 Alternative causes of obesity-related 
elevated endocannabinoid tone are obesity-associated insulin resistance and leptin 
resistance, since these hormones were found to suppress endocannabinoid tone.12 
Endocannabinoid activity could hence be increased progressively in a feed-forward 
manner further contributing to the problem, but, at the same time allows disruption 




 With the identification of the endocannabinoid system as a target for weight 
loss medication, new pharmaceutical therapies for obesity have emerged. However, 
the first CB
1
 antagonist (in fact an inverse agonist), rimonabant, was not designed for 
the treatment of obesity, but rather as an anti-psychotic agent. Although rimonabant 
was not successful in ameliorating symptoms when tested in schizophrenic patients, 




then, large clinical trials have been conducted to test rimonabant as an anti-obesity 
drug. Besides succesfully reducing weight, weight loss-independent improvement of 
metabolic risk factors was observed with rimonabant-treatment. However, so far safety 
concerns have obstructed approval by the FDA. Registration of rimonabant in a number 
of European countries has been withdrawn after increased risks of depression and 
suicide were reported. Since these side-effects are related to central functions of the 
endocannabinoid system, it is essential to find pharmaceutical strategies that bypass 
these unwanted central effects. To be able to design drugs specifically targeted to 
evoke weight-reducing effects and favourable effects on metabolic risk factors without 
adverse central effects, it is essential to elucidate exactly how the endocannabinoid 
system is involved in the regulation of fuel metabolism and energy balance.
Interaction between the endocannabinoid and dietary long chain 
polyunsaturated fatty acids (LC-PUFA) intake
Dietary fatty acids can affect cellular functions by incorporation into membrane 
phospholipids. Since arachidonic acid (20:4n-6, AA) is a precursor of endocannabinoids, 
the presence of AA in membranes is expected to be a factor in control of 
endocannabinoid tone. This leads to the hypothesis that dietary fatty acid composition 
can influence endocannabinoid tone. It was also suggested that n-3 LC-PUFA might act 
as competitive inhibitors in the peripheral endocannabinoid system, thereby promoting 
energy metabolism and exerting anti-obesity effects.42,43 Only a few studies were aimed 
at investigating how dietary fatty acids could affect endocannabinoid levels. First, an in 
vitro study by Matias et al. showed that in mouse adipocytes incubation with (22:6n-3, 
DHA) significantly decreased both the proportion of AA in membrane phospholipids 
and the cellular concentrations of anandamide and 2-AG, while incubation with AA 
significantly increased AA in membrane phospholipids and the 2-AG concentration, 
but not the concentration of anandamide.44 Secondly, short-term maternal 
supplementation of both AA and DHA were found to increase anandamide levels in 
brain of newborn piglets.45 However, Watanabe et al. found that n-3 LC-PUFA deficiency 
elevates 2-AG levels in the brain of mice and supplementation with a n-3 enriched diet 
reduces brain 2-AG levels in mice.46 Finally, in a study in rats fed AA, higher levels of 
anandamide were found in brain, liver and small intestine but higher levels of 2-AG 
were found in small intestine. Rats fed fish oil showed lower levels of anandamide in 
small intestine and liver.47 Since LC-PUFA supplementation is currently recommended 
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for its presumed favourable metabolic effects, the relation between dietary LC-PUFA 
levels and endocannabinoid tone and the possible interaction is of great interest and 
needs further investigation.48
Scope of this thesis
The aim of this thesis is to explore the role of the endocannabinoid system in the 
regulation of energy balance in mice with a focus on peripheral metabolic effects of 
endocannabinoid signalling and on the interaction between dietary fatty acid intake 
and effects of intervening with endocannabinoid signalling. Since increased prevalence 
of obesity and associated comorbidities is especially alarming in children, we did not 
study the endocannabinoid system in a model of established obesity, but we choose 
deliberately for adolescent and young adult mice. 
 In the experiments described in this thesis two models were used; 1) mice treated 
with rimonabant, a CB
1
-receptor antagonist, compared to controls; and 2) mice with a 






-/-), compared to 
wild type littermates.
 Previously reported data on body weight gain in young CB
1
-/- mice showed reduced 
body weight compared to wild type mice, however, since these pups had respectively 
CB
1
-/- parents or WT parents, this reduction in body weight could be a consequence of 
maternal phenotype. Therefore we first studied phenotype of pups of heterozygous 
breeding to determine the contribution of genotype and maternal phenotype to the 
decrease in body weight gain in CB
1
-/- pups compared to WT pups (chapter 2). The 
experiment described in chapter 2 was furthermore designed to determine phenotype 
differences between male and female pups. Based on these results we only used male 
mice in the following experiments.
 Based on reported effects suggesting a potential role of endocannabinoid signalling 
in lipogenesis, adipogenesis and LPL-activity, we next explored possible mechanisms 
for CB
1
-mediated regulation of lipid metabolism. Since endocannabinoids are derived 
from PUFA and since PUFA are known to influence lipid fluxes (i.e., decrease hepatic 
lipogenesis), we hypothesized that dietary fatty acid intake would influence the effects 
of treatment with rimonabant. In chapter 3 effects of treatment with rimonabant 
in mice on either a chow (standard low fat diet), or a high-fat (HF) diet or a high-fat 






-/- mice to diet-induced hepatic steatosis are evaluated in mice on 
chow, HF diet or HF/FO diet. 
 Data on hepatic lipogenesis described in chapter 3 and 4 were not able to explain 
peripheral effects of endocannabinoid activity, and therefore we shifted our focus 
on adipose tissue. Adipogenesis, adipocyte morphology, adipose tissue lipolysis, and 
adipose tissue lipogenesis were studied in CB
1
-/- mice in relation to dietary fat intake 
and these data are described in chapter 5. 
 Since metabolic effects of endocannabinoid signalling are partly independent 
of food intake, an effect on energy expenditure might be expected. Data on energy 
expenditure, substrate utilization and circadian rhythm in nutrient partitioning in CB
1
-/- 
mice compared to WT mice are presented in chapter 6.
 Finally, in chapter 7, results of the studies in this thesis are summarized and 
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The endocannabinoid system (ECS) plays an important role in energy homeostasis. It 
was previously demonstrated that cannabinoid 1 receptor deficient (CB
1
-/-) mice have 
decreased body weight compared to wild type (WT) mice during lactation, which 
was attributed to reduced suckling behaviour of CB
1
-/- mice. Since offspring in these 
experiments was obtained from homozygous breeding pairs, a potential maternal 
contribution to reduced body weight gain of CB
1
-/- offspring versus WT mice could not 
be excluded. To rule out such an effect, we investigated offspring parameters during 
lactation of 41 heterozygous CB
1
+/- breeding couples. At weaning on day 20 there was a 
significant decrease in body weight of CB
1
-/- pups compared to WT pups in both sexes. 
In males reduction in body weight was based on reduction in both lean and fat mass, 
whereas in females only reduction in fat mass was responsible for reduced body weight 
in CB
1




Conclusions: These results confirm that the CB 
1
-receptor contributes to bodyweight 
gain during lactation in both male and female mice, potentially in a gene-dose effect 
relationship. Secondly, they rule out that these effects are mediated through differences 
in the maternal environment. 




Failure to thrive (FTT) is a common problem in paediatric practice. FTT is diagnosed 
in an infant or child whose growth is significantly less than that of his or her peers.1 
Organic FTT is growth failure based on an underlying medical condition. In the majority 
of patients, however, an underlying medical condition can not be found and these 
patients are categorized as non-organic FTT.1 Originally, cases of non-organic FTT were 
attributed to psychosocial factors (i.e. emotional deprivation, failure to offer adequate 
calories, inadequate meal-time settings, and maternal depression).2 Alternatively, 
non-organic FTT could originate from an imbalance in hypothalamic orexigenic and 
anorexigenic pathways in the newborn. These neural pathways are formed relatively 
late in fetal development, but are nonetheless necessary to thrive during the early 
postnatal stage.3 
 Recently, the endocannabinoid system (ECS) emerged as a potentially important 
system to regulate nutrient intake and handling of the newborn. First of all, it has 
been shown that anandamide and 2-arachidonoyl glycerol (2-AG), the two most 
studied endocannabinoids, are present in mammalian milk (bovine as well as human) 
at sufficient concentrations to stimulate suckling behaviour in the newborn by acting 
on CB
1
-receptors.4-6 Secondly, levels of 2-AG in the rat brain peak during the first day 
postpartum.7 Fride et al. suggested that derangements in endocannabinoid signalling 





mice have decreased body weight compared to wild type (WT) mice during lactation, 
which they attributed to reduced suckling behaviour of CB
1
-/- mice.8 Since offspring in 
their experiments was obtained from homozygous breeding couples i.e., a comparison 








-/-, a potential maternal contribution to 
reduced body weight gain of CB
1
-/- offspring compared to WT mice could not be excluded. 
The ECS not only plays a role in the neonatal period but also in control of adult energy 
homeostasis. Since food intake during pregnancy and lactation should be optimal, it 
can be expected that endocannabinoid activity is maximized during pregnancy and 
lactation. Endocannabinoid deficiency in the mother may result in alterations in 
maternal care, maternal nutritional and neuro-endocrine status which may have 
secondary effects on prenatal and postnatal development. Therefore, targeted deletion 
of the CB
1
-receptor in the mothers (CB
1
-/- mothers) could very well have secondary 
consequences in the offspring, apart from the primary consequences resulting from 





independent of the effects of maternal nutritional factors, we investigated growth in 
offspring of 41 heterozygous CB
1
+/- breeding couples during lactation. We compared 










-/-) with a C57BL/6J background and their WT-littermates were 
bred in our own facility. Initial breeding pairs were kindly provided by Prof. Dr. A. 
Zimmer, Laboratory of Molecular Neurobiology, Department of Psychiatry, University 
of Bonn, Germany. Heterozygous breeding couples were obtained by breeding male 
WT C57BL/6j with female CB
1
-/- mice. Mice were housed as breeding couples in a light-
controlled (lights on 4 AM- 4 PM) and temperature-controlled (21oC) facility. Mice 
were allowed tap water and food (standard chow) ad libitum. Experimental protocols 
were approved by the local Experimental Ethical Committee for Animal Experiments. 
Retrospectively, we determined genotype distribution in offspring of our heterozygous 
breeding couples and, over a four-month period while we maintained the breeding 
colony, we registered mortality of weaned pups that were included in a series of 
experiments. 
Experimental procedures
Pups of 41 heterozygous CB
1
+/- breeding couples were followed throughout lactation. 
Pregnant dams were daily checked for the presence of litters. At day two of life, pups 
were coded (by toe clips), genotyped, sexed and weighed. Litters were culled to six 
pups within one week after birth. Pups were weighed again at day 6 and day 13. At 
weaning, on day 19, 20 or 21, pups were weighed and then sacrificed by cardiac 
puncture under inhalation anaesthesia followed by cervical dislocation. Epididymal fat 
pads were removed and stored at -80oC until further analysis. Carcasses were stored at 
-20oC until carcass analysis.
Body composition
In specific cohort of offspring, anal-chin length was measured in defrosted carcasses, 
after which carcasses were dried to constant weight at 103 oC, and fat was extracted by 
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petroleum ether (Boom BV, Meppel, The Netherlands) in a soxlet distillation apparatus. 
Fat mass of carcasses was determined from weight differences before and after the fat 







Total RNA was isolated from frozen epididymal adipose tissue using the TRI-reagent 
method (Sigma). Using random primers, RNA was converted to cDNA with M-MuLV 
Reverse Transcriptase (Sigma) according to the manufacturer’s protocol. For realtime-
PCR, cDNA was amplified using the primers and probes listed in Supplemental Table 1. 
Relative gene expression levels were normalized to β-actin.
Statistical analysis
All values in the tables and figures represent means ± standard error of the mean for 
the number of animals indicated in the table and figure legends. Data were statistically 
analyzed by the ANOVA test with post hoc Bonferroni correction. Statistical significance 
of differences was accepted at a P-value of less than 0.05. Analyses were performed 
using SPSS 16.0 for Windows software (SPSS, Chicago, IL).
Results
Genotype distribution and mortality
Genotypes were distributed according to Mendelian segregation, indicating no 
difference in intra-uterine mortality between different genotypes (Table 1). Our 
evaluation of mortality of male pups included in several experiments demonstrated an 
increased mortality of CB
1
-/- mice, especially in the first week after weaning (Table 2).








n 204 184 399
genotype distribution (%) 25,9 23,4 50,7
Body weight during lactation
No significant difference in body weight of pups was found at day 2 and 6 (Figure 1). 





were significantly lower compared to male WT mice (day 13, p = 0.011 and day 20, 
p < 0.001) (Figure 1a). Female mice showed a similar pattern as males, although the 
difference between CB
1
-/- mice and WT mice was not significant until day 20 (p = 0.031) 
(Figure1b). At day 20, body weights of male and female CB
1
-/- mice were also reduced 
compared to CB
1
+/- mice (p < 0.001 and p < 0.005). The decrease in body weight at day 
20 in male CB
1
+/- mice compared to male WT mice was not significant and there was no 
difference in body weight at day 20 between female CB
1




-/- mice showed a significant reduction in anal-chin length (p = 0.006) on day 20 
compared to WT mice (Figure 2). Also, male CB
1
-/- mice showed a significant reduction 
in lean mass (p = 0.008) on day 20 compared to WT mice (Figure 3a). Furthermore, male 
CB
1
-/- mice showed a significant reduction in fat mass (p < 0.01) on day 20 compared to 
WT mice (Figure 3b). Thus, reduction in body weight of male CB1-/- mice compared to 
WT mice, was caused by a decrease in lean mass and in fat mass, indicating that not 
only adiposity but also changes in structural body size contributed to the reduced body 
weight. Lean mass and fat mass of male CB
1
-/- mice tended to be reduced compared 
to CB
1
+/- mice, however this did not reach statistical significance. Differences between 
CB
1
+/- mice and WT mice were neither significant. Remarkably, no significant differences 
in anal-chin length and in lean mass were found in female mice (Figures 2 and 3a). 
Therefore, the observed reduction in body weight in female CB
1
-/- mice compared to WT 












-/- mice was undetectable. Cnr
1
-
expression in female WT mice was lower compared to Cnr
1
-expression in male WT 
mice (Cnr
1
-expression in female WT mice 9.9 versus 12.7 in male WT mice), however 
this difference did not attain significance. Cnr
1
-expression was significantly reduced 
in female CB
1
+/- mice compared to female WT mice (female CB
1
+/- mice 4.0 versus 9.9 
in female WT mice, p = 0.001). The reduction in Cnr
1
-expression in male CB
1
+/- mice 
compared to WT mice did not reach statistical significance (male CB
1
+/- mice 8.4 versus 





significantly reduced compared to both CB
1
+/- mice and WT littermates (female CB
1
-/- 
mice 0.0 versus 4.0 in female CB
1
+/- mice, p = 0.018, female CB
1
-/- mice 0.0 versus 9.9 
in female WT mice, p < 0.001 and male CB
1
-/- mice 0.0 versus 8.4 in male CB
1
+/- mice,
























































-/-), wild type (WT) and heterozygous (CB
1
+/-) mice. Continuous lines, WT mice; 
irregular dotted lines, CB
1
+/- mice; dotted lines, CB
1
-/- mice. Values are means; n = 27-47, * WT 
versus CB
1
-/- p = 0.011 at day 13 and ** WT versus CB
1





p = 0.000 at day 20. B) Growth curves during lactation in female CB
1
-/-, WT and heterozygous 
mice. Continuous lines, WT mice; irregular dotted lines, CB
1
+/- mice; dotted lines, CB
1
-/- mice. 
Values are means; n = 17-45, * WT versus CB
1




































-/-), wild type (WT) and heterozygous (CB
1
+/-) mice. Open bars, WT mice; gray bars, CB
1
+/- 
mice; closed bars, CB
1




p = .005, male CB
1
-/- mice 0.0 versus 12.7 in male WT mice, p < 0.001). Cnr
1
-expression 
in heterozygous mice was approximately two-third of the expression level found in WT 
mice. Cnr
1
-expression in female heterozygous mice was significantly reduced compared 
to Cnr
1
-expression in male heterozygous mice.






Total number of mice included in experiments 88 85
Mortality after inclusion 0 16
within 1 week after weaning 0 13
more than 1 week after weaning 0 3




































-/-), wild type (WT) and heterozygous (CB
1
+/-) mice. Open bars, WT mice; gray bars, CB
1
+/- 
mice; closed bars, CB
1
-/- mice. Values are means +/- SEM; n = 5-13; * p = 0.008 male WT 
versus CB
1
-/-. B) Fat mass in male and female CB1-/-, WT and heterozygous mice. Open bars, 
WT mice; gray bars, CB
1
+/- mice; closed bars, CB
1
-/- mice. Values are means +/- SEM; n = 5-13; 
* p = 0.009 male WT versus CB
1






The results of our study show that the CB 
1
-receptor contributes to body weight gain 
during lactation in both male and female mouse pups, potentially in a gene-dose effect 
relationship, and they rule out that these effects are mediated through differences in 
the “maternal environment”. Secondly, these results show that male CB
1
-/- pups have a 
more pronounced lean phenotype compared to female CB
1
-/- mice.
 Results of our experiments confirm previous observations of Fride and colleagues 
demonstrating that CB
1
-/- mice have decreased body weight gain compared to WT 
mice during lactation.8 While Fride et al. showed in their experiments already from 
day 5 postpartum a significantly lower body weight of newborn pups of CB
1
-/- mothers 
compared to pups of WT mothers, we first observed from day 13 postpartum a 
significantly lower body weight in CB
1
-/- pups compared to their WT littermates.8 Based 
on this discrepancy between results of Fride et al. and results of these experiments, 
our results do not exclude maternal contribution to reduction in body weight gain 
in CB
1
-/- pups during lactation. However, since most of the difference in body weight 
between CB
1
-/- pups and WT pups is preserved in our experiments comparing CB
1
-/-, 
heterozygous and WT littermates of heterozygous mothers, the effect on body weight 
is mostly independent of maternal factors. This implies that endocannabinoid signalling 
is crucial for body weight development in the neonatal period.
 In view of the crucial role of the ECS in the neonatal period, impaired endocannabinoid 
signalling was already suggested by Fride et al. to be a pathophysiological substrate 
for non-organic FTT.9,10 They suggested that CB
1
-antagonist (SR141716)-treated pups 
had severe oral-motor impairment based on a series of experiments showing that 
SR141716-treated pups approached the nipple of an anaesthetized nursing dam like 
vehicle-injected pups did, but they did not suckle adequately.10 When SR141716-
treated pups were exposed to a dish with milk, they were able to ingest the same 
amount of milk as controls suggesting that suckling, but not ingestion is impaired. 
Fride and colleagues speculated that treatment with a CB
1
-antagonist at birth leads 
to incomplete synaptogenesis of the hypoglossal nerve with resulting impairment of 
suckling.10 Interestingly, there are also reports on oral-motor dysfunction in children 
with non-organic FTT.11,12 In a large whole-population survey conducted by Reilly and 
colleagues, 17 children of a group of 47 children with non-organic FTT were shown to 
have significant oral-motor dysfunction without global developmental delay.11 Ramsay 
et al. reported that feeding difficulty at 10 months of age is related to non-organic FTT 
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but they could not confirm a relation between maternal depression and non-organic 
FTT.13 Impaired endocannabinoid signalling could be a possible explanation for the 
observed vulnerability to non-organic FTT.
 Another indication for a maternal contribution to the results obtained by Fride et 
al. is the fact that we did not observe increased perinatal mortality as they described 
for CB
1
-/- pups derived from CB
1
-/- mothers.8 Absence of mortality in the CB
1
-/- pups 











+/- breedings across a large 
number of studies. Several interacting mechanisms could contribute to the increased 
mortality in CB
1
-/- pups observed by Fride and colleagues (i.e., stunted growth by 
insufficient lactation, cannibalism of pups by the CB
1
-/- mothers). We noticed, however, 
an increased mortality in male CB
1
-/- pups immediately after weaning and speculate that 
this is a consequence of the impaired capacity of the CB
1
-/- pups to adjust to solid food. 
Feeding difficulties in children with non-organic FTT have been reported to involve 
problematic transition from one kind of food to another, and these effects could be 
homologous to those resulting from deficient endocannabinoid signalling observed in 
the present study.
 Results of our experiments suggest a gene-dose effect relationship in the 
contribution of the CB
1
-receptor to body weight gain. This is in contrast with results 





+/+ at any age.14 During lactation we did observe reduced body weight in male 
heterozygous CB
1
+/- mice compared to their male WT littermates. Moreover, in males 
as well as females we observed reduced fat mass in heterozygous CB
1
+/- mice compared 
to their WT littermates. Differences between WT and heterozygous littermates in body 
weight and fat mass did not reach significance, but there was a clear trend towards 





-receptor activation in neural tissue, partially compensating for the 
decrease in receptor density in heterozygous mice.15 In agreement with a gene-dose 
effect, we showed a decrease in Cnr
1
-receptor expression in white adipose tissue of 
heterozygous CB
1
-deficient mice compared to WT littermates. The observed gene-dose 
effect on body weight and fat mass in these pups does illustrate the crucial role of 
endocannabinoid signalling early in life.
 As mentioned, our results show a significant decrease in body weight at weaning 
(day 20) in male as well as in female CB
1
-/- pups compared to WT pups. Remarkably, 
the difference in fat mass between male CB
1





-/- and WT pups; in the latter case the difference between CB
1
-/- and WT pups 
was not statistically significant. This gender-specific effect was even more pronounced 
for lean mass. Male CB
1
-/- pups showed a more pronounced phenotype compared to 
female CB
1
-/- pups in this respect. Cota et al. also reported on gender–specificity in adult 
mice, with a less pronounced lean phenotype in female CB
1




 A possible explanation for this gender-specificity could lie in an interaction of 
endocannabinoid signalling with the hypothalamic-pituitary-gonadal axis. There are 
several lines of evidence supporting such an interaction. First of all, gonadal steroids 
have been extensively linked to adipogenesis.16,17 In evaluating gene expression of 
adipogenic factors in relation to gender and CB
1
-genotype in white adipose tissue of 
mice sacrificed at weaning, however, we did not observe any differences in expressions 
of genes encoding AP2, PPAR alpha2, CEBP alpha, PEPCK (chapter 5). Instead, central 
mechanisms could be involved in the differential modulation of metabolic phenotype 
of impaired endocannabinoid signalling by gonadal steroids. Gonadal steroids are 
recognized to modulate central nervous system effectors of energy homeostasis that 
are also influenced by endocannabinoids. For example, cannabinoid effects on gene 
expression of corticotrophin-releasing hormone and proopiomelanocortin were 
found to be differentially regulated in male and female rats18 and endocannabinoid 
modulation of neurotransmission was found to be influenced by gonadal steroids.19,20 
Moreover, there are several reported studies describing gonadal steroid influence on 
endocannabinoid tone.21-23 González et al. showed that expression of the CB
1
-receptor 
gene in the anterior pituitary gland of rats is regulated by gonadal steroids in both 
males and females. They found that whereas estradiol had a stimulatory effect on Cb
1
-
expression in males, it had an inhibitory effect on Cb
1
-expression in females. They also 
showed that female rats had higher anandamide levels in the anterior pituitary gland 
and in the hypothalamus and concluded that there are sex dependent differences in 
ligand-receptor ratios. It is possible that these ligand-receptor ratio differences are 
responsible for the observed gender-specificity resulting in a more pronounced lean 
phenotype in male CB
1
-/- mice. 
 In conclusion, our results show that the CB 
1
-receptor contributes to body weight 
gain during lactation in both male and female mice, potentially in a gene-dose effect 
relationship and these effects are not mediated through differences in the prenatal 
environment. Moreover, we demonstrated gender-specificity for the role of the 
CB
1
-receptor with a more pronounced lean phenotype in male CB
1
-/- pups. Impaired 
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endocannabinoid signalling could be involved in failure to thrive in humans and future 
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The anti-obesity effects of suppressed endocannabinoid signalling may rely, at least 
in part, on changes in lipid fluxes. As fatty acids exert specific effects depending on 
their level of saturation, we hypothesized that the dietary fatty acid composition would 
influence the outcome of treatment with a CB
1
-receptor antagonist (rimonabant). 
Therefore we performed a controlled study in mice in which we analyzed the effects 
of treatment with rimonabant on (markers of) lipid fluxes and obesity-associated 
derangements in relation to differences in dietary fatty acid composition. Mice were 
treated with rimonabant (10 mg kg-1 body weight per day) or vehicle while equicalorically 
fed either a low-fat diet (chow, LF), a high-fat (HF) diet or a HF diet in which 10% of the 
saturated fatty acids (SFA) were displaced by polyunsaturated fatty acids (PUFA) from 
fish oil (FO). Food intake and body weight were registered daily. Indirect calorimetry 
was performed and feces were collected. After three weeks, mice were sacrificed for 
blood and tissue collection.
Results showed that relative to the LF (chow) diet, the HF diet caused anticipated 
metabolic derangements, which were partly reversed by the HF/FO diet. The HF/FO 
diet, however, was most obesity-promoting despite inhibiting lipogenesis as indicated 
by low gene expression levels of lipogenic enzymes. On all three diets, rimonabant 
treatment improved metabolic derangements and led to significantly lower body 
weight gain than their respective controls. This latter effect appeared largest in the 
HF/FO-group, but occurred without major changes in nutrient absorption and energy 
expenditure.
Conclusion: The effects of chronic rimonabant treatment on body weight gain occurred 
irrespective of diet-induced changes in lipogenic activity, food intake and daily energy 
expenditure, and were, in fact, most pronounced in the HF/FO mice. The effects of 
dietary PUFA replacement in an HF diet on expansion of adipose tissue might allow 
the favourable effects of dietary PUFA on dyslipidemia and hepatic steatosis. In light of 
other disadvantageous effects of weight gain, this might be a risky trade-off. 




Detailed understanding of the mechanisms involved in regulation of energy balance 
is crucial for treatment and prevention of obesity and associated comorbidities. The 
endocannabinoid system (ECS) has recently been implicated in the regulation of energy 
balance.1-3 The psychoactive substance, ∆9-tetrahydrocannabinol (THC), as well as 
endogenous ligands of the ECS, anandamide and 2-arachidonoylglycerol, stimulate food 




-receptor-null mice are lean and resistant 
to diet-induced obesity.8-11 Consistent with these findings, the CB
1
-receptor antagonist 
SR141716, also known as rimonabant, was shown to be able to reduce food intake and 
body weight in obese humans.12,13 In humans as well as in rodents the effects of CB
1
-
receptor antagonism on food intake are generally transient, whereas changes in body 
fat content upon treatment are more persistent,7,14-16 suggesting a role for the ECS in 
energy fluxes independent of food intake. 
 In line with this are several reports to indicate that CB
1
-receptor activity affects 
lipid mobilization and utilization. With respect to fat tissue, for example, Matias et al.7 
observed direct effects of endocannabinoids on lipid droplet formation in mouse and 
human adipocytes, and these effects could be prevented by CB
1
-receptor antagonism.2 
Furthermore, Cota et al.10 found that stimulation of CB
1
-receptors of primary adipocytes 
increases lipoprotein lipase activity, an effect that could be blocked by co-administration 
of the CB
1
-receptor antagonist rimonabant. Jbilo et al.17 found that treatment with this 
CB
1
-receptor antagonist increases gene expression of enzymes involved in lipolysis and 
β-oxidation in white and brown adipose tissue. Herling et al.18 and Osei-Hyiaman et al.19 
independently reinforced these results by showing increased rates of lipid oxidation (by 
indirect calorimetry) following bolus administration of rimonabant, particularly during 
the post-ingestive phase. Finally, CB
1
-receptor antagonist in obese patients consistently 
improved plasma lipid profiles.12,13,20 With respect to the liver, Osei-Hyiaman et al.11 
observed that feeding a high-fat diet increases hepatic levels of anandamide and CB
1
-
receptor-density, and showed that pharmacological activation of CB
1
-receptors by 
HU210 in mice increases hepatic gene expression of Srebp-1c (srebf1), Acc1 (Acaca) 
and Fasn, all indicative of increased lipogenesis. While CB
1
-receptor-null mice have 
reduced lipogenesis,19 which was suggested to explain their lean phenotype, data on 
the effects of chronic rimonabant-treatment on markers of lipogenesis are currently 
lacking. Taken together, these data indicate that CB
1
-receptor antagonism is a useful 
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tool against disturbance in lipid fluxes known to be underlying, or at least associated 
with, the ‘metabolic syndrome’.
 It is generally accepted that not only the quantity of dietary fat intake, but also its 
quality affects lipid fluxes in the body.21 Thus, while a high-saturated-fat diet stimulates 
the expression of genes encoding lipogenic enzymes in the liver such as Srebp-1c and 
Fasn expression,22 a diet with a high content of poly-unsaturated fatty acids (PUFA) has 
the opposite effects.23,24 Since changes in lipid fluxes are suggested to be, at least in part, 
responsible for the anti-obesity effect of rimonabant treatment, it can be hypothesized 
that efficacy of rimonabant treatment may depend on changes in lipid fluxes resulting 
from differences in dietary fat composition. Up till now, relatively little attention has 
been paid to the role of dietary fat composition in relation to the efficacy of rimonabant 
treatment. Humans consume food that varies considerably in fat content and in the 
ratio of saturated fatty acids (SFA) to PUFA. In fact, because of presumed favourable 
effects on lipid profiles and on the risk for atherosclerosis, PUFA supplementation is 
popular in those at risk of obesity-associated comorbidities. 
 As different fatty acids have specific effects on lipid fluxes and compartmentalization 
of triglycerides in the body, we hypothesized that differences in dietary fatty acid 
composition will influence the outcome of treatment with a CB
1
-receptor antagonist like 
rimonabant. Therefore we performed a controlled study in mice in which we analyzed 




Eight-week-old male C57BL/6J mice were obtained from Harlan (Zeist, The Netherlands) 
and were individually housed in a light-controlled (lights on 8 AM – 8 PM) and 
temperature-controlled (21oC) facility. Mice were allowed tap water and food ad libitum. 
Experimental protocols were approved by the local Experimental Ethical Committee 
for Animal Experiments. We certify that all applicable institutional and governmental 
regulations concerning the ethical use of animals were followed during this research. 
Experimental diets
All experimental diets were obtained from Abdiets bv, Woerden, The Netherlands. Mice 
received either a low-fat (LF) diet (standard laboratory chow RMH-B 2103), a high-fat 
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diet (HF) containing 36 weight % fat consisting of bovine fat (custom synthesis, diet 
number 4031.45) or a high-fat fish-oil-enriched diet (HF/FO) containing 36 weight % 
fat consisting for 58% of bovine fat and for 42% of fish oil (FO), (custom synthesis, 
diet number 4031.54). After preparing pellets, diets were stored at -20oC. The HF/FO 
diet was replaced every two days to prevent oxidation of fatty acid species. For diet 
composition, see Table 1. 
Table 1. Fatty acid profiles of experimental diets in mg g-1.
 chow (LF) HF HF/FO
C14:0 0,5 12,2 16,1
C16:0 8,4 92,5 79,5
C16:1 0,7 11,5 18,0
C18:0 3,7 76,3 50,5
C18:1 13,7 133,2 101,0
C18:2 16,9 11,5 9,7
C18:3 1,9 2,9 15,2
C20-22 0,4 4,0 53,3
C16 desaturation index 0,1 0,1 0,2
C18 desaturation index 3,7 1,7 2,0
ratio n-6/n-3 12,0   ND* 0,4
total dietary fat content 6% 36% 36%
Abbreviations: FO, fish oil; HF, high-fat; LF, low-fat; ND, not detectable.
The level of n-6 PUFA in the HF diet are non-detectable ND. Composition of experimental diets.
Experimental procedures
The effect of dietary PUFA and fat intake, the effect of treatment with a CB
1
-receptor 
antagonist and the interaction between diet and this treatment were studied in a Latin 
square design. On arrival, mice were divided into three dietary groups: chow, HF, HF/FO. 
Mice were matched for plasma lipids, glucose and body weight. Half of the animals in 
each dietary group were subjected to CB
1
-receptor antagonist (rimonabant) treatment. 
Thus, six groups of eight mice were compared in this experiment. 
 Intake and body weight were registered daily. Rimonabant (reference compound 
kindly provided by Solvay) was administered orally at a dose of approximately 10mg kg-1 
body weight per day by thoroughly mixing it through the diet. Oral rimonabant treatment 
was started after 3 weeks on the various diets. Indirect 24-h calorimetry was performed 
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before start of treatment with the CB
1
-antagonist and 2 weeks after start of treatment. 
Feces were collected before start of treatment and after 18 days of treatment. After 3 
weeks of oral rimonabant treatment (and thus 6 weeks after start of the diet), treated 
and control mice were sacrificed, blood and tissue were collected. 
Indirect calorimetry
Mice were placed in an open-circuit, indirect calorimeter system for 24h with access to 
water and food. Gas-exchange measurements were performed in an eight-channel, open 





 concentrations of dried inlet and outlet air from each chamber were measured 
every 10 min with a paramagnetic O
2
 analyzer and an infrared CO
2
 gas analyzer. Data 
were collected from each metabolic cage separately. The respiratory quotient (RQ) was 
defined as CO
2
 production (l)/ O
2
 consumption (l). Energy expenditure was calculated 





*0.001). Lipid oxidation and carbohydrate oxidation were calculated according to 
Lusk using the following equations:26
Lipid oxidation (g h-1): 38.461*(VO
2
 (mol h-1) - VCO
2
 (mol h-1))
Carbohydrate oxidation (g h-1): 94.017*VCO
2




The energy content of dried, homogenized feces was determined using a bomb calori-
meter (CBB 330, standard benzoic acid 6320 cal g-1, BCS-CRM No.90N)
Plasma lipids and adipokines
Plasma lipids were measured using commercially available kits from Roche (Mannheim, 
Germany) for triglycerides and cholesterol. Plasma leptin, resistin and tumor necrosis 
factor-α levels were determined using a commercially available adipokine lincoplex kit 
(Linco Research, St Charles, MO, USA). Adiponectin was measured using a commercially 
available RIA kit (Linco Research).
Hepatic lipids 
Livers were removed and freeze-clamped. Before further analysis, livers were crushed 
on liquid nitrogen and stored at -80oC. For hepatic lipid extraction, frozen crushed 
livers were homogenized in ice-cold saline. Hepatic lipids were extracted according 
to Bligh and Dyer27 and hepatic triglycerides and total cholesterol were measured 
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using commercially available kits from Roche; free cholesterol was measured using 
commercially available kit from Wako Chemicals (Neuss, Germany). Phospholipid 
content of the liver was determined according to Böttcher et al.28
Gene expression in liver and epididymal adipose tissue
Total RNA was isolated from frozen liver and epididymal adipose tissue using the TRI-
reagent method (Sigma, Zwijndrecht, The Netherlands). Using random primers, RNA 
was converted to cDNA with M-Mulv Reverse Transcriptase (Sigma) according to the 
manufacturer’s protocol. For realtime-PCR, cDNA was amplified using the appropriate 
primers and probes. The sequences of the primers and probes for β-actin, Srebp-1c, 
Fasn, Acc1 and Acc2 have been published (http://www.labpediatricsRUG.nl Realtime 
Primers Datalist Pediatrics UMCG). Relative gene expression levels were normalized to 
β-actin.
Body composition
Carcasses were eviscerated and stored at -20oC. Carcasses and organs were dried to 
constant weight at 103 oC, and fat was extracted by using petroleum ether (Boom BV, 
Meppel, The Netherlands) in a soxlet apparatus. Percentage fat of carcasses and organs 
were determined from weight differences before and after the fat extraction procedure.
Statistics 
All values in the figures and in the tables represent means ± standard errors of the means 
for the number of animals indicated in the figure and table legends. To evaluate effects 
of diet, rimonabant treatment, and their interactions, data were statistically analyzed 
using a general linear model with Bonferroni post hoc analyses. Treatment effects were 
further analyzed by Student’s t-test. In case of non-parametric distribution, Mann-
Whitney U-test was used for statistical analysis. Statistical significance of differences 
was accepted at a P-value of less than 0.05. Analyses were performed using SPSS 16.0 




Effects of dietary fat composition on body weight gain, adiposity and food 
efficiency in C57BL/6J mice
Mice were matched for serum levels of glucose, triglycerides and total cholesterol, as 
well as for body weight at the onset of the experiment. Figure 1a shows changes in body 
weight relative to initial weights from the start of the experimental diets. In the control 
groups on all the three experimental diets, body weights increased over the course 
of the experiment, but most pronounced in HF/FO-fed mice. At day 22, body weights 
of mice fed HF/FO were significantly increased compared to mice fed chow and mice 
fed the HF diet (Figure 1b). Data on body composition shown in Table 2 illustrate that 
increased body weight in the HF/FO fed mice was associated with increased adiposity 
in these mice as compared to that in HF-fed mice and the chow-fed mice. There was a 
significant increase in fat mass in mice fed the HF/FO diet as compared with that in mice 
fed chow as well as that in mice fed the HF diet. Dietary fat composition did not affect 
body fat distribution as is shown in Figure 1c. 
 Increased weight gain in the HF/FO group could not be explained by higher food 
intake. In fact, mice fed HF/FO had slightly reduced caloric intake; however, this trend 
did not reach statistical significance (Figures 1d and e). To assess whether increased 
absorption could contribute to increased body weight gain in mice fed HF/FO, residual 
energy contents in feces collected over a period of 48 h were determined using bomb 
calorimetry (Figure 2a). Fecal energy excretion was significantly lower in the HF/FO 
control group (1.58 kcal 24h-1 ± 0.45) as compared with that in the chow control group 
(3.11 kcal 24h-1 ± 0.47; p = 0.000) and the HF control group (2.22 kcal 24h-1 ± 0.37; 
p = 0.037). Reduction of fecal energy excretion in the HF control group as compared 
with that in the chow control group was also significant (p = 0.008). However, calculated 
as absorbed energy (food intake in kcal 24h-1 minus residual fecal energy in kcal 24h-1), 
the amount of absorbed energy was not affected by diet as shown in Figure 2b. 
 Food efficiency (body weight gain in gram per kilocalorie intake) calculated for the 
treatment period is shown in Figure 2c. Food efficiency of mice in the HF/FO control 
group was significantly higher as compared with food efficiency in the chow control 
group (113.7% higher in the HF/FO control group compared with levels calculated in the 
chow control group; p = 0.006) and in the HF control group (99.4% higher in the HF/FO 
control group compared with levels calculated in the HF control group; p = 0.010).



































































































Figure 1. Body weight gain and food intake. A) Body weight gain compared to body weight at 
start of diet expressed in grams per day. On day 0, treatment with rimonabant was started as 
indicated by the arrow. Open squares, chow C (low-fat control group); black squares, chow R 
(low-fat treatment group); open triangles, HF C (high-fat control group); black triangles, HF R 
(high-fat treatment group); open circles, HF/FO C (HF/FO control group); black circles, HF/FO 
R (HF/FO treatment group). Values are means for n = 8 mice per group. Body weight at day 0 
(means ± SD for n = 16 mice per diet group) chow 25.6 ± 1.4, HF 28.3 ± 2.0, HF/FO 27.0 ± 2.2. B) 
Body weight gain between day 0 and day 22. Open bars, control groups; black bars, rimonabant 
treatment groups. Values are means ± SEM for n = 8 mice per group. * chow R versus chow 
C p = 0.002, † HF R versus HF C p = 0.001, ‡ HF/FO R versus HF/FO C p = 0.000. Trend towards 
significant interaction between treatment and diet p = 0.063. C) Cumulative intake day 0 until 
day 22 expressed in kilocalories. Open bars, control groups; black bars, rimonabant treatment 
groups. Values are means ± SEM for n = 8 mice per group, * HF R versus HF C p = 0.020, † HF/
FO R versus HF/FO C p = 0.000. Significant interaction between treatment and diet p = 0.003. 
D) Cumulative intake day 11 until day 22 expressed in kilocalories. Open bars, control groups; 
black bars, rimonabant treatment groups. Values are means ± SEM for n = 8 mice per group. No 









































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. A) Fecal energy excretion. Residual energy in feces collected during 48 h, measured by 
bomb calorimetry. Open bars, control groups; black bars, rimonabant treatment groups. Values 
are means ± SEM for n = 4-8 mice per group, HF C versus chow C * p = 0.008, HF/FO C versus 
chow C † p = 0.000, HF C versus HF/FO C ‡ p = 0.037. B) Energy absorption. Absorbed energy 
calculated from food intake in kilocalories per day minus residual fecal energy in kilocalories 
per day. Open bars, control groups; black bars, rimonabant treatment groups. Values are means 
± SEM for n=4-8 mice per group. No significant differences. C) Food efficiency day 0 – day 22 
expressed in gram body weight gain per kilocalorie intake. Open bars, control groups; black 
bars, rimonabant treatment groups. Values are means ± SEM for n = 8 mice per group, * HF/FO 
C versus chow C p = 0.006, † HF/FO C versus HF C p = 0.010, ‡ chow R versus chow C p = 0.002, 
§ HF R versus HF C p = 0.001, HF/FO R versus HF/FO C p = 0.000. Significant interaction between 
treatment and diet p = 0.027. FO, fish oil; HF, high-fat.
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Effects of dietary fat composition on lipid profile and lipogenic markers in 
C57BL/6J mice
Plasma concentrations of triglycerides were significantly lower in the HF/FO control 
group as compared with that in the chow and HF control groups (Table 3). In the HF 
control group as well as HF/FO control group, plasma cholesterol concentrations were 
significantly elevated as compared with that in the chow fed control group. Hepatic 
triglycerides, hepatic total cholesterol, free cholesterol and cholesterol esters were 
significantly elevated in the HF group as compared with that in the chow group (Table 
3). The hepatic levels of total cholesterol, free cholesterol and cholesterol esters 
normalized in mice fed HF/FO as compared with that in the HF group, and became 
indistinguishably from those in chow controls. Hepatic triglyceride levels were 
decreased in the HF/FO control group as compared with that in the HF control group, 
but remained significantly elevated compared with that in the chow control group. 
Both plasma leptin and adiponectin levels were significantly increased in the HF/FO 
control group as compared with that in the other control groups (Table 3). 
 Consistent with previous data from our laboratory, hepatic expression of genes 
encoding lipogenic enzymes (shown in Figure 3) were significantly elevated in the HF 
control group as compared with that in the chow control group, and in the HF/FO group 
expression levels were similar to the chow control group or even lower.
Effects of dietary fat composition on RQ and oxygen consumption in 
C57BL/6J mice 
As expected, calorimetry data showed higher RQs for mice in the chow group as 
compared with those in the HF group and the HF/FO group (Table 4). In the dark phase 
and in the light phase, oxygen consumption and calculated energy expenditure were 
significantly increased in the HF-fed mice as compared with that in the chow control 
group and the HF/FO control group. There were no significant differences between 
the HF/FO-fed mice and the chow-fed mice regarding oxygen consumption or energy 
expenditure. There was a significant reduction in CO
2
 production in the HF/FO-fed mice 
as compared with that in chow-fed mice and HF-fed mice. 
 Lipid oxidation was significantly increased in the HF control group as compared 
with that in the chow control group in the dark as well as light phase. This increase was 
even more pronounced in the HF/FO control group. HF/FO-fed mice had significantly 
elevated lipid oxidation compared with that in HF-fed mice. In the light and in the dark 
phase, HF/FO-fed mice had significantly decreased carbohydrate oxidation compared 
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with both the HF control group and the chow control group. In the HF-fed mice 
carbohydrate oxidation was also significantly decreased in the light phase and in the 
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Figure 3. Hepatic lipogenic gene expression. A) Relative hepatic mRNA expression of Srebp-
1c (srebf1) in control mice (white bars) and mice treated with rimonabant (black bars) on 
either chow (LF), HF or HF/FO. Results are normalized to β-actin. Values are means ± SEM for 
n=3-8 mice per group. HF C versus chow C * p = 0.027, HF/FO C versus HF C † p = 0.003. B) 
Relative hepatic mRNA expression of Fasn in control mice (white bars) and mice treated with 
rimonabant (black bars). Results are normalized to β-actin. Values are means ± SEM for n=3-8 
mice per group. HF C versus chow C * p = 0.019, HF/FO C versus HF C † p = 0.001. C) Relative 
hepatic mRNA expression of Acc1 (Acaca) in control mice (white bars) and mice treated with 
rimonabant (black bars). Results are normalized to β-actin. Values are means ± SEM for n=3-8 
mice per group. HF C versus HF/FO C * p = 0.012, HF/FO C versus chow C † p = 0.034. D) Relative 
hepatic mRNA expression of Acc2 (Acacb) in control mice (white bars) and mice treated with 
SR141716 (black bars). Results are normalized to β-actin. Values are means ± SEM for n=3-8 
mice per group. HF C versus HF/FO C * p = 0.007, HF/FO C versus chow C † p = 0.013. FO, fish 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effects of rimonabant treatment on food intake and ‘food efficiency’ and 
fecal energy excretion in C57BL/6J mice on different diets
We observed no effect of administering the CB
1
-receptor antagonist on food intake in 
the chow-fed treatment group as compared with the chow-fed control group. However, 
after start of treatment, food intake was significantly lower in the HF treatment group 
and in the HF/FO treatment group. The effects on food intake diminished during the 
first week of treatment. At day 4, there was no difference in food intake between the 
HF treatment group and the HF control group anymore, and after 10 days the difference 
in food intake had also disappeared between the HF/FO treatment group and the HF/
FO control group (data not shown). The cumulative caloric intake calculated for the 
treatment period was significantly reduced in the HF/FO treatment group as compared 
with that in the HF/FO control group (HF/FO treatment versus HF/FO control p < 
0.001), and in the HF treatment group compared with that in the HF control group (HF 
treatment versus HF control p = 0.02), as is illustrated in Figure 1c. However, there were 
no significant differences in the cumulative caloric intake calculated from day 11 until 
day 22 (Figure 1d), illustrating the observation that the effect of treatment with a CB
1
-
receptor antagonist on food intake is transient.
 To assess if decreased absorption could contribute to decreased weight gain in 
treated mice, we measured residual energy contents in feces by bomb calorimetric 
analysis of feces collected over a period of 48 h. Treatment with CB
1
-receptor 
antagonist had no significant effect on fecal energy excretion on either diet (Figure 2a) 
and calculated as absorbed energy (food intake in kcal 24h-1 minus residual fecal energy 
in kcal 24h-1) the amount of absorbed energy was not affected by treatment (Figure 2b).
 On all three diets, rimonabant treatment led to a significant reduction in food 
efficiency (Figure 2c; chow treatment versus chow control, p = 0.002; HF treatment 
versus HF control, p = 0.001; HF/FO treatment versus HF/FO control, p < 0.001). There 
was a significant interaction between diet and treatment (p = 0.027). Indeed, effect of 
treatment was most prominent in the HF/FO treatment group as compared with that in 
the HF/FO control group. Again, this was a consequence of higher food efficiency in the 
HF/FO control group rather than of lower food efficiency in the HF/FO treatment group. 
Effects of rimonabant treatment on RQ and oxygen consumption in 
C57BL/6J mice on different diets
Table 4 shows that treatment with rimonabant significantly reduced the RQ during both 
the light phase and the dark phase in the chow-fed mice (light-phase chow treatment 
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versus chow control p = 0.004, dark-phase chow treatment versus chow control 
p < 0.001) and in the HF-fed mice (light-phase HF treatment versus HF control p = 0.003, 
dark-phase HF treatment versus HF control p = 0.033). In the HF/FO treatment group, 
a significant reduction in RQ as compared with that in the HF/FO control group was 
only observed in the dark phase (HF/FO treatment versus HF/FO control p = 0.011). 
A significant increase in lipid oxidation and a significant decrease in carbohydrate 
oxidation was observed in the chow-fed mice upon rimonabant treatment in the light 
phase as well as in the dark phase. There was no treatment effect on lipid oxidation 
in the HF groups nor in the HF/FO groups. Yet, there was a significant decrease in 
carbohydrate oxidation in the HF treatment group as compared with that in the HF 
control group in the light phase and in the dark phase, and in the HF/FO treatment 
group compared with that in the HF/FO control group only in the dark phase. 
Rimonabant treatment did not affect oxygen consumption or energy expenditure as 
calculated from indirect calorimetry data, neither in the light phase nor in the dark 
phase in any of the groups (Table 4).
Discussion
In the present study, we compared the effects of treatment with rimonabant, a 
selective endocannabinoid CB
1
-receptor antagonist, on food intake and on hormonal 
and metabolic characteristics, in young adult mice fed diets with differences in the 
total amount and ratio of SFA versus PUFA. Despite notable differences in hormonal 
and metabolic profiles among mice fed the different experimental diets, we found that 
rimonabant treatment prevented weight gain and improved metabolic derangements, 
without major differences in energy intake and expenditure. This highlights a role for 
the ECS in triglyceride deposition in adipose tissue as well as in the liver irrespective of 
dietary fat content or composition. 
 Compared with mice fed a fibered chow, carbohydrate-rich diet, feeding a diet 
with HF content caused increase in body fat mass and hyperleptinemia, and a massive 
increase in hepatic triglyceride content in mice. These well-known derangements are 
major risk-factors for development of hepatic steatosis and type-2 diabetes mellitus.29-31 
The increased hepatic fat deposition – being a hallmark of the metabolic syndrome - 
appeared to be abolished when mice were fed a diet with a fat content similar as the 
aforementioned HF diet, but in which 10 % of the SFA were replaced by PUFA derived 
from FO (HF/FO diet). We observed, however, that lipid deposition inside adipose tissue 
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as well as plasma leptin levels were greatly augmented in HF/FO-fed mice as compared 
with that in those fed the HF diet. 
 The finding that a 10% displacement of SFA by PUFA caused a reduction of hepatic 
triglyceride deposition almost back to the level observed in the chow-fed mice fits 
well with the documented effects of PUFA to stimulate hepatic lipid utilization,32 and 
to reduce hepatic lipogenesis.23 Indeed, mice in the present study fed the HF/FO diet 
showed reduced hepatic gene expression levels of lipogenic enzymes Srebp-1c, Acc1, 
Acc2 and Fasn compared with those observed in the HF group. In addition, the rate of 
lipid oxidation assessed by indirect calorimetry was clearly highest in the HF/FO group. 
For these reasons, it is counterintuitive that ingestion of a HF/FO diet potentiated the 
level of body adiposity well above the levels observed in the HF and chow group. Mice 
fed the HF/FO diet showed significantly elevated plasma levels of adiponectin, which 
could have, in part, prevented fat deposition in extra-adipose tissues, and at the same 
time, mediated the increased expansion of adipose tissue in this group. Such an effect 
has been proposed by Kim et al.,33 who showed that overexpression of adiponectin 
leading to elevated plasma adiponectin levels, also led to increased adipose tissue mass. 
Like in our study, the increased plasma adiponectin levels together with expanded fat 
mass were associated with normalization of hepatic and plasma lipid profiles. Another 
issue relevant to the beneficial effect of the HF/FO diet on metabolic endpoints while 
enhancing fat mass (that is, relative to those observed in the HF diet condition), is the 
observation that the HF/FO diet seems to augment, percent-wise, the subcutaneous fat 
depot (subcutaneous adipose tissue) more than the visceral fat depot (visceral adipose 
tissue) as compared with the HF diet, and with respect to the corresponding values 
at day 22 in the chow diet. While both diets augment subcutaneous adipose tissue 
more than visceral adipose tissue, the difference is approximately 20% higher with 
the HF/FO diet. In view of the well-established strong connections between visceral 
adipose tissue and some metabolic disorders,34 this perhaps may have contributed to 
the higher adiponectin levels (despite the stronger increase in body weight) and also to 
the beneficial effects of on hepatic lipogenesis observed with the HF/FO diet.
 The exaggerated expansion of adipose tissue of HF/FO-fed mice as compared 
with the other groups could not be attributed to an increase in food intake or to an 
increased gastrointestinal absorption rate, which indicates that these animals were 
more ‘food efficient’ than those fed the HF and chow diet. Indeed, calculation of body 
weight gain per absorbed energy content revealed a doubling of food efficiency in 
the HF/FO group as compared with that in the HF and chow groups. Food effciency 
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depends on energy expenditure (EE), which in turn is comprised of resting metabolic 
rate, activity thermogenesis, and thermic effects of food. Resting metabolic rate 
comprises thermogenesis, detoxification, maintenance of membrane potentials and 
tissue differentiation and tissue maintenance. EE during the light and the dark phase 
and resting metabolic rate calculated from indirect calorimetry were indeed lower in 
the HF/FO group as compared with that in the levels found in the HF group, which 
may have underlied the increased food efficiency and adipose tissue expansion in the 
HF/FO group relative to the HF group. Compared to the chow-fed mice, however, this 
lowering of EE and resting metabolic rate in the HF/FO group was not significant. This 
discrepancy of increased food efficiency and weight gain in the HF/FO group versus the 
chow group without alterations in EE may be explained by a shift between the various 
components of energy expenditure without affecting total energy expenditure. For 
example, a decrease in the thermic effects of food could make more energy available for 
storage and tissue expansion. We are currently performing experiments to specifically 
address these possibilities.
 As pointed out above, rimonabant treatment prevented weight gain and ameliorated 
adiposity in all three experimental diet groups despite marked differences in adiposity 
and metabolic profiles between the diet groups. After start of treatment with the CB
1
-
receptor antagonist, there was a slight and temporal reduction of food intake in the 
HF and HF/FO group, which explains the reduction in body weight by rimonabant-
treatment only to a limited degree. Since total absorbed energy (as assessed by bomb 
calorimetry of feces) was not different among groups, this indicates that body weight 
loss induced by treatment with rimonabant was mediated by changes in metabolism. 
In fact, rimonabant treatment rendered mice remarkably food inefficient, such that 
the diet-induced differences in food efficiency were entirely lost upon rimonabant 
treatment. However, the effects of rimonabant could not be explained by differences in 
metabolic rate since EE measured by indirect calorimetry was similar in treated versus 
non-treated mice in the respective diet groups. It is tempting to speculate that metabolic 
coupling was affected by rimonabant treatment in the different diet groups, which 
contributed to prevent weight gain. While efficiency of metabolic coupling as a potential 
mechanism has to be addressed, our results regarding discrepancies between weight 
loss by blockade of CB
1
-signalling, without changes in energy intake and expenditure 
corresponds with findings in several other recent studies.10,35 Reports that, in contrast 
to these results, do demonstrate an increase in EE in animals and humans treated with 
a CB
1
-receptor antagonist 19,36-38 frequently employ an acute rather than continuous 
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treatment. Kunz et al.36 clearly demonstrated rapid development of tolerance to 
rimonabant towards induction of oxygen consumption, stressing differences in effects 
of acute versus chronic treatment. Moreover, investigators frequently normalize EE and 
oxygen consumption to total body weight, thereby ignoring fat-free versus fat mass, 
which causes an over-estimation of EE when fat mass is lost without changes in lean 
mass.19,37 
 The effect of CB
1
-receptor antagonism to prevent weight gain and to ameliorate 
adiposity levels in the chow, HF, as well as HF/FO-fed mice corresponds with other 
studies showing treatment effects irrespective of diet composition.14-17,20 It is, however, 
rather surprising in light of the findings by others showing that HF diets given to mice 
cause dysregulation of the ECS, either via alterations in the expression of CB
1
-receptors, 
via alterations in the levels of endogenous ligands, or both.7,39-41 Also the fatty acid 
composition of dietary fat may influence endocannabinoid action.42 For example, the 
presence or absence of n-3 PUFA in the diet affects endocannabinoid levels in the brain, 
as shown by Berger et al.43 and Watanabe et al.44 Batetta et al.45 recently found that 
dietary n-3 PUFA can reduce inflammatory markers and liver triglyceride levels, and 
these effects were associated with lower levels of endocannabinoid ligands in peripheral 
organs. Finally, there is an in vitro study showing that n-3 PUFA can reduce the levels 
of both anandamide and 2-arachidonoylglycerol in differentiated mouse adipocytes, 
whereas n-6 PUFA (that is, arachidonic acid) were found to increase endocannabinoid 
levels.46 The efficacy of an antagonist such as rimonabant should depend on the extent 
of tonic activation of CB
1
-receptors by, among other things, endocannabinoids. Since 
n-6 PUFA content is relatively high in FO (that is, with a ratio of n-6/n-3 of 0.4 in the HF/
FO diet, and no n-6 at all in the HF diet), this may provide an explanation for the finding 
that rimonabant is more efficacious in mice fed the HF/FO diet to induce weight loss in 
the present study. Associated with reversal of HF-diet-induced obesity by rimonabant, 
studies generally reported lowering of hepatic triglyceride accumulation and plasma 
leptin levels, and increased plasma adiponectin levels by rimonabant treatment.11,15,17,20 
The reversal of these comorbidities by rimonabant was not observed in the present 
study. It is possible that the discrepancy between the results of our study and others is 
due to differences in the age of mice and experimental duration. In our study, endpoint 
measurements were performed at 14 weeks of age, whereas in all other mice used were 
6 months or older, and mice in those studies were subjected to experimental diets for 
months.11,15,17,20 nevertheless, we did find profound inhibitory effects of the HF/FO diet 
on markers for hepatic lipogenesis relative to the HF diet condition. It was previously 
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suggested by Osei-Hyiaman et al. 11 that HF-diet-induced obesity was a consequence 
of increased lipogenesis (by increased hepatic Srebp-1c expression), with a permissive 
role for hepatic CB
1
-signalling in these effects. This is in contrast with our results that 
showed reduction of body weight gain in mice treated with rimonabant on all three 
diets, and, in fact, reduction of body weight gain was most pronounced in treated mice 
on the HF/FO diet in which lipogenesis was suppressed. Thus, our results suggest that 
suppression of hepatic lipogenesis does not play a role in the effect of rimonabant on 
body weight, at least in young adult mice. This fits with the most recent observation 
of Osei-Hyiaman et al.19 that liver-specific CB
1
-/- mice are not resistant to diet-induced 
obesity, whereas total CB
1
-/- mice are. 
 In conclusion, our results show that treatment with a CB
1
-receptor antagonist is 
not only effective in reducing body weight gain in mice fed a HF diet based on SFA, but 
that a significant reduction in body weight is achieved irrespective of dietary fat quality 
and quantity. Furthermore, the effect of chronic rimonabant treatment to limit body 
weight gain occurred independent of basic lipogenic activity and, in fact, appeared 
to be most pronounced in mice fed a diet with a mixed SFA/PUFA composition, by 
which lipogenic activity was lowest. Finally, we demonstrated that SFA replacement 
in a HF diet by PUFA not only results in improvement of HF-diet-induced metabolic 
derangements, but also in augmentation of adipose tissue stores. While the effects of 
dietary PUFA replacement in a HF diet on expansion of adipose tissue might allow the 
favourable effects of dietary PUFA on dyslipidemia and hepatic steatosis, this might be 
a risky trade-off in light of other disadvantageous effects of weight gain. Thus, if FO 
supplements are used to prevent the adverse metabolic effects of a Western-type diet 
in children and adolescents, based on the findings in the present study, the outcome will 
be an exacerbation of the development of obesity in young people. If other preventive 
measures (for example, exercise programs, avoiding Western-type diets, and so on) 
turn out to be fruitless, improvement of pharmacotherapy might remain the last resort 
for the treatment of obesity at exceedingly young age. 
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Hepatic expression of cannabinoid (CB) receptors is markedly upregulated in several 
liver diseases and may play a role in development of hepatic steatosis. To elucidate 




-/-) mice to diet-
induced hepatic steatosis, we measured hepatic lipogenic fluxes in CB
1
-/- mice and wild 
type (WT) littermates fed 1) a low-fat control diet, 2) a high-saturated fat diet (HF) 
which induces lipogenesis and steatosis, or 3) a HF diet in which part of the saturated 
fat was replaced by fish oil (HF/FO) that inhibits hepatic lipogenesis. Despite resistance 
of CB
1
-/- mice to HF diet-induced hepatic steatosis, we did not observe any suppression 
of de novo lipogenesis as assessed by incorporation of 13C-acetate into hepatic fatty 
acids in CB
1
-/- mice as compared with that in their WT littermates. In addition, we could 
confirm that VLDL-triglyceride production by the liver is not affected by ablation of 
the CB
1
-receptor. Since hepatic pools of C16:0 and C18:1 as well as hepatic C18:2 were 
decreased in HF diet-fed CB
1
-/- versus WT mice, resistance of CB
1
-/- mice to hepatic 
steatosis must be caused by decreased fatty acid delivery to the liver and/or increased 
fatty acid oxidation. Results of indirect calorimetry, showing significantly decreased 
respiratory quotients in CB
1
-/- mice fed either chow or HF diet as compared with that in 
their respective controls, are consistent with increased fatty acid oxidation.
Conclusions: Resistance of CB
1
-/- mice to a high-fat diet-induced hepatic steatosis cannot 
be attributed to suppressed hepatic lipogenesis nor to increased VLDL-production. A 
decrease in fatty acid uptake and/or an increase in fatty acid oxidation by the liver in 
CB
1
-/- mice more likely attribute to resistance to hepatic steatosis in CB
1
-/- mice. 
Lipid metabolism in resistance of CB
1




The metabolic syndrome comprises a cluster of risk factors (obesity, glucose intolerance, 
dyslipidemia and hypertension) for cardiovascular diseases and type 2 diabetes mellitus.1 
Non-alcoholic fatty liver disease (NAFLD), which predisposes to hepatic fibrosis and 
cirrhosis, is considered to represent the hepatic feature of the metabolic syndrome.2 The 





their endogenous ligands called endocannabinoids, has been recognized as a potential 
target for treatment and prevention of aspects of the metabolic syndrome. Anti-obesity 
effects of CB
1
-receptor antagonists are established in both animals and in humans.3,4 
Moreover, in rodents and in humans, pharmacological blockade of the CB
1
-receptor 
also favourably affects other risk factors of the metabolic syndrome in part independent 




-/-) in mice 
results in an obesity-resistant phenotype5-8 and CB
1
-/- mice are resistant to high-fat diet-
induced hepatic fat accumulation.8 Treatment with a CB
1
-antagonist reduces obesity 
and hepatic steatosis in Zucker rats.9 The role of the endocannabinoid system in the 
pathophysiology of liver disease has only recently become a focus of attention. Hepatic 
expression of cannabinoid receptors is relatively low in healthy subjects, but appeared 
to be markedly up regulated in patients with several liver diseases.10 CB
1
-receptors are 
not only implicated in the development of hepatic steatosis but also in the progression 
to fibrosis.10,11 Osei-Hyiaman and colleagues showed that liver-specific CB
1
-/- mice were 
not resistant to diet-induced obesity but that these mice did show an improved hepatic 
lipid profile suggesting that endocannabinoid signalling is involved in the development 
of hepatic steatosis independent of its effects on body weight.6 Since Osei-Hyiaman and 
colleagues showed induction of hepatic lipogenic genes and increased hepatic fatty acid 
synthesis upon pharmacological CB
1
-activation (by administration of the CB
1
-receptor 
agonist HU210), the endocannabinoid system has been implicated in control of de novo 
lipogenesis in the liver.6,8 However, other studies show opposing results. Noguieras et 
al. reported decreased mRNA expression of Scd-1 (desaturation) and observed no effect 
on lipogenic gene expression in adipose tissue and livers of rats treated with a CB
1
-
receptor antagonist compared with controls.12 For a better understanding of the role 
of endocannabinoids in the development of hepatic steatosis, it is essential to directly 
evaluate the relevant metabolic fluxes under physiological conditions since mRNA levels 
do not always reflect the magnitude of metabolic processes.1 Therefore, we directly 
quantified de novo lipogenesis and chain elongation in CB
1
-/- mice under various dietary 
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conditions. Effects of genetic disruption of CB
1
-receptors might be different in mice on 
diets that differ in fatty acid composition since it has been suggested that feeding high-
fat diets modifies endocannabinoid system activity in peripheral tissues.13,14 It should 
be realized, however, that suppression of lipogenesis is not the only mechanism by 
which CB
1
-blockade can prevent hepatic steatosis. For instance, reduced hepatic uptake 
of circulating fatty acids might also contribute as well as increased fatty acid oxidation 
and/or stimulation of VLDL-triglyceride production.2 
 To elucidate mechanisms underlying resistance of CB
1
-/- mice to diet-induced hepatic 
steatosis, we measured hepatic lipogenic fluxes (by determination of incorporation of 
13C-acetate into fatty acids followed by mass isotopomer distribution analysis) in CB
1
-/- 
mice and wild type (WT) littermates fed either 1) chow, 2) a high-saturated fat diet (HF) 
known to induce steatosis and lipogenesis, or 3) a HF diet in which part of the saturated 
fat was replaced by fish oil (HF/FO) as a lipogenesis-suppressing diet.15,16 Furthermore, 
we determined expression of genes involved in hepatic fatty acid uptake, transport 
and hepatic fatty acid oxidation and we quantified VLDL-triglyceride production in 
vivo to determine the contribution of these mechanisms to the reported resistance 
of CB
1
-/- mice to diet-induced steatosis. Finally, indirect calorimetry was performed to 





-/- on a C57BL/6J background and their WT littermates were bred in our facility. Initial 
breeding pairs were kindly provided by Prof. Dr. A. Zimmer, Laboratory of Molecular 
Neurobiology, University of Bonn, Germany. Mice were individually housed in a light-
controlled (lights on 4 AM- 4 PM) and temperature-controlled (21oC) facility. Mice were 
allowed tap water and food ad libitum. Experimental protocols were approved by the 
local Experimental Ethical Committee for Animal Experiments.
 
Experimental diets
All experimental diets were obtained from Abdiets BV, Woerden, The Netherlands. 
Mice received either standard laboratory chow (RMH-B), a high-fat diet (HF) containing 
36 weight % fat consisting of bovine fat (diet number 4031.45), or a high-fat diet 
containing 36 weight % fat consisting for 58% of bovine fat and for 42% of fish oil (diet 
number 4031.54). Composition of these experimental diets has been published before 
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(Supplemental Table 2).15 The HF/FO diet was replaced every two days to prevent 




-/- mice and WT littermates were divided into three groups by matching 
for body weight. For six weeks, each group was fed one of the three experimental diets. 
Intake and body weight were registered twice a week. 
 Mice were sacrificed under inhalation-anaesthesia by cardiac puncture, followed 
by cervical dislocation. Livers were removed, weighed, two small parts were kept apart 
for histology (frozen in isopenthane), the remainder of the liver was freeze clamped and 
stored at -80oC. Separate experiments were conducted for determination of lipogenic 
fluxes and quantification of VLDL-TG production rates in vivo.
Hepatic and plasma lipid analyses
Before further analysis, freeze-clamped frozen livers were crushed on liquid nitrogen 
and stored at -80 oC. For hepatic lipid extraction, frozen crushed livers were homogenized 
in ice-cold PBS. Hepatic lipids were extracted according to Bligh and Dyer17 and hepatic 
triglycerides and total cholesterol were measured using commercially available kits from 
Roche (Mannheim, Germany) and free cholesterol was measured using a commercially 
available kit from Wako Chemicals (Neuss, Germany). Phospholipid content of the liver 
was determined according to Böttcher et al.18 Protein concentrations in livers were 
determined according to Lowry et al. using bovine serum albumin as standard (Pierce).
Liver histology
Liver morphology was visualized by standard Hematoxilin Eosin (HE)-staining. Liver 
histology was further examined on frozen liver sections after standard Oil-Red-O 
staining for neutral lipids. 
Hepatic gene expression
Total RNA was isolated from frozen crushed liver using the TRI-reagent method 
(Sigma). Using random primers, RNA was converted to cDNA with M-MuLV Reverse 
Transcriptase (Sigma) according to the manufacturer’s protocol. For realtime-PCR, 
cDNA was amplified using the appropriate primers and probes. The sequences of the 
primers and probes for Srebp-1c (Srebf1), Fas (Fasn), Acc1 (Acaca), Acc2 (Acacb), Scd1, 
Cd36, Lcad (Acad1), Hmgcs2, Aox (Acox1) and Elovl6 have been published (http://www.
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labpediatricsRUG.nl Realtime Primers Datalist Pediatrics UMCG). For other primers and 
probes used in this study, sequences are listed in Supplemental Table 1. Relative gene 
expression levels were normalized to cyclophilin G expression. 
Determination of hepatic lipogenic fluxes in vivo
During the fifth week of the dietary manipulation, they were equipped with a permanent 
heart catheter via the right jugular vein, as described previously.19 Mice recovered their 
pre-operative body weights after 3-6 days following surgery, after which the actual 
experiment took place (week 6). They were kept on the experimental diets until the 
actual experiment. A baseline blood sample was taken from the tail of the mise after a 
three hour fasting period, before infusion of [1-13C] acetate was started (0.18 mmol/hr). 
After an infusion period of 6 hours, mice were anaesthetized with isoflurane, followed 
by cervical dislocation and removal of the liver. The liver was freeze clamped and stored 
at -80oC until further analyses.
 Liver homogenates were prepared in PBS and C17:0 was added as internal standard. 
Lipids were hydrolyzed in HCl/acetonitrile (1:22 v/v) for 45 minutes at 100 °C. Fatty acids 
were extracted in hexane and derivatized for 15 minutes at room temperature using 
α-Br-2,3,4,5,6-pentafluorotoluene (PFB) /acetonitrile /triethanolamine (1:6:2 v/v). 
Derivatization was stopped by adding HCl and fatty acid-PFB derivatives were extracted 
in hexane. The fatty acid-PFB isotopomer patterns were analyzed using a Agilent 
5975 series GC/MSD (Agilent Technologies, Santa Clara, CA). Gas chromatography 
was performed using a ZB-1 column (Phenomenex, Torrance, CA). Mass spectrometry 
analysis was performed by electron capture negative ionization using methane as 
moderating gas.
 To determine de novo fatty acid synthesis, mass isotopomer distribution analysis 
(MIDA) was applied. The theoretical background of MIDA is described in detail 





) were corrected for the fractional distribution due to natural abundance 
of 13C by multiple linear regression as described by Lee et al.21 to obtain the excess 




) due to incorporation of the infused 
labelled compound i.e. [1-13C]-acetate. This distribution was used in MIDA algorithms 
to calculate isotope incorporation and dilution according to Hellerstein et al.20 
Incorporation of [1-13C]-acetate into palmitate was assumed to solely result from de 





of palmitate were used to calculate the acetyl-CoA precursor pool enrichment (p
acetate
) 
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and fractional palmitate synthesis (f
C16:0
). Stearate is synthesized by chain elongation of 
de novo synthesized and/or pre-existing palmitate. The M
1
 mass isotopomer of stearate 
represents the sum of these two processes, while the M
3
 mass isotopomer solely 






 of palmitic, 
stearic and oleic acid were used to calculate fractional synthesis rates and to asses 
the contribution of de novo lipogenesis and chain elongation using the formulas as 
described previously by Oosterveer et al.15
Fatty acid profiles
Hepatic fatty acid composition was analyzed by gas chromatography after 
transmethylation using C17:0 as internal standard.22
VLDL-triglyceride production and VLDL-composition
In a separate experiment, in WT and CB
1
-/- mice, after being fed one of the three 
experimental diets for 6 weeks and after a fasting period of 3 hours, plasma lipolysis was 
blocked by intraperitoneal injection of Poloxamer 407 (0,1 mg/g body weight as a saline 
solution).23 Blood samples were obtained from the retro-orbital plexus under inhalation 
anaesthesia, before, 30 minutes, 120 minutes and 240 minutes after Poloxamer 407 
injection. To assess VLDL-TG-production rate, triglycerides were determined in these 
blood samples, using a commercially available kit (Roche, Mannheim, Germany). VLDL-
production rate was calculated from the slope of the triglyceride concentration versus 
time curve. Immediately after the last blood draw, mice were sacrificed by terminal 
cardiac puncture under inhalation anaesthesia followed by cervical dislocation and 
followed by removal of liver and adipose tissue. From the cardiac plasma sample, the 
plasma VLDL-fraction was isolated by ultracentrifugation. 
VLDL-isolation and analyses
Plasma VLDL/intermediate-density lipoprotein (density <1.006 g/ml) was isolated by 
density gradient ultracentrifugation. Hereto, 300 μl plasma was adjusted to 700 μl with 
a NaCl-solution of density 1.006 g/ml and centrifuged at 108,000 rpm for 125 minutes 
in a Optima LX tabletop ultracentrifuge (Beckman Instruments, Palo Alto, CA). The top 
layer containing the VLDL-fraction was isolated by tube slicing, and the volume was 
recorded by weight. VLDL-TG and cholesterol content of the nascent particles were 
determined as described.23 Phospholipid content was determined using a commercial 
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kit (Wako Chemicals). VLDL-particle diameter was estimated according to Fraser et al.24 
VLDL-particle volume was subsequently derived from its diameter.
Indirect calorimetry
Mice were placed in an open circuit indirect calorimetry system for 24 hours with 
access to water and food. Gas exchange measurements were performed in an eight-





 concentrations of dried inlet and outlet air from each chamber 
were measured every 10 minutes with a paramagnetic O
2
 analyzer and an infrared 
CO
2
 gas analyzer. Data were collected from each metabolic cage separately. The RQ 
(respiratory quotient) was defined as CO
2




All values in the figures and in the tables represent means ± standard errors of the 
means for the number of animals indicated in the figure and table legends. To evaluate 
effects of diet, genotype, and their interactions data were statistically analyzed using a 
general linear model with Bonferroni post hoc analyses. Treatment effects were further 
analyzed by Student’s t-test. In case of non-parametric distribution, Mann-Whitney 
U-test was assed for statistical analysis. Statistical significance of differences was 
accepted at a p-value of less than 0.05. Analyses were performed using SPSS 16.0 for 




-/- mice are resistant to high-fat diet-induced hepatic steatosis
Exposure of WT mice to the HF diet for 6 weeks resulted in significantly increased 
hepatic triglyceride (TG) contents as compared with that in mice fed either chow or HF/
FO (Figure 1A). Hepatic total cholesterol and hepatic cholesterol ester contents were 
also elevated in WT mice fed HF diet as compared with that in WT mice fed chow or 
HF/FO diet (Table 1). There were no significant differences in liver weights between the 
WT mice fed either one of the three experimental diets. HF-fed CB
1
-/- mice did show a 
decreased hepatic TG content and a significantly decreased liver weight as compared 
with that in HF-fed WT controls (Figure 1A and Table 1). Thus, as expected, CB
1
-/- mice 
are resistant to HF diet induced hepatic steatosis. Although genetic ablation of the CB
1
-
receptor had a significant effect on liver TG content, hepatic morphology/histology were 
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still minimally affected as illustrated by Figure 1B. The absence of significant differences 
in plasma transaminase levels indicate that feeding the HF diet to WT mice at this age, 
despite the presence of hepatosteatosis, did not damage hepatocytes (Table 1). 
No effects of CB
1
-deficiency on hepatic lipogenesis
In WT mice, key genes of lipogenesis showed a small increase in hepatic expression, i.e., 
Srebp-1c, Fas, Acc2 and Scd1, when fed a HF diet compared with chow: only differences 
in Acc2 and Scd1 were statistically significant (Figure 2). Expression of lipogenic genes 
was suppressed in HF/FO-fed mice, as expected.16 
 Based on the previously suggested involvement of endocannabinoids in regulation 
of hepatic lipogenesis,6,8 we expected to find effects of genotype on hepatic expression 
of lipogenic genes and on fractional synthesis of fatty acids. However, compared with 
WT mice, we did not observe any specific difference in the expression of lipogenic 
genes in CB
1
-/- mice fed either one of the three diets (Figure 2).
 In agreement with gene expression data, the results of MIDA analysis revealed 
no significant differences in lipogenic pathways between CB
1
-/- mice and WT mice fed 
either one of the three experimental diets. Figure 3 and Table 2 illustrate the effects 
of both diet and genotype on hepatic de novo lipogenesis. Calculated enrichments of 
the acetyl-CoA pools showed no dietary effects, however, values in CB
1
-/- mice were 
higher in the HF-condition as well as in the HF/FO condition, suggesting a decreased 
turnover of the acetyl-CoA pool in the CB
1
-/- mice. The fractional contribution of de 
novo lipogenesis to hepatic palmitic acid and to hepatic stearic acid were increased 
in WT mice fed HF diet as compared with that in WT mice fed chow whereas WT mice 
fed HF/FO showed a decrease in the fraction of de novo synthesized palmitate but no 
effect for stearic acid (Table 2). In parallel with our results on hepatic lipogenic gene 
expression, we did not observe any effect of genotype on fractional contribution to 
de novo lipogenesis of hepatic palmitic acid and hepatic stearic acid. Thus, hepatic 
lipogenesis was not suppressed in CB
1
-/- mice. 
 In agreement with our results on expression of genes involved in elongation 
showing an induction of Elovl6 in mice fed HF diet (Figure 2f), fractional contribution 
of chain elongation of existing palmitate to stearic acid, in particular in case of de novo 
synthesized stearic acid, was increased in WT mice fed HF diet (Table 2). Despite the 
observed significantly decreased expression of Elovl6 in CB
1
-/- mice fed HF diet (Figure 
2f), we found no genotype effect in fractional contribution of chain elongation of 
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Figure 1 A) Hepatic triglyceride content after 3h of fasting in cannabinoid-1 receptor deficient 
(CB
1
-/-) mice and in wild type (WT) mice fed chow, high-fat (HF) diet or high-fat fish-oil 
enriched (HF/FO) diet. Open bars, WT mice; closed bars, CB
1
-/- mice. Values are means +/- SEM; 
n = 6-8; * p < 0.05 chow versus HF, ‡ p < 0.05 HF versus HF/FO, # p < 0.05 HF CB
1
-/- versus HF WT, 
§ p < 0.05 HF/FO CB
1
-/- versus HF/FO WT. B) Liver histology. Oil-Red-O staining of frozen liver 
sections of WT mice and CB
1






























































































































































































































Figure 2. Hepatic expression of genes involved in lipogenesis and elongation. Relative hepatic 
mRNA expression of a) Srebp-1c, b) Fas, c) Acc1, d) Acc2, e) Scd1, and f) Elovl6 in cannabinoid-1 
receptor deficient (CB
1
-/-) mice (closed bars) and in wild type (WT) mice (open bars) fed chow, 
high-fat (HF) diet or high-fat fish-oil enriched (HF/FO) diet. Results are normalized to cyclophilin 
G. Values are means +/- SEM; n=5; * p < 0.05 chow versus HF, † p  <0.05 chow versus HF/FO, 
‡ p < 0.05 HF versus HF/FO, # p < 0.05 HF CB
1
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Figure 3. Hepatic lipogenesis in cannabinoid-1 receptor deficient (CB
1
-/-) mice (closed bars) 
and in wild type (WT) mice (open bars) fed chow, high-fat (HF) diet or high-fat fish-oil enriched 
(HF/FO) diet, assessed by incorporation of labelled acetate. Absolute synthesis rates are 
expressed as micrograms per gram liver per hour. Values are means +/- SEM; n = 6-7; * p < 0.05 
chow versus HF, † p < 0.05 chow versus HF/FO, ‡ p < 0.05 HF versus HF/FO. A) Absolute palmitate 
synthesis from de novo lipogenesis, B) Absolute stearate (C18:0) synthesis from elongation of 
de novo synthesized (C16:0*) palmitate, C) Absolute stearate (C18:0) synthesis from elongation 
of pre-existing (C16:0) palmitate, D) Absolute oleate (C18:1) synthesis from elongation of de 




Reduced uptake of circulating fatty acids or increased fatty acid oxidation 
indicated by hepatic fatty acid profiles of CB
1
-/- mice
Hepatic lipid accumulation may also be prevented in CB
1
-/- mice by a decreased uptake 
of circulating fatty acids into the liver and/or an increased hepatic fatty acid oxidation. 
In parallel with reduced TG content in livers of CB
1
-/- mice fed HF diet, fatty acid profiles 
of livers of CB
1
-/- mice fed HF diet revealed reduced pools of the three major fatty acids 
comprising the hepatic TG pool; C16:0, C18:1 and C18:2 (Table 1). Since C18:2 is an 
essential fatty acid, reduction in hepatic pool of C18:2 suggests that reduced TG content 
in livers of CB
1
-/- mice fed HF diet as compared with that in WT littermates on the same 
diet is either due to decreased uptake of fatty acids or increased fatty acid oxidation. 
However, we did not find any genotype effect on expression of genes involved in hepatic 
uptake of fatty acids from the circulation nor on expression of genes involved in fatty 
acid oxidation to support this suggestion (Table 3).
Decreased respiratory quotients in CB
1
-/- fed chow or HF diet are in support 




Figure 4 shows respiratory quotients (RQ) in the dark and in the light period. As 
expected, in both the dark and light period RQ were significantly higher in mice fed 
chow as compared with that in mice fed either HF diet or HF/FO diet. Interestingly, 
CB
1
-/- mice fed chow and HF diet exhibited significantly decreased RQ in the light period 
as compared with WT controls, indicating an increase in the ratio of fatty acid oxidation 
to carbohydrate oxidation. 
VLDL-TG production is not affected by CB
1
-receptor-deficienc. 
VLDL-TG production rates were similar in WT mice fed chow and WT mice fed HF 
diet. VLDL-TG production rate was significantly decreased in mice fed HF/FO diet as 
compared with that in mice fed the HF diet, as expected. CB
1
-deficiency did not affect 
VLDL-TG production rate (Table 4). CB
1
-deficiency also did not affect VLDL-composition 
as shown in Table 4. Particle size was increased in WT mice fed HF diet as compared 
with that in WT mice fed HF/FO diet. 
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Figure 4. Respiratory quotients (RQ) in A) the dark phase or B) the light phase in cannabinoid-1 
receptor deficient (CB
1
-/-) mice (closed bars) and in wild type (WT) mice (open bars) fed chow, 
high-fat (HF) diet or high-fat fish-oil enriched (HF/FO) diet. Values are means +/- SEM; n = 6-7; 
* p < 0.05 chow versus HF, † p < 0.05 chow versus HF/FO, # p < 0.05 chow CB
1
-/- versus chow 
WT, $ p < 0.05 HF CB
1
-/- versus HF WT.
Discussion
The presented data confirm earlier findings from our laboratory that lipogenesis is 
increased in mice fed a HF diet and that it is suppressed by feeding a HF/FO diet.15,16 
WT mice fed a HF diet showed hepatic lipid accumulation, whereas CB
1
-/- mice were 
resistant to this diet-induced hepatic steatosis, as reported by Osei-Hyiaman et al.6,8 
However, our data unequivocally demonstrate that this resistance to development 
of hepatic steatosis cannot be attributed to a failure to induce hepatic lipogenesis 
as proposed by Osei-Hyiaman et al. Using an adapted MIDA procedure, we showed 
that both lipogenesis as well as chain elongation were unaffected by CB
1
-receptor 
deficiency.15 Likewise, an enhanced production of TG-containing VLDL particles was 
shown not to be the cause of the resistance to diet-induced hepatic steatosis in the 
absence of CB
1
-signalling. Instead, our results indicate that altered fat distribution may 
contribute to absence of the diet-induced phenotype in CB
1
-/- mice. 
 The anticipated significant increase in hepatic TG content in WT mice fed HF diet 
(as compared with that in WT mice fed chow) and the blunting of this HF diet effect 
in CB
1
-/- mice correspond with findings of others showing that rodents treated with a 
CB
1
-receptor antagonist as well as CB
1
-/- mice are resistant to HF diet-induced hepatic 
steatosis.6,8,9 Pair-feeding studies have shown that beneficial effects of CB
1
-blockade 
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on hepatic steatosis are independent of food intake and body weight.9 Furthermore, 
Osei-Hyiaman and colleagues demonstrated that liver-specific CB
1
-/- mice had reduced 
hepatic steatosis as compared with WT mice, but this appeared to be independent 
of the persistence of HF-diet induced obesity in these liver-specific CB
1
-/- mice. This 
suggests that the endocannabinoid tone affecting resistance/proneness to diet-
induced hepatic steatosis is localized in the liver and is presumably independent of 
changes in body weight.6 The implication of CB
1
-receptors in development of hepatic 
steatosis and the established contribution of CB
1
-receptors to the progression of 
hepatic steatosis to hepatosteatitis, fibrosis and cirrhosis, makes the ECS an interesting 
target for the development of drugs aimed to prevent or treat NAFLD. Osei-Hyiaman 
and colleagues demonstrated that hepatocytes express CB
1
-receptors, activation of 
which by a synthetic ligand induced hepatic lipogenic gene expression and increased 
hepatic de novo fatty acid synthesis in vivo.8 These authors suggested accordingly that 
endocannabinoid activation of hepatic CB
1
-receptors likely contributes to HF diet-
induced steatosis via stimulation of hepatic lipogenesis.6,8 However, others have found 
no involvement of CB
1
-signalling in the control of hepatic lipogenesis.12 To resolve the 
controversy regarding the role of CB
1
-receptors in hepatic lipogenesis, we re-evaluated 
findings of Osei-Hyiaman and colleagues with the additional differentiation between 
de novo lipogenesis and elongation of pre-existing fatty acids. This differentiation is 
not possible using the methodology of Osei-Hyiaman et al.6,8 The relative contribution 
of circulating fatty acids accounts for ~60% to hepatic triglyceride content in NAFLD 
patients, while that of dietary and de novo synthesized fatty acids is ~10% and ~30%, 
respectively. It is therefore of great interest to assess whether induction of lipogenesis 
and the role of the endocannabinoid system herein represents increased de novo 
lipogenesis, increased chain elongation, or both.25
 In agreement with our earlier observations and results of others,15,16 we found an 
overall induction in hepatic lipogenic gene expression (Srebp-1c, Fas, Acc2) paralleled 
by an increased de novo hepatic lipogenesis in HF-fed WT mice as compared with that 
in WT mice fed chow. A suppression of these parameters was observed in WT mice fed 
HF/FO diet as compared to WT mice fed chow. We did not observe, however, an effect 
of genotype on any of these parameters. In part, these results correspond to findings 
of Nogueiras and colleagues, who reported no effect of CB
1
-blockade on hepatic lipid 
metabolism in diet-induced obese rats.12 Consistently, we did not find a lower hepatic 
de novo lipogenesis in CB
1
-/- mice fed HF diet compared with WT littermates receiving 
the same diet and there was no genotype effect on fractional contribution of chain 
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elongation of pre-existing palmitate to hepatic stearic acid and oleate synthesis. HF/FO-
fed CB
1
-/- mice showed a significant decrease in hepatic triglyceride content, similar to 
what was observed in WT mice fed HF/FO diet. Taken together, this argues against the 
idea that inhibited lipogenesis plays a major role in the resistance of CB
1
-/- mice against 
hepatic steatosis.
 The discrepancy between our results and findings reported by Osei-Hyiaman and 
colleagues on the role of CB
1
-receptors in de novo hepatic lipogenesis seems to be 
related to methodological differences.6,8 Osei-Hyiaman et al. determined tritiated 
water incorporation into the total hepatic lipid pool (including cholesterol) following 
an overnight fast. In the current study, we quantified de novo lipogenic and elongation 
fluxes upon incorporation of the labelled C2 fatty acid precursor acetate into particular 
hepatic fatty acids (i.e., C16:0, C18:0, C18:1), which provides a more specific measure 
for lipogenic fluxes. Our results reflecting postprandial conditions showed no genotype 
effect on fatty acid synthesis, whereas Osei-Hyiaman et al. did find decreased total 
lipid synthesis in overnight-fasted CB
1
-/- mice fed HF diet compared with WT littermates 
receiving the same diet. Altogether, these data suggest a temporal effect, possibly 
as a consequence of a differential regulation of lipogenesis under postprandial and 
fasted conditions. Lipogenesis is regulated by many different factors (i.e., SREBP-1c, 
ChREBP, LXR, FXR, PPARs) and, apparently the mechanisms regulating hepatic de novo 
lipogenesis interact with CB
1
-signalling under specific metabolic conditions (i.e., after 
an overnight fast). Finally, an effect of differences in duration of dietary intervention in 
our study (i.e., 6 weeks) and the one performed by Osei-Hyiaman and colleagues (i.e., 
3 weeks) cannot be ruled out, although this is likely less explanatory than the previous 
arguments.
 LC-PUFA (long chain polyunsaturated fatty acids) diets have been reported to affect 
concentrations of endocannabinoid ligands. Therefore, it has been suggested that LC-
PUFA-rich diets might have similar effects as (pharmacological) CB
1
-antagonism.14,26 
In our experiments, HF/FO diet and CB
1
-inactivation indeed exerted similar effects on 
hepatic lipid deposition, but this appeared to be mediated via distinct mechanisms. For 
example, lipogenesis was found to be suppressed by feeding HF/FO diet, but not by CB
1
-
ablation. In fact, data presented in Table 2 and Figure 3 seem to indicate that the effect 
of feeding a HF/FO diet on hepatic de novo lipogenesis is even stronger in the absence 
of CB
1
-signalling, indeed suggesting mechanisms acting parallel to signalling via CB
1
. 
Thus, these findings indicate to our opinion that suppression of hepatic lipogenesis 
by dietary PUFA does not involve modifying endocannabinoid tone as was suggested 
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earlier. Moreover, endocannabinoid tone in itself possibly reduces suppression of 
hepatic lipogenesis by LC-PUFA. 
 The fatty acid profile we observed showed reduced hepatic levels of three 
predominant TG-derived fatty acids (16:0, 18:1 and 18:2) in livers of CB
1
-/- mice as 
compared with that in WT littermates receiving the same diet. Since C18:2 is an essential 
fatty acid, either decreased uptake from the circulation or increased oxidation has to 
contribute to the smaller hepatic C18:2 pool in CB
1
-/- mice. The mechanism underlying 
this putative decrease in uptake is expected to be related to the liver itself since Osei-
Hyiaman et al. showed that HF-fed liver-specific CB
1
-deficient mice are resistant to 
hepatic steatosis despite their obese phenotype. We speculated that down-regulation 
of transporters of fatty acids in the liver could be involved in this, but we did not observe 
differences between CB
1
-/- mice and WT littermates in hepatic expression of Cd36, Fatp5 
and L-Fabp, all involved in hepatic fatty acid uptake and transport (Table 3). We cannot 
exclude that CB
1
-receptor-deficiency is associated with post-transcriptional regulation 
of the expression of these proteins. 
 Both VLDL-production rate and VLDL-composition were not altered by CB
1
-
deficiency. Therefore a change in VLDL-production cannot explain resistance of 
CB
1
-/- mice to the development of hepatic steatosis. This corresponds with data of 
Ruby et al. who quantified VLDL-production rate in mice treated with a CB
1
-receptor 
antagonist.27 Another possible mechanism of resistance to hepatic steatosis is through 
increased fatty acid oxidation. Increased fatty acid oxidation has indeed been proposed 
to contribute to the protection against lipid accumulation in CB
1
-/- mice. Herling and 
colleagues demonstrated increased energy expenditure and increased calculated fat 
oxidation upon treatment with a CB
1
-receptor antagonist in female rats receiving candy 
diet compared with pair-fed controls.28 Osei-Hyiaman and colleagues demonstrated a 
decreased CPT-1 (carnitine palmitoyltransferase-1) activity in mice treated with a CB
1
-
receptor agonist and this decrease was absent in both global and liver-specific CB
1
-/- 
mice.6 Although we did not observe an induction of fatty acid oxidation genes in livers 
of CB
1
-/- mice compared with WT mice, on whole body level indirect calorimetry did 
reveal a significant decrease in respiratory quotient in the light phase in CB
1
-/- mice 
fed HF diet as well as in CB
1
-/- mice fed chow as compared with that in their respective 
littermates. This finding suggest increased fatty acid oxidation in CB
1
-/- mice fed HF diet 
or chow, however, this is measured on whole body level. Therefore, no conclusions on 
liver-specific alterations in fatty acid oxidation can be drawn from such analysis. 
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 In conclusion, resistance of CB
1
-/- mice to diet-induced hepatic steatosis can not 
be attributed to suppression of hepatic lipogenesis or to an increase in VLDL-TG 
production. Our data suggest that reduced hepatic entry of fatty acids may contribute 
to resistance to develop hepatic steatosis in HF-fed CB
1
-/- mice; however, increased 
fatty acid oxidation during certain phases of the day may be a contributing factor. 
Our data indicate that future research on the relation between hepatic steatosis and 
endocannabinoid signalling should focus on the effect of endocannabinoid signalling on 
hepatic uptake of circulating fatty acids and fatty acid oxidation. 
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Overactivity and/or dysregulation of the endocannabinoid system (ECS) contribute 
to the development of obesity. In vitro studies indicate a regulatory role for the 
cannabinoid receptor 1 (CB
1






mice are resistant to high fat diet-induced obesity. Whether this phenotype of CB
1
-/- 
mice is related to altered fat metabolism in adipose tissue is unknown. In the face 
of expected changes in energy balance we evaluated adipose tissue differentiation/





+/+ mice that were fed a high-fat (HF) or a high-fat/fish oil (HF/FO) diet as 
compared to animals receiving a normal low-fat chow diet. The comparison between 
the HF diet and the HF/FO diet allowed us to investigate the influence of dietary fat 
quality on adipose tissue biology in relation to CB
1
-functioning. The obesity-resistant 
phenotype of the CB
1
-/- mice was characterized by a lower adiposity index and reduced 
adipocyte size in HF and HF/FO-fed CB
1
-/- as compared to CB
1
+/+ mice. This was not 
associated with changes in expression of adipocyte differentiation/proliferation 




+/+ mice fed 
either of the three diets and fatty acid synthesis rates were unaffected. Whole-body and 
adipose-derived lipoprotein lipase (LPL) activities were also not altered in CB
1
-/- mice. 
Energy expenditure, however, was slightly but significantly increased in CB
1
-/- mice fed 
the HF and HF/FO diets.
In conclusion, these data indicate that protection against diet-induced obesity in CB
1
-
deficient mice is not related to changes in adipocyte function per se, but may rather 
result from an increased energy loss by oxidative and non-oxidative pathways. 






The endocannabinoid system (ECS) comprises the endogenous cannabinoids (endo-
cannabinoids), the cannabinoid receptors and the enzymes involved in the synthesis 
and degradation of endocannabinoids.1 The two most abundant endocannabinoids 
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are amides and esters, 
respectively, of long-chain polyunsaturated fatty acids (LC-PUFA).2 To date, two G 
protein-coupled cannabinoid receptors through which endocannabinoids exert their 
actions have been identified. Because of its role in the central regulation of food intake 
and energy balance, the cannabinoid 1 (CB
1
)-receptor has emerged as an interesting 
drug target for treatment of obesity, dyslipidemia and insulin resistance. CB
2
-receptors, 
on the other hand, are mainly involved in immune function.3 Administration of 
(endo)cannabinoids increases food intake, while CB
1





-/-) mice are lean and have less fat stores 
compared to their wild type (WT) littermates.5 This reduction in adiposity appears to be 
independent of food intake,5 suggesting that CB
1
-deficiency alters the balance between 
energy intake, utilization and storage. 
 CB
1
-receptors are localized in the brain, peripheral nerves and several peripheral 
organs including liver and adipose tissue.3 Particularly, adipose tissue represents an 





activity is critical for adipocyte function.5-7 CB
1
-expression has been reported 
to increase during adipocyte maturation8 and endocannabinoids are required for 
adipocyte differentiation and growth,7,9,10 supposedly by promoting lipid storage7,11-13 
via the induction of Fas, Scd1 and Dgat2 expression and/or by increasing lipoprotein 
lipase (LPL)-mediated fatty acid uptake.5,7 In line with these results, CB
1
-receptor 
antagonism has been shown to arrest adipocyte proliferation and to reduce lipogenic 
gene expression.7,13 Interestingly, growth retardation in CB
1
-/- mice is already apparent 
during the first weeks of life.5 Appropriate CB
1
-receptor functioning may therefore be 
critical for adipose tissue development in vivo.Overactivity and/or dysregulation of 
the EC system have been proposed to contribute to the development of obesity.6,11,14 
High-fat (HF) feeding induces obesity in rodents and has been reported to increase the 
endocannabinoid tone in their adipose tissue11,15 and CB
1
-deficient mice are resistant 
to HF diet-induced obesity.16 Interestingly, different types of dietary fats exert specific 
effects on body weight regulation17 and n-3 PUFA have been shown to decrease 





signalling directs metabolism towards fat storage7,11 while reducing fat catabolism.6,11,19 
The protection against diet-induced obesity in CB
1
-deficient mice may therefore, at 
least in part, be related to changes in fat cell metabolism in these animals. However, 
very few studies have evaluated the consequences of CB
1
-ablation for fat cell biology 
in vivo. Furthermore, it is unknown whether CB
1
-receptor mediated changes in adipose 
tissue function contribute to HF diet induced obesity in rodents. 
 In the face of the expected changes in energy balance, we determined the 
expression of differentiation/proliferation markers and quantified the rate of fatty acid 
synthesis and LPL-activity in vivo in the epididymal fat pads of young WT and CB
1
-/- mice 
receiving a standard, low-fat chow diet, a high-fat (HF) or a HF diet in which part of 
the fat was replaced by fish oil (HF/FO). The comparison between the two different 
HF diets allowed us to investigate the influence of dietary fat quality in relation to CB
1
-
functioning in adipose tissue. 
Methods
Animals and experimental design
Male WT and CB
1
-/- mice on a C57BL/6J background were bred within our own facility 
from heterozygous crossing. Initial breeding pairs were kindly provided by prof. dr. A. 
Zimmer, Laboratory of Molecular Neurobiology, Department of Psychiatry, University 
of Bonn, Germany. Animals were housed under light- and temperature-controlled 
conditions (lights on 4:00 AM-4:00 PM, 21°C) with free access to food and drinking 
water. From four weeks of age onwards, they were divided into groups and fed three 
different diets during six weeks. All diets were obtained from Abdiets, Woerden, 
The Netherlands. One group received normal laboratory chow (RMH-B), the second 
group received HF (beef tallow) diet and the third group received a diet in which 42% 
(w/w) of the beef tallow was replaced by fish oil (HF/FO diet; menhaden oil). For diet 
composition see Supplemental Table 2. The HF/FO diet was renewed three times per 
week to prevent oxidation. Body weight and food intake were registered regularly. 
During the 5th week of dietary intervention, feces were collected over a 72-hour period. 
Fecal energy content was determined as previously described.20 Prior to all experiments, 
mice were subjected to a short postprandial fasting period of 3 hours (6-9 AM) with 
drinking water available to exclude acute postprandial effects without the induction of 
a fasting response. Experimental procedures were approved by the Ethics Committees 
for Animal Experiments of the University of Groningen. 





Fat cell histology, plasma metabolite and gene expression analysis
Mice were sacrificed by cardiac puncture under isoflurane anaesthesia. Adipose tissue 
was quickly removed, snap-frozen in liquid nitrogen and stored at -80°C. Part of the 
epididymal adipose tissue was fixed in 4% paraformaldehyde in PBS and embedded in 
paraffin. For adipocyte histology, 3 µm paraffin sections were stained with hematoxylin 
and eosin and analyzed at 10x magnification. The area of 240-420 fat cells per group 
was quantified using image analysis software (Qwin, Leica, Wetzlar, Germany). Fat 
cell area data were analyzed using the percent relative cumulative frequency (PCRF) 
approach and EC50 values were calculated according to Riachi et al.21 Blood was 
centrifuged (4000 x g for 10 minutes at 4°C) and plasma was stored at -20°C. Plasma 
leptin, resistin and adiponectin concentrations were determined by Luminex® Multiplex 
technology (Luminex Corporation, Austin, TX) using Multiplex Immunoassays (Millipore, 
Amsterdam, The Netherlands). Adipose tissue-derived LPL-activity was determined 
as described below. RNA was extracted from adipose tissue using Tri reagent (Sigma-
Aldrich, St. Louis, MO) and subsequently converted into cDNA by a reverse transcription 
procedure using M-MLV and random primers according to the manufacturer’s protocol 
(Sigma-Aldrich). For quantitative PCR (qPCR), cDNA was amplified using the appropriate 
primers and probes. Primer and probe sequences for Acetyl-CoA carboxylase 1 (Acc1/
Acaca), Carnitine palmitoyltransferase-1a (Cpt-1a), Fatty acid synthase (Fas/Fasn), 
Lipoprotein lipase (Lpl), Phosphoenolpyruvate carboxykinase (Pepck/Pck1), Stearoyl-
CoA desaturase 1 (Scd1) and Sterol regulatory element binding protein-1c (Srebp-1c/
Srebf) have been published (www.LabPediatricsRug.nl). The sequences for all other 
primers and probes are given in Supplemental Table 1. All mRNA levels were calculated 
relative to the expression of cyclophilin G and normalized for expression levels of chow-
fed WT mice.
Indirect calorimetry
Separate groups of mice were place in an indirect calorimeter chamber with free 
access to food and drinking water. During 24 hours, gas exchange measurements were 
performed using an eight-channel open flow system. Flow rates were measured and 




 concentrations of dried inlet and outlet 
air from each chamber were measured at 10-minute intervals using a paramagnetic 
O
2 
detector and an infrared CO
2 
detector. Estimated energy expenditure in kcal per 24 








Data were normalized for lean body mass, which was determined as described earlier.20
Determination of de novo lipogenesis and chain elongation in adipose 
tissue
Separate groups of mice received sodium [1-13C]-acetate (99 atom %, Isotec/Sigma-
Aldrich) via the drinking water (2%) during the final 72 hours of the dietary period. 
After a postprandial fast, mice were sacrificed by cardiac puncture under isoflurane 
anaesthesia. Epididymal adipose tissue was quickly removed, snap-frozen in liquid 
nitrogen and stored at -80°C. Lipids were hydrolyzed in HCl/acetonitrile (1:22 v/v) for 45 
minutes at 100°C. Fatty acids were extracted in hexane and derivatized for 15 minutes 
at room temperature using α-Br-2,3,4,5,6-pentafluorobenzyl (PFB)/acetonitrile/
triethanolamine (1:6:2 v/v). Derivatization was stopped by adding HCl and fatty acid-PFB 
derivatives were extracted in hexane. The fatty acid-PFB mass isotopomer distributions 
were measured using an Agilent 5975 series GC/MSD (Agilent Technologies, Santa 
Clara, CA). Gas chromatography was performed using a ZB-1 column (Phenomenex, 
Torrance, CA). Mass spectrometry analysis was performed by electron capture negative 
ionization using methane as moderating gas.





corrected for natural abundance of 13C by multiple linear regression23 to obtain the 




) due to incorporation of 
[1-13C]-acetate. This distribution was used in mass isotopomer distribution analysis 
(MIDA) algorithms to calculate the acetyl-CoA precursor pool enrichment (p
acetate
), 
fractional palmitate synthesis rates (f
C16:0
) and the fraction of palmitate and oleate 
generated by elongation of de novo synthesized palmitate (f
C18:0/1(C16DNL)
), or by elongation 




Plasma LPL-activity was determined using a separate group of animals. Following the 
postprandial fast, a baseline blood sample was drawn by retro-orbital bleeding under 
isoflurane anaesthesia into heparinized capillaries. Mice subsequently received an intra-
orbital injection of heparin in saline (0.1 U/g). After 10 minutes, a post-heparin blood 
sample was drawn by retro-orbital bleeding. Mice were sacrificed by cardiac puncture 
and blood was centrifuged (4000 x g for 10 minutes at 4°C). Total lipase activities were 
determined as described in 10 μl of plasma.25 To determine post-heparin LPL-activity, 





post-heparin hepatic lipase activity was subtracted from the total post-heparin lipase 
activity.
 Adipose tissue specific LPL-activity was determined in biopsies collected after a 
postprandial fast. Tissue was first homogenized in 1 mL of a buffer containing sucrose 
(0.25 M), EDTA (1 mM), Tris.Hcl (10 mM) and Deoxycholate (12 mM), pH 7.4.26 Tissue 
homogenates were centrifuged (20 min at 12000 x g for at 4°C) and the fraction 
between the upper fat layer and the bottom sediment was collected. Lipase activities 
were determined as described using 50 μl of tissue fraction. LPL-activity was calculated 
by subtracting lipolytic activity determined in a final NaCl concentration of 0.83 M (non-
LPL) from total lipolytic activity measured without NaCl. Data obtained in adipose tissue 
were normalized for protein concentration of the tissue fraction.26
Statistics
All data are presented as mean values ± SEM. Statistical analysis was performed using 
SPSS for Windows software (SPSS 12.02, Chicago, IL, USA). To test dietary effects, 
genotype, and their interactions data were analyzed using a general linear model and 
Bonferroni post hoc analyses. Treatment effects were further analyzed by Student’s 
t-test. In case of non-parametric distribution, Mann-Whitney U-test was applied. The 
null hypothesis was rejected at the 0.05 level of probability.
Results
The resistance against high-fat diet-induced obesity in CB
1
-/- mice is 
associated with a reduced adipocyte size
We first evaluated the adiposity-inducing effects of two different HF diets in WT and 
CB
1
-/- mice. As expected, HF and HF/FO feeding resulted in a comparable increase in 
adipose tissue mass (Figure 1A) and a slightly higher body weight (Figure 1B) in WT 
mice, while CB
1
-/- mice remained lean on the HF and HF/FO diet. The leanness in CB
1
-/- 
mice was independent of caloric intake since we did not observe differences in energy 
consumption between WT and CB
1
-/- mice during the dietary interventions (Figure 1C). 
Fecal energy loss was also similar in WT and CB
1
-/- mice, indicating that intestinal nutrient 
absorption was comparable (Figure 1D). Fish-oil replacement, however, increased 
nutrient absorption in HF-fed mice, since fecal energy loss was reduced in WT and CB
1
-/- 





/- mice compared to WT mice, however, the difference reached statistical significance 





-/- mice had smaller adipocytes (Figure 2A), which is also indicated by the 
separate 95%-confidence intervals of the fat cell area EC50s in CB
1
-/- versus WT mice fed 
either of the three diets (Figure 2B). Adipose tissue expression of Faah, Pparγ2, Cebp/α, 
Ap2 and Adiponectin were not affected by CB
1
-deficiency or HF and HF/FO feeding, 
while Napepld expression was increased in HF-fed mice of both genotypes (Table 1). 
Plasma leptin concentrations were elevated with HF or HF/FO induced adiposity in WT 
mice while adiponectin and resistin levels were comparable in all mice (Table 2). 
Fatty acid synthesis in adipose tissue is not affected in CB
1
-/- mice 
To assess whether lipogenesis was reduced in CB
1
-/- mice, we determined fatty 
acid synthesis in adipose tissue using 13C-acetate incorporation. Acetyl-CoA pool 
enrichments were increased in HF-fed WT and CB
1
-/- mice as compared to chow-fed 
animals (Table 3) and normalized by FO replacement. No differences between WT and 
CB
1
-/- mice were observed. Fractional palmitate synthesis from de novo lipogenesis was 
similar in WT and CB
1
-/- mice, but was reduced in mice fed the HF and HF/FO diets as 
compared to chow-fed animals (Table 3). Furthermore, fractional synthesis of stearate 
and oleate from elongation of de novo synthesized palmitate was reduced in WT and 
CB
1
-/- mice fed the HF and HF/FO diets as compared to chow-fed animals (Table 3) with 
no differences between WT and CB
1
-/- mice. In contrast to the lower fractional synthesis 
rates fromelongation of de novo synthesized palmitate, fractional stearate and oleate 
synthesis from elongation of unlabeled palmitate were maintained in WT and CB
1
-/- 
mice fed the HF and HF/FO diets as compared to chow-fed animals (Table 3). The 
unaltered fatty acid synthesis rates in CB
1
-/- mice were supported by gene expression 
analysis in adipose tissue: we did not observe any changes in lipogenic gene expression 
between WT and CB
1
-/- mice under the different dietary conditions (Table 1). HF and HF/
FO feeding did not affect Fatp4, Acc1, Fas and Pepck (Table 1) expression. HF feeding 
induced Scd1 expression in both WT and Cb
1
-/- mice while we observed a tendency for 
an increased Srebp-1c expression. These inductions were normalized in HF/FO-fed WT 
and CB
1
-/- mice (Table 1). 

















































































































-/-) and wild type 
(WT) mice fed chow, HF or HF/FO diet during 6 weeks. A) Adiposity index, representing 
the percentage fat mass over total body mass. B) Body weights at the end of the dietary 
intervention. C) Caloric intake. D) Fecal energy output and E) Energy expenditure, derived from 
indirect calorimetry. Values are given as means ± SEM for n = 5-8. Open bars, WT mice; closed 
bars, CB
1
-/- mice. * p < 0.05 chow versus HF, # p < 0.05 HF versus HF/FO (Bonferroni). § p < 0.05 
CB
1
-/- versus WT (Student’s t-test).
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-/-) and wild type (WT) mice fed chow, 
HF or HF/FO diet during 6 weeks. A) Representative pictures of 3 µm paraffin hematoxylin 
and eosin-stained sections and B) percent relative cumulative frequency (PCRF) curves of 240-
420 fat cell areas. Inset: EC50 values of the PCRF curves and their 95%-confidence intervals. 
$ p < 0.05 CB
1
-/- mice versus WT.































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Plasma adipokine concentrations in cannabinoid-1 receptor deficient (CB1-/-) mice 
and in wild type (WT) mice fed chow, high-fat (HF) diet or high-fat fish-oil enriched (HF/FO) 
diet.








Leptin (ng ml-1)  0.7 ± 0.1  0.6 ± 0.1#  2.1 ± 0.5*  1.0 ± 0.2*#  2.2 ± 0.5  1.7 ± 0.3
Adiponectin (μg ml-1) 14.3 ± 1.3 18.5 ± 2.4 15.4 ± 1.5 17.0 ± 2.9 18.1 ± 2.2 19.1 ± 2.2
Resistin (ng ml-1)  2.3 ± 0.2  2.5 ± 0.4  3.0 ± 0.5  2.9 ± 0.3  2.1 ± 0.2  2.6 ± 0.4
Values are means +/- SEM; n=6-8; * p < 0.05 chow vs HF, # HF CB
1
-/- vs HF WT.





-receptor agonist treatment enhances lipolytic activity in vitro.5 As a consequence, 
CB
1
-deficiency may result in a reduction of lipoprotein triglyceride lipolysis, thereby 
limiting fat storage in adipose tissue. Yet, adipose tissue Lpl and Fatp4 expression were 
not affected by CB
1
-deficiency or HF and HF/FO feeding (Table 1). To test whether an 
increased lipid clearance contributed to the obesogenic effects of the HF diets, we also 
determined LPL-activity. Post-heparin plasma LPL-activity as well as adipose tissue-
derived LPL-activity were similar in all groups (Figure 3A and 3B). In addition, we did 
not observe significant differences in adipose tissue expression of Hsl, Atgl and Cpt-1a 














































-/-) and wild type (WT) mice fed 
chow, HF or HF/FO diet during 6 weeks. A, Post-heparin plasma lipoprotein lipase (LPL) activity 
and B, Adipose tissue-derived LPL-activity. Values are given as means ± SEM for n = 5-6. Open 
bars, WT mice; closed bars CB
1
-/- mice.


















































































































































































































































































































































































































































































































































































Overactivity and/or dysregulation of the ECS may contribute to the development of 
obesity.6,11,14 Several in vitro studies suggest an involvement of the CB
1
-receptor in 
controlling adipocyte development and function.5-13 To our knowledge, we are the first 




Yet, we also show that the 
protection against HF diet-induced obesity in CB
1
-/- mice is not related to alterations 
in adipocyte differentiation and proliferation markers or to changes in the rates of in 
vivo lipogenesis and lipoprotein lipolysis in fat tissue. Impaired CB
1
-signalling has been 
shown to protect against HF diet-induced obesity in adult mice,16,27 however, underlying 
mechanisms have not been resolved. The ECS has been implicated in the regulation 
of adipocyte proliferation and differentiation in vitro5-13 and CB
1
-deficient mice are 
retarded in growth from an early age on.5 We therefore decided to study the metabolic 
consequences of HF feeding in young CB
1
-/- mice, i.e. in a phase when the body weight 
of the mice is still increasing. Six weeks of HF and HF/FO feeding induced obesity in WT 
mice which was accompanied by an increased adipocyte size. This effect was clearly 
blunted in CB
1
-/- mice, however, the CB
1
-/- mice did become heavier on the HF and HF/FO 
diets as compared to chow-fed CB
1
-/- mice. Gene expression analysis indicated that this 
is unlikely due to an impaired ability of adipocyte differentiation and/or proliferation in 
CB
1
-/- mice, since we did not observe differences in Pparγ2, Cebp/α and Ap2 expression. 
The expression of these genes was also not different prior to the start of the HF diet 
interventions (at three weeks of age, data not shown). PPARγ and CEBP/α play key 
roles in controlling adiponectin transcription.28,29 We did not observe a differences in 
adiponectin mRNA levels, indicating that, in parallel to their unaltered expression levels, 
the transcriptional activity of PPARγ and CEBP/α was not impaired by CB
1
-deficiency. 
This is supported by the comparable plasma adiponectin concentrations among the 
different groups studied. HF feeding has been reported to decrease plasma adiponectin 
concentrations in WT mice.27,30 In those studies, 6-10 week old mice were fed a HF 
diet for 14 weeks, whereas in the current study, 4-week old mice were subjected to a 
6-week dietary challenge. These experimental differences may underlie the discrepant 
findings in the current study as compared to others.27 Although adiponectin expression 







activation and blockade do not directly affect adiponectin 
expression in cultured adipocytes.12,31 The observed changes in adiponectin expression 
and secretion may rather be attributed to acute changes in food intake.32 Similar to 





what has been found by others,27 we did not observe major differences in voluntary 
caloric intake between WT and CB
1
-/- mice. Interestingly, isocaloric replacement of 
the saturated fat in the HF diet for PUFA increased intestinal fatty acid uptake in both 
genotypes, as indicated by the lower fecal energy loss. This can presumably be ascribed 
to upregulation of fatty acid transport proteins and consequently increased nutrient 
uptake in animals on the HF/FO diet.33 However, no differences in fecal energy loss were 
observed between CB
1
-/- mice and WT mice fed either of the three diets. Altogether, 
these data indicate that reduced adiposity in CB
1
-/- mice does not result from an intrinsic 
disability of adipocytes to expand or from a different nutrient availability. 
 Pharmacological CB
1
-receptor activation promotes lipid storage in adipocytes7,11-13 
and induces the expression of lipogenic genes in fat tissue.7 We therefore studied the 
lipogenic flux in vivo in adipose tissue of WT and CB
1
-/- mice that were fed diets differing 
in fat quantity and quality. Fractional fatty acid synthesis rates were not affected by CB
1
-
deficiency, paralleled by an unaltered expression of lipogenic genes. In both genotypes, 
HF and HF/FO feeding resulted in a reduction of the fractional fatty acid synthesis 
from de novo lipogenesis (indicated by lower fractional palmitate synthesis as well as 
reduced stearate and oleate synthesis from de novo synthesized palmitate). This is in 
agreement with a recent report showing that fatty acid synthesis from glucose is in the 
fat tissue of HF- fed mice compared to animals fed a low-fat diet.34 These observations 
indicate that HF feeding promotes adiposity by accelerating elongation of dietary fatty 
acids. Fractional fatty acid elongation of pre-existing palmitate, on the other hand, was 
maintained. 
 Dietary fatty acids enter the body after their incorporation into triglycerides that 
are subsequently packaged into chylomicron particles in the intestine. Tissue-specific 
LPL- activity catalyzes the liberation of fatty acids from chylomicron-triglycerides, after 
which the fatty acids can be taken up by organs and tissues. To assess whether the 
protection against HF diet-induced adiposity in CB
1
-/- mice was secondary to a reduced 
lipolytic activity, we determined whole-body and adipose tissue-specific LPL-activity. 
WT and CB
1
-/- mice fed either of the three diets exhibited comparable LPL-activities. 
Previous studies have shown that CB
1
-receptor antagonism inhibits LPL-activity, only 
when cells were co-treated with a CB
1
-receptor agonist.5 Furthermore, elevated 
plasma endocannabinoid concentrations were found to be associated with increased 
LPL-activity.35 On the other hand, CB
1
-receptor antagonist treatment by itself did not 
inhibit LPL-activity in vitro.5 Consistent with previous work,27 we did not observe an 





-deficient mice was not related impaired LPL-mediated lipolysis of circulating 
triglycerides or to reduced adipocyte lipogenesis. The comparable expression levels 
of Hsl and Atgl and Cpt-1a in adipose tissue of CB
1
-/- mice suggest that triglyceride 
hydrolysis and fatty acid oxidation were also not altered in this tissue.
 Altogether, the protection against diet-induced adiposity in CB
1
-/- mice may not 
be related to intrinsic alterations in adipocyte biology due to absence of the receptor. 
The reduced accumulation of energy as fat in CB
1
-/- mice reflects a less positive energy 
balance as compared to their WT littermates. Since energy intake was similar in both 
genotypes,the reduction in fat mass must therefore be due to a higher energy loss 
in CB
1
-/- mice. Indirect calorimetry indeed revealed higher energy expenditure in CB
1
-
/- mice. This difference was mainly attributable to increased fat utilization in the light 
phase (chapter 6). CB
1
-receptor deficiency may furthermore increase energy dissipation 
as heat. CB
1
-receptor blockade induces a mitochondria-rich, thermogenic phenotype in 
adipocytes.36 It furthermore increases brown adipose tissue temperature concomitantly 
with an increase in Ucp-1 expression, which is attenuated upon denervation.37 
CB
1





-deficiency have recently been shown to 
increase mitochondrial function.38,39 In addition, CB
1
 antagonism enhanced substrate 
oxidation and increased mitochondrial uncoupling, thereby increasing oxidative and 
non-oxidative energy expenditure.38
 In summary, our data indicate that the obesity-resistant phenotype of CB
1
-/- mice is 
not due to changes in adipose tissue differentiation/proliferation, lipogenesis or or fat-
derived LPL-activity in vivo. Energy expenditure was increased in CB
1
-/- mice compared to 
their WT littermates. Dietary energy intake and fecal energy loss remained unaffected, 
which resulted in lower adiposity and fat cell size upon HF feeding. We therefore 
propose that the protection against diet-induced obesity in CB
1
-/- mice is not related to 
functional alterations in fat tissue per se, but rather results from of an increased energy 
loss by oxidative and potentially non-oxidative pathways. 
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The endocannabinoid system (ECS), comprising cannabinoid receptors and endogenous 
ligands for these receptors, not only plays a pivotal role in the regulation of feeding 
behaviour but also in the modulation of fuel metabolism and partitioning. The 
resistance of cannabinoid-1 receptor deficient (CB
1
-/-) mice to diet-induced obesity 
compared to pair-fed wild type (WT) mice was recently attributed to increased daily 
energy expenditure. It has been suggested that increased energy expenditure in mice 
with impaired CB
1
-signalling is driven by increased fatty acid oxidation (FAO). Previous 
data of our laboratory showed increased FAO in mice treated with rimonabant, a CB
1
-
receptor antagonist. Based on physiological diurnal fluctuations in FAO, CB
1
-receptor 
deficiency should affect energy expenditure primary in the inactive phase, when FAO 
predominates over carbohydrate oxidation. For this reason we investigated substrate 
oxidation patterns in WT and CB
1
-/- mice subjected to chow or a high-fat (HF) diet or to 
a HF diet supplemented with fish oil (HF/FO). Results showed that energy expenditure 
expressed per lean mass is increased in CB
1
-/- mice compared to WT in both the 
inactive and the active phases. This increased expenditure is fuelled by an increased 
FAO, expressed per lean body mass, in the inactive phase and increased carbohydrate 
utilization in the active phase. Free fatty acid (FFA) levels are lower in CB
1
-/- mice than 
in WT mice in the middle of the light phase, i.e., at a time when FAO is elevated in CB
1
-/- 
mice compared to WT mice. Diurnal patterns of food intake did not differ between 
CB
1
-/- mice fed chow and WT controls, indicating that the pronounced substrate shift 
towards FAO in the inactive phase in CB
1
-/- mice and towards carbohydrate utilization in 
the active phase can not be attributed to a changed food intake pattern. 









-receptor), endogenous ligands for these receptors and enzymes 
involved in synthesis and degradation of these so-called endocannabinoids, has been 
shown to be an important regulator of energy metabolism. The ECS not only plays a role 
in the regulation of feeding behaviour but also in the modulation of fuel utilization. This 




-/- mice) are 
resistant to diet-induced obesity when compared with pair-fed wild type (WT) controls.1 
This could be due to a higher energy expenditure in CB
1
-/- mice and, indeed, this is what 
we (chapter 5) and others2,3 have recently demonstrated. Increased fatty acid oxidation 
in CB
1
-/- mice has been put forward as a mechanism underlying resistance to high-fat 
diet-induced obesity and associated derangements such as hepatic steatosis (chapter 
4). Since carnitine palmitoyltransferase-1 (Cpt1) activity is reduced in mice treated with 
a CB
1
-receptor agonist, an effect that is not observed in CB
1
-/- mice as reported by Osei-
Hyiaman et al.,3 these data appear to indicate that signalling of cannabinoids via the 
CB
1
-receptor plays a pivotal role in controlling energy expenditure.
 Fluctuations in fat and carbohydrate oxidation in rodents are linked to the diurnal 
cycle – with fat oxidation predominating during the inactive phase and carbohydrate 
utilization during the active phase. Since mice are nocturnal animals, the light period 
is the inactive phase whereas the dark period is the active phase. When differences 
in fat oxidation are relevant for differences in energy expenditure between WT and 
CB
1
-/- mice, one might predict that these differences are particularly present during the 
light period. It is therefore of interest to establish temporal circadian patterning of fuel 
oxidation and energy expenditure in WT and CB
1
-/- mice. Since differences in energy 
expenditure between WT and CB
1
-/- mice were found to be largest in mice subjected 
to high-fat diets, we determined circadian substrate utilization patterns by indirect 
calorimetry in WT and CB
1
-/- mice subjected to either a mainly carbohydrate-containing 
laboratory chow diet or to an obesogenic high-fat (HF) diet consisting of saturated fat, 
or a HF diet supplemented with fish oil (HF/FO). The latter comparison is of interest 
because effects of CB
1
-antagonism on energy balance regulation were found to be 
largest in mice subjected a HF/FO diet (chapter 3-5). Carcass analysis was performed to 







-receptor deficient mice (CB
1
-/-) on a C57BL/6J background and their WT littermates 
(WT) were bred in our own facility. Initial breeding pairs were kindly provided by 
Prof. Dr. A. Zimmer, Laboratory of Molecular Neurobiology, Department of Psychiatry, 
University of Bonn, Germany. Mice were individually housed in a light-controlled (lights 
on 4 AM- 4 PM) and temperature-controlled (21oC) facility. Mice were allowed tap water 
and food ad libitum. Experimental protocols were approved by the local Experimental 
Ethical Committee for Animal Experiments. These regulations are consistent with the 




All experimental diets were obtained from Abdiets BV, Woerden, The Netherlands. 
Mice received either standard laboratory chow (RMH-B), a high-fat diet (HF) containing 
36 weight % fat consisting of bovine fat (custom synthesis, diet number 4031.45), or 
a high-fat diet containing 36 weight % fat consisting for 58% of bovine fat and for 42% 
of fish oil (custom synthesis, diet number 4031.54). Composition of experimental diets 
has been published previously (Supplemental Table 2).4,5 The HF/FO diet was replaced 




-/- mice and WT littermates were divided into groups by matching for 
body weight and fed one of the three diets during six weeks. Intake and body weight 
were registered twice a week. Indirect 24h-calorimetry was performed between 
four and five weeks after start of diets. When mice were six weeks on experimental 
diets, they were sacrificed by cardiac puncture under inhalation anaesthesia followed 
by cervical dislocation after a fasting period of three hours. Blood and tissues were 
collected. Carcasses were stored at -20oC until carcass analysis. We choose to sacrifice 
at age of ten weeks because of the described increase in mortality in CB
1
-/- mice from 
the tenth week of life onwards.6




Carcasses were eviscerated and stored at -20oC. Carcasses and organs were dried to 
constant weight at 103oC, and fat was extracted by using petroleum ether (Boom BV, 
Meppel, The Netherlands) in a soxlet apparatus. Percentage fat of carcasses and organs 
were determined from weight differences before and after the fat extraction procedure.
Indirect calorimetry
Mice were placed in an open circuit indirect calorimetry system for 24 hours with 
access to water and food. Gas-exchange measurements were performed in an eight-





 concentrations of dried inlet and outlet air from each chamber 
were measured every 10 minutes with a paramagnetic O
2
 analyzer and an infrared CO
2
 
gas analyzer. Data were collected from each metabolic cage separately. 
 The respiratory quotient (RQ) was defined as CO
2
 production (l)/ O
2
 consumption 





(ml h-1)*0.001).7 Energy expenditure 
was expressed per lean body mass. Lipid oxidation and carbohydrate utilization 
(expressed per lean body mass) were calculated according to Lusk using the following 
equations:8
Lipid oxidation (g h-1):  38.461*(VO
2
 (mol h-1) - VCO
2
 (mol h-1))
Carbohydrate utilization (g h-1): (94.017*VCO
2
 (mol h-1)) - (66.239*VO
2
 (mol h-1))
Measurement of plasma free fatty acids, ketone bodies, blood glucose 
and insulin
Plasma free fatty acids (FFA), β-hydroxybutyrate (β-HB) and lactate concentrations were 
determined using commercially available kits from Wako Chemicals (Neuss, Germany) 
for FFA and from Roche Diagnostics (Mannheim, Germany) for β-HB and lactate. A 
Euroflash glucose meter (Lifescan Benelux, Beerse, Belgium) was used to measure 
blood glucose concentrations. Plasma insulin concentrations were determined by 
Luminex Multiplex technology (Luminex Corporation, Austin, TX, USA) using multiplex 
Immunoassays (Millipore, Amsterdam, The Netherlands). 
Circadian patterning of food intake
To rule out differences in circadian rhythm of food intake as an underlying cause of 
differences in fat oxidation in the light phase, we added an experiment to determine 
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circadian patterning of food intake. Since difference in fat oxidation in the light phase 
were largest between WT and CB
1
-/- fed chow, we measured food intake every two hour 
over a 24-hour-period in CB
1
-/- and WT controls fed chow. 
Statistics 
All values in Figure 1 and in the tables represent means ± standard errors of the means 
for the number of animals indicated in the figure and table legends. All values in 
Figures 2, 3 and 4 represent means. Data were analyzed using General Linear Model 
(GLM) Repeated Measures for temporal patterning of RQ, energy expenditure, fatty 
acid oxidation and carbohydrate utilization. Periods analyzed were defined as period 
A, ZT12-16 (Zeitgeber Time, ZT0 is the start of the dark phase, i.e., 4 PM); period B, 
ZT16-20; period C, ZT0-12; period D, ZT12-20; and period E, ZT0-20. To evaluate 
effects of diet, genotype, and their interactions on body weight, weight gain, results 
concerning body composition and average values per period on energy expenditure, 
lipid oxidation and carbohydrate utilization, and plasma parameters, these data were 
statistically analyzed using a General Linear Model Univariate Analysis with Bonferroni 
post hoc analyses. Treatment effects were further analyzed by Student’s t-test. In case 
of non-parametric distribution, Mann-Whitney U-test was assed for statistical analysis. 
Statistical significance of differences was accepted at a P-value of less than 0.05. 
Analyses were performed using SPSS 16.0 for Windows software (SPSS, Chicago, IL).
Results
Induction of obesity and adiposity of WT mice fed HF diet or HF/FO diet
After the six week dietary intervention, body weights of WT mice fed HF diet or HF/
FO diet were comparable to those of mice fed chow (Figure 1a). When expressed as 
body weight gain from start of diet manipulations, the HF/FO diet was more weight-
promoting in WT mice compared with chow and there was a trend towards a higher 
body weight gain in WT mice fed HF diet compared to WT mice fed chow (Figure 1b). 
Total fat mass as well as visceral fat mass and subcutaneous fat mass were significantly 
higher in WT mice fed either HF diet or HF/FO diet compared to mice fed chow (Table 
1).





-/- mice are resistant to diet-induced obesity
After being on the experimental diets for 6 weeks CB
1
-/- mice on all three diets weighed 
significantly less than their WT littermates (Figure 1a). This difference in body weight 
was attributed to a significant reduction in adiposity in CB
1
-/- mice as compared with 
that in WT littermates on all three experimental diets (Table 1). In mice fed chow, HF 
diet or HF/FO diet, total fat mass was respectively 21.3%, 41.8% and 41.4% lower in 
CB
1
-/- mice as compared with that in WT mice fed the same diet. 
 Caloric intake was similar among CB
1
-/- mice and WT littermates as was energy 
absorption as determined by bomb calorimetry of feces of these mice (chapter 5 of this 
thesis). So, as compared with WT littermates, we found a lean phenotype (meaning a 
phenotype characterized by reduced adiposity) in CB
1
-/- mice on all three experimental 
diets and we confirmed that CB
1
-/- mice are resistant to diet-induced obesity. Reduction 


















































-/-) mice and wild type (WT) 
mice fed chow, high-fat diet (HF) or high-fat fish-oil enriched diet (HF/FO). Open bars, WT 
mice; closed bars, CB
1
-/- mice. Values are means +/- SEM; n =6-7, * p < 0.05 chow CB
1
-/- versus 
chow WT, † p < 0.05 HF CB
1
-/- versus HF WT, chow versus HF/FO, ‡ p <0.05 CB
1
-/- HF/FO versus 
HF/FO WT, # p < 0.05 chow versus HF/FO. B) Body weight gain during week 3-6 in male CB
1
-/- 
mice and WT mice fed chow, HF or HF/FO diet. Open bars, WT mice; closed bars, CB
1
-/- mice. 
Values are means +/- SEM; n =6-7, † p < 0.05 HF CB
1
-/- versus HF WT, chow versus HF/FO, 
‡ p < 0.05 CB
1
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Circadian rhythm of energy expenditure in CB
1
-/- mice 
Accordingly, increased energy output was expected to contribute to the observed lean 
phenotype of CB
1
-/- mice. Figure 2a shows circadian patterning of energy expenditure 
in CB
1
-/- mice compared to WT mice fed the three experimental diets. Analysis of these 
data by overall GLM repeated measures demonstrated no significant interactions 
between diet and genotype on energy expenditure. A significant diet effect irrespective 
of genotype on energy expenditure was observed in both the dark and light period and 
analysing sources of significance with post hoc tests revealed a significant reduction in 
energy expenditure in mice fed chow as compared with that in HF-fed mice (in all periods 
p < 0.05) and HF/FO-fed mice (period B, C and E p < 0.05). With respect to genotype, 
energy expenditure was only found to differ in the middle of the light period (period 
B, ZT 16-19), with CB
1
-/- mice having an increased energy expenditure compared to WT 
mice (p = 0.016). From the majority of mice that had participated in indirect calorimetry 
measurements, we also obtained data on body composition (n = 4-6 instead of n = 5-7). 
When results of this subgroup of mice were expressed per lean mass, the observed 
differences were generally more pronounced (Figure 2b). GLM repeated measures on 
data of energy expenditure expressed per lean mass revealed no interaction between 
genotype and diet. After normalization, diet effects in the dark (active) phase were lost, 
whereas in the light (inactive) phase energy expenditure expressed per lean mass was 
higher in mice fed chow as compared with that in HF-fed or HF/FO-fed mice. Effects of 
genotype on energy expenditure expressed per lean mass became significant for all 
periods analyzed (p < 0.001 for all analyzed periods).
Substrate shift towards lipid oxidation in CB
1
-/- mice in the light phase and 
towards carbohydrate utilization in the dark phase 
Figure 3 shows circadian patterning of respiratory quotients (RQ). GLM repeated 
measures demonstrated no significant interactions between diet and genotype on RQ 
in the light phase or the dark phase. GLM repeated measures revealed that RQ was 
significantly higher in chow-fed mice as compared with that in HF-fed or HF/FO-fed 
mice in both the light period and the dark period. CB
1
-/- mice exhibited significantly 
decreased RQ in the light period compared to WT controls (p = 0.004), indicating an 
increase in the ratio of fatty acid oxidation (FAO) to carbohydrate utilization (Figure 3). 
Indeed, GLM repeated measures revealed an increase in lipid oxidation calculated from 





-/- mice compared to WT mice (p = 0.026). Rates of carbohydrate utilization were not 

































































-/-) mice and wild type (WT) 
mice fed chow, high-fat diet (HF) or high-fat fish-oil enriched diet (HF/FO). Open symbols, WT 
mice; closed symbols, CB
1
-/- mice; triangles, chow; squares, HF; circles, HF/FO. Each data point 
represents mean for n =5-7 mice. The dark bar on the X-axis represents the dark period. ZT0 
(Zeitgeber time) is start of the dark period (i.e., 4PM). B) Energy expenditure (EE) expressed 
per gram lean body mass. Open symbols, WT mice; closed symbols, CB
1
-/- mice; triangles, 
chow; squares, HF; circles, HF/FO. Each data point represents mean for n =4-6 mice. The dark 
bar on the X-axis represents the dark period. ZT0 (Zeitgeber time) is start of the dark period 
(i.e., 4PM).
 Indirect calorimetry revealed a shift in RQ in mice fed chow during transition from 
the light period to the dark period and vice versa, since FAO predominates in the light 
period and carbohydrate utilization predominates in the dark period. Chow-fed or HF-





-/- mice showed a pronounced shift in RQ during transition from dark period to 
the light period and vice versa as compared with that in WT mice fed these diets. In 
the dark period, mice of either genotype had similar RQ with values depending on the 
diet. In the light period, however, CB
1
-/- mice fed chow or HF-diet exhibited significantly 
lower RQ, resulting in greater shift in RQ in CB
1
-/- mice as compared with WT mice 
(Figure 3). This effect was most pronounced in CB
1
-/- mice fed chow. As compared with 
that in WT controls, chow-fed CB
1
-/- mice not only exhibited a faster decline in RQ in the 
light period, but they also showed a slower return to the levels of RQ in the dark phase 
(Figure 3). Thus, in the transition from dark to light phase, CB
1
-/- mice demonstrated an 































-/-) mice and wild type (WT) 
mice fed chow, high-fat diet (HF) or high-fat fish-oil enriched diet (HF/FO). Open symbols, WT 
mice; closed symbols, CB
1
-/- mice; triangles, chow; squares, HF; circles, HF/FO. Each data point 
represents mean for n =6-8 mice. The dark bar on the X-axis represents the dark period. ZT0 
(Zeitgeber time) is start of the dark period (i.e., 4PM).
 When corrected for lean body mass, besides the still significant increase in FAO 
in CB
1
-/- mice as compared with that in WT mice in the light phase, GLM repeated 
measures analysis revealed a significant increase in carbohydrate utilization in the dark 
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Figure 4. A) Fatty acid oxidation (FAO) calculated from oxygen consumption and carbodioxide 




-/-) mice and wild type (WT) mice fed chow, high-fat 
diet (HF) or high-fat fish-oil enriched diet (HF/FO). B) Carbohydrate utilization (CHO ox) 
calculated from oxygen consumption and carbodioxide production in male CB
1
-/- mice and 
WT mice fed chowHF or HF/FO. Open symbols, WT mice; closed symbols, CB
1
-/- mice; triangles, 
chow; squares, HF; circles, HF/FO. Each data point represents mean for n =5-7 mice. The dark 
bar on the X-axis represents the dark period. ZT0 (Zeitgeber time) is start of the dark period 
(i.e., 4PM). C) Fatty acid oxidation (FAO) expressed per lean body mass. D) Carbohydrate 
utilization (CHO ox) expressed per lean body mass. Open symbols, WT mice; closed symbols, 
CB
1
-/- mice; triangles, chow; squares, HF; circles, HF/FO. Each data point represents mean for 
n =4-6 mice. The dark bar on the X-axis represents the dark period. ZT0 (Zeitgeber time) is start 
of the dark period (i.e., 4PM).
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Blood glucose, plasma insulin, FFA and ketone bodies levels in the middle 
of the light phase in CB
1
-/- mice
Table 2 shows blood glucose levels, and plasma levels of FFA, β-HB, lactate, and insulin. 
Plasma FFA levels were significantly decreased in mice fed HF/FO compared to mice 
fed HF diet (p = 0.000) and plasma FFA levels were significantly decreased in CB
1
-/- fed 
chow compared to WT controls (p = 0.029). We found no differences between diet 
groups or genotypes in ß-HB and lactate. For glucose no significant effect of diet was 
observed. However, CB
1
-/- mice fed HF diet showed decreased glucose concentrations 
as compared with that in WT controls (p = 0.002). Glucose levels of HF/FO-fed CB
1
-/- 
mice were also decreased; however this difference did not reach statistical significance. 
Insulin levels did not differ between diet groups or genotypes. 
Changes in fuel partitioning in CB
1
-/- mice can not be attributed to shifted 
circadian pattern in food intake
Energy expenditure corrected for lean body mass appears increased in CB
1
-/- mice in 
the light phase as well as the dark phase and, apparently this increase is accounted 
for in the light phase by increased fatty acid oxidation whereas in the dark phase it 
is accounted for by increased carbohydrate utilization. Since this changed pattern in 
fuel partitioning might be based on a shifted pattern in food intake, we analyzed 24 
hour food intake pattern in CB
1
-/- mice and WT mice fed chow, the latter being the diet 
with the most pronounced differences in RQ and substrate oxidation. Measurements of 
2h-intake of food over a 24h- period did not reveal changes between CB
1
-/- and WT mice 















































































































































































































































































































































































































































































































































-/-) mice and wild type 
(WT) mice fed chow. Food intake was estimated every 2 hours for a 24-hour period. Open 
symbols, WT mice; closed symbols, CB
1
-/- mice. Each data point represents mean for n =7 mice; 
n =7 mice. ZT0 (Zeitgeber time) is start of the dark period (i.e., 4PM). No significant differences.
Discussion
Results of our experiments demonstrate that increased energy expenditure corrected 
for lean body mass, in the dark period as well as in the light period, contributes to 
the observed lean phenotype of fat-fed CB
1
-/- mice. According to our expectation, 
a significantly increased FAO during the light period as calculated from oxygen 
consumption and carbon dioxide production was observed to underlie this effect in 
CB
1
-/- mice compared to WT mice. In the dark period, however, differences in energy 
expenditure could not be accounted for by fatty acid oxidation, but by increased 
carbohydrate utilization instead. Finally, our data suggest involvement of CB
1
-mediated 
endocannabinoid signalling in substrate shift during the transition from the active to 
the inactive phase and vice versa. 
 Our data are consistent with previous reports describing a phenotype of CB
1
-/- 
mice on both chow and HF-diet that is characterized by a lower body weight gain 
and decreased adiposity compared to WT mice, independent of caloric intake.1,9-12 
Previously, we found no increases in fecal energy loss in mice treated with rimonabant 
compared to controls (chapter 3)5 or in CB
1
-/- mice compared to WT mice (chapter 5), 
disqualifying a potential role for intestinal malabsorption. In chapter 5, evaluating 
energy balance of CB
1
-/- mice compared to WT mice fed chow, HF or HF/FO, we did 
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observe an increase in daily energy expenditure. Results described in this chapter 
show that energy expenditure expressed per lean mass is increased in CB
1
-/- mice 
compared to WT in both the light period and the dark period. A remarkable finding 
of this study is the effect of genetic CB
1
-ablation on circadian variation in RQ and, thus 
in substrate oxidation. In the light period, FAO expressed per lean mass is increased in 
CB
1
-/- mice compared to WT whereas carbohydrate utilization expressed per lean mass 
is increased in the dark period. Thus, the overall increased energy expenditure in CB
1
-
/- mice compared to WT mice was found to be fuelled differently during the light (i.e., 
by increased FAO) versus the dark phase (i.e., by increased carbohydrate utilization). 
Consequently, there is a more pronounced substrate shift in CB
1
-/- mice compared to 
WT controls during transition from the light period to the dark period. Since these 
observed CB
1
-mediated effects on diurnal patterns in fuel utilization might be a 
reflection of a different pattern in food intake in the CB
1
-/- mice compared to WT mice, 
we investigated circadian rhythm of food intake. This study was conducted in mice fed 
chow, because the largest differences in diurnal patterns in fuel utilization were found 
in mice fed chow. Diurnal patterns of food intake did not differ between CB
1
-/- mice and 
WT controls, indicating that the more pronounced substrate shift from carbohydrate 
utilization in the dark period towards fat oxidation in the light period in CB
1
-/- mice can 
not be attributed to a changed pattern in food intake. 
 Herling et al. suggested that increased energy expenditure in CB
1
-/- mice is due 
to enhanced oxidation of fatty acid which is permitted by increased lipolysis of 
triglycerides in adipose tissue.13 If this chain of events indeed occurs, one would 
expect that temporal patterns of energy expenditure observed in CB
1
-/- mice would be 
synchronized with changes in fatty acid oxidation. The results of our experiments are 
only in agreement with this view during the light period, in which fatty acid oxidation 
prevails. Involvement of CB
1
-mediated signalling specifically related to carbohydrate 
utilization during the dark period should also be considered. Indeed, in another report 
by Herling et al.,14 levels of liver glycogen exhausted more rapidly in rats treated with a 
CB
1
-receptor antagonist than in untreated controls. 
 An important question is whether low activity of the ECS leads to an increased 
mitochondrial fatty acid availability driving fatty acid oxidation or to an increased fatty 
acid oxidation that reduces fatty acid availability for accumulation. In the first scenario, 
a possible mechanism could be imagined allowing increased entry of fatty acids in 
mitochondria and/or decreased entry of fatty acids into adipose tissue. Data described 
in chapter 5 do not support a decreased uptake of fatty acids in adipose tissue, while 
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Flamment et al.15 did demonstrate increased entry of fatty acids in mitochondria from 
rats treated with rimonabant. The next issue then is whether the increased entry into 
metabolically active tissue is “pushing” fatty acid oxidation or whether increased fatty 
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research project  
FFA↓ FFA↑
“pull ” “push ”
Primary FAO ↑ Primary storage↓
Figure 6. Schematic representation of the possible relations between fatty acid oxidation (FAO) 
and levels of free fatty acids (FFA) as influenced by FAO itself, lipogenesis, fatty acid storage and 
release of fatty acids from adipose tissue.
This issue was also raised by Flamment et al.15 They suggested that the rimonabant-
induced increased entry of fatty acids into mitochondria may attribute to the increase 
in fatty acid oxidation. In a simplified model depicting potential mechanisms underlying 
increased lipid oxidation, increased “push” of fatty acid would be expected to result in 
elevation of available circulating free fatty acid (FFA), whereas increased “pull” would 
result in decreased availability of circulating FFA. In our studies, we observed decreased 
availability of circulating FFA (reflected by plasma FFA levels) in HF/FO-fed WT mice 
as compared to WT mice fed either chow or HF diet. No differences in plasma FFA 
levels were found between WT mice and CB
1
-/- mice fed HF diet or HF/FO diet. However, 
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plasma FFA levels in chow-fed CB
1
-/- mice were significantly decreased as compared with 
that in chow-fed WT littermates which also corresponds to the fact that chow-fed CB
1
-/- 
mice and WT mice showed the largest differences in diurnal shift of substrate oxidation. 
Collectively, our data suggest a primary “pull” of fatty acids through increased fatty acid 
oxidation at least in CB
1
-/- mice fed chow. 
 Taken together, the increased energy expenditure in CB
1
-/- mice as compared with 
that in WT littermates is apparently not driven by increased fatty acid oxidation during 
the entire circadian cycle. In fact, our data suggest that increased energy expenditure 
in CB
1
-/- mice is fuelled differently with with an increased fatty acid oxidation in the light 
period and an increased carbohydrate utilization in the dark period. Future experiments 
should be designed to investigate these specific effects.
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In most mammalian species, including humans and rodents, the pattern of food intake 
is characterized by specific meals that are interspaced by periods of varying duration. 
This is allowed because ingested nutrients can be stored in the form of glycogen and 
triglycerides which buffer the flow of fuels that maintain ongoing cellular oxidative 
phosphorylation. Several signalling and effector systems are essential to maintain 
energy balance and fuel homeostasis over prolonged periods of time. Over the last 
two decades, knowledge on mechanisms that regulate energy balance and fuel 
compartmentalization and metabolism has truly exploded. A recently discovered system 
involved in this regulation is the endocannabinoid system (ECS). This system consists 




-receptors), endogenous ligands for these 
receptors called endocannabinoids and enzymes involved in synthesis and degradation 
of endocannabinoids. Among many functions, the ECS was found to be involved in 
regulation of food intake via the CB
1
-receptor. Studies in animals and humans showed 
that blockade of CB
1
-signalling causes temporal reduction in food intake and sustained 





-/-) mice was forced onto wild type (WT) mice for several weeks, CB
1
-/- mice 
were still leaner than WT mice. This demonstrates that CB
1
-mediated effects on body 
weight are partly independent of food intake and suggests that the ECS not only plays 
a pivotal role in regulation of feeding behaviour, but also in modulation of peripheral 
metabolism. Moreover, CB
1
-blockade causes prevention of lipid accumulation in the 
bloodstream and in the liver, which are risk factors for development of hepatic steatosis, 
atherosclerosis, and insulin resistance, all components of the metabolic syndrome.1-3 
Since these effects are observed independently of weight loss, they support the notion 
that regulation of peripheral metabolism contributes to the metabolic effects of 
endocannabinoid signalling. The aim of the work described in this thesis was to explore 
involvement of the ECS in modulation of energy balance in mice and, more specifically, 
the effects of endocannabinoid signalling in fuel partitioning and metabolism. The main 
results of this research are summarized and discussed below. 
Cannabinoid-1 receptor deficient mice





-/- mice (i.e., generated by Zimmer et al.) represent a valid animal model to 




The first study was designed to determine whether the ECS system plays a role in 







+/+ pups born from heterozygous (CB
1
+/-) breeding couples (chapter 2). Compared 
to WT littermates, CB
1
-/- pups at three weeks of age not only showed significantly 
lower body weights but also reduced fat mass. These results reinforce a role for CB
1
-
signalling in neonatal thrift, as has been pointed out by Fride et al.4 In addition to the 
results published by Fride et al., the data in Chapter 2 demonstrate that the phenotypic 
differences between CB
1
-/- and WT mice cannot be attributed to maternal genotype, an 
issue left unresolved in previous research. Moreover, the attenuation of neonatal thrift 
was more pronounced in male pups than in female pups. Findings described in chapters 
3, 4, 5 and 6 are based on results derived from experiments conducted in male mice 
only.
The endocannabinoid system and lipid metabolism
The weight-reducing effects of suppressed endocannabinoid signalling were 
previously suggested to rely, at least in part, on changes in lipid fluxes. Considering 
that endocannabinoids are lipid signalling molecules derived from long chain 
polyunsaturated fatty acids (LC-PUFA) and that specific fatty acids exert pronounced 
effects on lipid fluxes, it was expected that not only dietary fat content but also dietary 
fatty acid composition would influence the outcome of impaired CB
1
-signalling. For 
this reason, the effects of the receptor antagonist SR141716, with the generic name 
rimonabant, were investigated in mice fed either standard laboratory chow (i.e., low-
fat, high-carbohydrate fibered diet), a high saturated fat (HF) diet, or a HF diet in which 
part of the saturated fat was replaced by fish oil (HF/FO) (chapter 3). Since feeding a 
HF diet was found previously to increase hepatic lipogenesis and feeding a HF/FO was 
found to suppress hepatic lipogenesis, we were especially interested in the interaction 
between dietary supplementation of LC-PUFA (i.e., abundant in fish oil) and treatment 
with rimonabant. As expected, feeding a HF diet to control mice induced dyslipidemia 
and hepatic steatosis which were not found in control mice fed the HF/FO diet. 
However, at the same time, the HF/FO diet was found to be most adiposity-promoting 
and effects of treatment with rimonabant to prevent weight gain and adiposity were 
the largest in the HF/FO group. This is in contrast with the previously suggested role 
of hepatic lipogenesis in the anti-adiposity effects of CB
1
-blockade since lipogenesis is 
already remarkably suppressed in mice on HF/FO enriched diet. In mice receiving a HF 
diet as well as in mice receiving either chow or HF/FO diet, rimonabant-treatment led 
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to significantly lower body weight gain than their respective controls without major 
changes in nutrient absorption or energy expenditure.
 Although it was argued that suppressed hepatic lipogenesis is not responsible 
for the anti-adiposity effect of CB
1
-blockade, suppressing hepatic lipogenesis was not 




 To determine the contribution of hepatic lipogenesis to CB
1
-blockade-mediated 
resistance to diet-induced hepatic steatosis, hepatic lipogenesis in CB
1
-/- mice and WT 
littermates on either chow, a HF diet or HF/FO diet was evaluated (chapter 4). Based on 
the results described in this chapter, three arguments can be put forward to exclude the 
possibility that suppressed lipogenesis is a major factor in resistance to diet-induced 
hepatic steatosis in CB
1
-/- mice. First of all, on all three diets, no suppression of hepatic 
lipogenesis was found in CB
1
-/- mice compared to WT mice by measuring incorporation 
of labelled acetate into fatty acids. Secondly, compared to WT littermates, CB
1
-/- mice 
fed HF/FO diet also showed a significant reduction of hepatic triglyceride content, also 
suggesting that hepatic lipogenesis does not contribute to this effect since lipogenesis 
is already suppressed in WT mice fed HF/FO diet. Finally, hepatic fatty acid profiles 
of CB
1
-/- mice fed any of the three experimental diets not only showed decreased 
levels of C16:0 and C18:1 compared to WT littermates, but also decreased levels of 
C18:2. Since C18:2 is an essential fatty acid, this indicates that not suppressed de novo 
lipogenesis, but rather decreased fatty acid uptake or increased fatty acid oxidation 
is involved in resistance to diet-induced hepatic steatosis in CB
1
-/- mice. Furthermore, 
results described in chapter 4 confirmed that VLDL-production is not affected by 
genetic ablation of CB
1
-receptors. Thus, results of chapter 3 and 4 indicate that the 
anti-adiposity effect of treatment with rimonabant can not be attributed to an effect on 
hepatic lipogenesis, nor can resistance to diet-induced hepatic steatosis in CB
1
-/- mice 
be attributed to suppressed hepatic lipogenesis or increased VLDL-production. Results 
so far suggested a decrease in fatty acid uptake by the liver or an increase in fatty acid 
oxidation as a contributor to resistance to hepatic steatosis in CB
1
-/- mice. 
 To further explore the relation between endocannabinoid signalling and lipid 
fluxes, we evaluated effects of CB
1
-deficiency on adipogenesis, adipose tissue lipolysis 
and adipose tissue lipogenesis in relation to dietary fat intake (chapter 5). On all three 
experimental diets, CB
1
-/- mice were resistant to obesity and showed a reduced fat 
mass compared to WT mice. Adipocyte size was reduced in CB
1
-/- mice compared to 






-/- mice and WT mice in expression of differentiation and proliferation 
markers in adipose tissue. Rates of adipocyte fatty acid synthesis were only stimulated by 
HF feeding only and CB
1
-deficiency did not reduce fatty acid synthesis in adipose tissue. 
Post-heparin and adipose tissue-derived LPL activity were comparable in all groups. It is 
therefore concluded that the resistance of CB
1
-/- mice to high-fat diet-induced obesity is 
not related to altered adipocyte function per se but rather results from a lower amount 
of energy available for storage due to an increase in energy expenditure. 
The endocannabinoid system, energy expenditure and substrate utilization
In chapter 6 the effects of endocannabinoid signalling on energy expenditure and 
substrate utilization were explored in relation to circadian rhythm. Based on previous 
results, showing decreased RQ in mice treated with rimonabant compared to controls, 
and based on reported data suggesting increased fatty acid oxidation in CB
1
-/- mice 
underlying increased energy expenditure, we expected energy expenditure in CB
1
-/- 
mice to be temporally related to increased rate of fat oxidation. Since carbohydrate 
and fat oxidation are known to fluctuate over the diurnal cycle - with high levels of fat 
oxidation during the inactive (i.e. light) phase and increased carbohydrate oxidation 
during the active (i.e., dark) phase – we focussed on diurnal variations in energy 
expenditure and substrate utilization in CB
1
-/- mice and wild type littermates subjected 
to either chow, a HF diet or HF/FO diet (chapter 6). The results showed that energy 
expenditure normalized for lean mass is increased in CB
1
-/- mice compared to WT in 
both the inactive phase and the active phase. Remarkably, this increased expenditure 
is fuelled differently during the day with an increased fatty acid oxidation expressed 
per lean mass in the inactive phase and increased carbohydrate oxidation expressed 
per lean mass in the active phase. Thus, these data do not support a role for fatty 
acid oxidation in driving energy expenditure in CB
1
-deficient mice. This is supported by 
significantly decreased plasma free fatty acid (FFA) availability in CB
1
-/- mice halfway the 
inactive phase. Diurnal patterns of food intake did not differ between CB
1
-/- mice fed 
chow and WT controls, indicating that the more pronounced substrate shift towards 
fatty acid oxidation in the inactive phase in CB
1
-/- mice and towards carbohydrate 




The endocannabinoid system and lipid metabolism
Data described in this thesis demonstrate that both pharmacological blockade of 
the CB
1
-receptor and targeted deletion of the CB
1
-receptor result in decreased body 
weight gain and reduced body fat mass compared to respectively vehicle-treated or 
WT controls, confirming the association between a lean phenotype and disruption of 
CB
1
-signalling (chapter 2-6). However, contrary to the hypothesis suggested by others 
that this lean phenotype is based on primary changes in adipose tissue functioning 
itself (chapter 5), a reduced availability of fatty acids left for storage appears to be a 
key issue in the effect of CB
1
-disruption. This reduced availability of fatty acids is not 
a consequence of changes in lipogenesis, since lipogenesis in vivo neither in adipose 
tissue nor in the liver differed between CB
1
-/- and WT mice (chapter 4 and 5). Potentially, 
increased fatty acid oxidation, as suggested by results described in this thesis (chapter 
4 and 6) and by results reported by others, might contribute to decreased availability 
(Figure 1). 
Peripheral effects on energy balance of 
impaired CB1-signalling: 
data of this thesis 
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Figure 1. Summarized of peripheral effects of impaired CB
1
-signalling on energy balance 
based on data described in this thesis. Abbreviations; VLDL, very low density lipoproteins; FA, 




 An important question is whether low activity of the ECS leads to an increased 
mitochondrial fatty acid availability driving fatty acid oxidation (for example as a 
consequence of decreased uptake of fatty acids by adipose tissue) or an increased 
fatty acid oxidation reducing fatty acid availability for fat accumulation. Data described 
in chapter 5 do not support a decreased uptake of fatty acids in adipose tissue. An 
increased entry of fatty acids into mitochondria was put forward by Flamment et al.5 
leading in turn to the discussion whether this increased entry is either the consequence 
of increased fatty acid oxidation or causing increased fatty acid oxidation (chapter 6 
figure 6). Flamment et al., based on their data on mitochondrial function in rats treated 
with rimonabant, suggested that the rimonabant-induced increased entry of fatty acids 
into mitochondria may contribute to the increase in fatty acid oxidation. Our data 
showing significantly decreased plasma FFA levels in CB
1
-/- mice fed compared to WT 
littermates suggest that increased fatty acid oxidation is the primary factor (chapter 
6). In this event, FFA are pulled into mitochondria away from plasma to fuel fatty acid 
oxidation. 
 Part of the controversy on primary and secondary mechanisms by which reduced 
activity of CB
1
-signalling contributes to leanness is explained by short-term versus 
chronic manipulation of the CB
1
-signalling. For example, Herling et al. reported an 
immediate increase in plasma FFA level after a single dose of rimonabant administered 
to rats in the postprandial state and concluded that rimonabant induces lipolysis in vivo.6 
By contrast they observed that long-term treatment with rimonabant reduced plasma 
FFA levels and they stated that this reflected decreased fat mass. They hypothesized 
that treatment with rimonabant results in mobilization of fat stored in adipocytes via 
stimulation of lipolysis. According to their hypothesis this mobilization of fat initially 
results in increased plasma FFA levels, whereas later on, when total fat mass is reduced, 
plasma FFA levels will decrease during treatment with rimonabant.6 Although acute 
administration of compounds can easily induce non-physiological changes, the point 
raised by Herling et al. has to be taken into account to fully understand the driving 
forces of CB
1
-mediated changes in lipid metabolism. Taken together, increased fatty 
acid oxidation appears to contribute to the lean phenotype of CB
1
-/- mice. To establish 
in animal models the contribution of fatty acid oxidation to diet-induced increases in 
adiposity and diet-induced hepatic steatosis it is essential to determine changes in 
lipid fluxes over time. This is a challenging task since several intermediates of lipid 
metabolism are involved and have to be taken into account. 
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Interaction of dietary LC-PUFA intake and endocannabinoid tone
Long chain polyunsaturated fatty acids (LC-PUFA), abundant in fish oil, are suggested 
to favourably affect metabolic risk factors like hepatic steatosis and insulin resistance 
compared to saturated fatty acids. They improve plasma lipid profiles and suppress 
de novo lipogenesis. Because of the suppression of hepatic lipogenesis demonstrated 
in mice fed HF/FO diet and the suggested role of CB
1
-mediated hepatic lipogenesis in 
the development of obesity and hepatic steatosis, we expected mice fed HF/FO 1) to 
have a reduced fat mass; 2) to be resistant to diet-induced hepatic steatosis; and 3) 
to be less sensitive to the effects of treatment with a CB
1
 receptor antagonist. The 
work described in this thesis demonstrates indeed favourable effects on dyslipidemia 
and hepatic steatosis after supplying a HF/FO diet to young male mice. However, this 
HF/FO diet was found to be remarkably obesity-promoting and although anti-obesity 




-deficiency were observed in mice on 
either chow or HF diet or HF/FO diet, the most prominent effects of CB
1
-blockade to 
cause body weight loss and reduced adiposity were observed in the HF/FO group. A 
possible explanation for the obesity-inducing effects of dietary LC-PUFA replacement 
in a HF diet might involve expansion of adipose tissue via increased adiponectin as 
was proposed by Kim et al.7 This adipose tissue expansion might allow the favourable 
effects of dietary LC-PUFA to ameliorate dyslipidemia and hepatic steatosis , and this is 
apparently mediated via the CB
1
-receptor (this thesis).
 Another explanation for an interaction between dietary LC-PUFA content 
and treatment effect of a CB
1
-receptor antagonist would be an effect of dietary 
LC-PUFA content on endocannabinoid tone. As endocannabinoid precursors, LC-
PUFA could theoretically influence activity of the endocannabinoid system. There 
are reports suggesting decreased endocannabinoid levels following dietary LC-
PUFA supplementation.8,9 In contrast, results of others point in the direction of a 
stimulating effect of LC-PUFA on the ECS.10 Overactivity of the endocannabinoid 
system is associated with increases in body adiposity. Therefore, an interesting 
explanation for the significantly increased body weight and fat gain in mice fed HF/
FO diet compared to mice fed chow and mice fed HF diet would be a stimulation of 
the endocannabinoid system by dietary LC-PUFA supplementation. If dietary fish oil 
stimulates endocannabinoid activity, treatment with a CB
1
-receptor antagonist would 
have a stronger effect in mice on HF/FO diet than in mice fed a HF diet without LC-
PUFA supplementation. Although we were not able to detect an effect of HF/FO diet 
on expression of CB
1




(responsible for synthesis of anandamide) (data not shown), these data do not exclude 
an interaction between fish-oil supplementation and activity of the endocannabinoid 
system. To reveal a potential interaction it is necessary to directly determine the effect 
of dietary fish oil on endocannabinoid levels in relevant tissues. A pitfall of investigating 
effects of fish-oil supplementation on endocannabinoid signalling is that the ratio n-3 
to n-6 PUFA can vary between various forms of fish oil. This ratio could be responsible 
for differential effects on endocannabinoid tone with n-6 PUFA presumably increasing 
endocannabinoid levels via increased precursor availability and n-3 PUFA suppressing 
endocannabinoid levels via competing with n-6 for location in membranes. This could 
explain controversy in reported findings. 
 It is especially relevant to further investigate an interaction between fish-oil 
supplementation and activity of the endocannabinoid system also in relation to fish-oil 
supplementation-induced expansion of adipose tissue mass, since fish oil is nowadays 
broadly advertised as being beneficial for health. In fact, LC-PUFA are being added to 
many food products (i.e., butter, bread, oil), before having evaluated all advantages and 
disadvantages thoroughly. 
Endocannabinoid interference with energy balance
Weight gain and weight loss result from an imbalance between energy intake and energy 
expenditure. Consequently, reduced body weight gain is either caused by decreased 
food intake or increased energy expenditure or both. As such, indirect calorimetry in 
chapters 5 and 6 identified differences in energy expenditure between CB
1
-/- and WT 
mice, which could contribute to the resistance of (diet-induced) weight gain in the 
first. However, results of experiments described in chapter 3 of this thesis revealed 
a dramatic reduction in body weight gain and adiposity in rimonabant-treated mice 
versus controls despite a transient and small reduction in food intake and no increase 
in oxygen consumption (Figure 2). 
 Since differences in absorption were also excluded by measuring fecal energy 
contents, these results suggest a form of energy dissipation in mice treated with 
rimonabant independent from oxygen consumption. Indirect calorimetry offers 
an estimation of energy expenditure based on oxygen consumption whilst oxygen 
consumption might result in different amounts of ATP-production. The latter is, for 
example, the case when the coupling between ongoing oxidative phosphorylation and 
the proton gradient across the mitochondrial membrane is disrupted. This example 
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illustrates the limitation of indirect calorimetry in estimating energy expenditure in 
vivo. 
Energy in Energy out
Similar intake as
compared to controls
Similar O2 consump	on 
as compared to controls






reduced body weight gain
Figure 2. Schematic representation of presumed effect of impaired CB1-signalling on energy 
balance.
Several studies indicate that decreased mitochondrial efficiency is indeed involved in 
resistance to weight gain in mice treated with rimonabant. First, microarray analysis 
of transcriptional patterns in adipose tissue after treatment with rimonabant in WT 
and CB
1
-/- mice fed HF diets indicated increased energy expenditure mainly through 
futile cycling (via simultaneous induction of glycogen phosphorylase and glycogen 
synthase and via induction of expression of calcium-binding proteins that transport 
calcium across membranes in opposite directions).11 Secondly, Shearman et al. 
showed induction of uncoupling protein 1 and uncoupling protein 3 mRNA expression 
in brown adipose tissue of mice with diet-induced obesity that were treated for 
9 days with a CB
1
-antagonist.12 Moreover, Tedesco et al. described that rimonabant 
increased mitochondrial DNA amount, mRNA levels of genes involved in mitochondrial 
biogenesis, mitochondrial mass and function, via eNOS induction as discussed in 
chapter 6.13 Finally, Flamment et al. determined mitochondrial enzyme activity in 
isolated liver mitochondria, mitochondrial DNA quantity and oxygen consumption with 
various substrates in Sprague Dawley rats on HF diet treated with rimonabant for three 
weeks compared to vehicle-treated, pair-fed controls. They showed that treatment 
with rimonabant results in improvement of mitochondrial function via facilitation of 
substrate oxidation and via increasing fatty acid entry into mitochondria and increasing 




 In case of uncoupling or other forms of energy dissipation, energy is thought to 
be lost as heat. We therefore conducted a pilot experiment to evaluate whether mice 
generate more heat when treated with rimonabant. We hypothesized that, if decreased 
mitochondrial efficiency contributes to the lean phenotype upon CB
1
-blockade, these 
mice should generate more heat and radiate this heat to the environment. Hence, 
these mice should become hyperthermic under enthermic conditions. In contrast to our 
hypothesis, we found no differences in body temperature between rimonabant-treated 
mice and vehicle-treated controls when room temperature was maintained at 33oC for 
12 hours. Clearly, further studies are needed to determine the role of thermogenesis 
and mitochondrial efficiency in CB
1
-mediated effects on energy balance.
 As mentioned above, results of experiments described in chapter 5 and 6, 
comparing CB
1
-/- mice to WT mice, did show small elevations in energy expenditure 
in CB
1
-/- mice compared to WT mice. It is, however, conceivable that decreased 
mitochondrial efficiency also contributes to the observed lean phenotype in CB
1
-/- mice. 
A possible contribution of mitochondrial function to resistance of CB
1
-/- mice compared 
to WT mice to diet-induced weight gain and adiposity-related metabolic derangements 
needs to be further explored.
 If it is believed that hyperactivity of the ECS predisposes to weight gain and related 
metabolic profiles, then what is the relevance of this system that is so abundantly 
present in the nervous system and so well-preserved throughout evolution? In 1962, 
Neel proposed that obesity and associated diseases could be attributed to the existence 
of ‘thrifty genes’.14,15 According to his hypothesis a “thrifty genotype” is responsible for 
a phenotype that is exceptionally efficient in intake and utilization of food and hence 
to be of high selective value in pre-historic times when most species had to survive 
periods of food deprivation. Based on this theory, most species are biased towards 
conserving energy, because starvation used to be a major threat for survival. Since the 
environment has changed dramatically for humans in Western society over a relative 
short time, this initially successful biologically adaptive mechanism has become 
maladaptive and contributes to the current pandemic of obesity and associated 
metabolic derangements.14,16 Since the function of the ECS in the regulation of fuel 
metabolism and partitioning can be qualified as “energy-conserving”, one can consider 
endocannabinoid signalling to be an explicit thrifty mechanism. Thus, according to 
Neel’s hypothesis, overactivity of the endocannabinoid system could have been of 
survival advantage in pre-historic times whereas it is considered “dysfunctional” in 
many scientific evaluations.17-20 
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A totally different view, but not necessarily excluding the previous one, is that 
conserving energy serves a purpose in the sense of protecting from oxidative stress as 
was put forward by Nunn et al.21 These authors stated that endocannabinoids play a 
role in storing fat safely to prevent toxic effects of fatty acid overload. According to this 
view, thriftiness should not be considered as a “remnant adaptation following survival 
advantage to past periods of starvation”, but as a pivotal mechanism in dealing with 
oxidative stress.
Clinical relevance of manipulating the endocannabinoid system in relation 
to regulation of energy balance 
Shifting from fundamental research on the involvement of the ECS in the regulation 
of energy balance in animal models to clinical implications seems a giant leap. 
However, the obesity epidemic has led to an unprecedented search for new targets 
for weight loss medication. Worldwide, 1.6 billion adults (over 15 years of age) are 
overweight and 400 million adults are obese according to the definition of the World 
Health organization. In addition, 20 million children under the age of 5 are overweight 
globally.22 According to Statistics Netherlands (Centraal Buro voor de Statistiek), based 
on the criteria of the World Health Organization, one out of nine children is overweight 
in the Netherlands.23 Obese patients are at risk for cardiovascular disease and type II 
diabetes and obesity has been associated with other metabolic risk factors such as 
hypertension, hepatic steatosis, dyslipidemia, and insulin resistance. Obesity-related 
diseases like diabetes type II are diagnosed at continuously younger age. These dramatic 
numbers stress the urgent need to develop strategies to prevent and treat obesity and 
related derangements. Consequently, it is important to identify mechanisms underlying 
disturbances in energy balance.
 The emerging role of the ECS in the regulation of energy balance and fuel 
homeostasis seems to offer new possibilities. Interestingly, the endocannabinoid system 
appears to be involved in several aspects of the complex pathophysiology of obesity 
and its comorbidities. It is not only involved in rewarding and satiety aspects of food 
intake, but also in regulation of lipid and glucose metabolism, adipocyte proliferation 
and differentiation, gastro-intestinal function and energy expenditure. Despite recent 
registration of anti-obesity drugs based on antagonizing endocannabinoid activity, 
many aspects of endocannabinoid regulation of energy balance and beyond are still 
unknown today. Thus, although the CB
1
-receptor antagonist rimonabant has already 




European countries, registration was recently withdrawn due to concerns related to 
adverse psychological effects. These latter issues are to be taken seriously since subjects 
with obesity and related metabolic risk factors more frequently suffer from mood 
disturbances than healthy subjects. So, it is relevant to discuss clinical implications to 
make the connection between current basal knowledge and clinical practice. Clinical 








-mediated endocannabinoid signalling affects weight gain via central and 
peripheral modulation of energy balance.
3. Endocannabinoid signalling via CB
1
-receptors is involved in many physiological 
functions including cognitive processes, nociception, emotion, and neuroprotection 
thus increasing the risk of adverse effects when interfering with endocannabinoid 
signalling.
4. Increased mortality of CB
1
-/- mice and the fact that the ECS is a phylogenetically old 
system that is well preserved throughout evolution, suggest that endocannabinoid 
activity is pivotal for survival for example via protection against oxidative stress.
5. Males, as compared to females, show a more pronounced phenotype with respect 
to effects of CB
1
-blockade.
Since the recognition of the regulatory role of the ECS in energy balance, it was identified 
as a promising target for weight loss medication. However, in line with the many 
physiological functions of the ECS, there is a high risk of adverse, especially centrally-
evoked side effects. Targeting future CB
1
-antagonists/ inverse agonists to bypass central 
effects while maintaining peripheral effects on obesity and its comorbidities is a logical 
next step.24 Further elucidation of peripheral effects of endocannabinoids on metabolic 




(1) den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the 
metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644-
649.
(2) Haffner SM. The prediabetic problem: development of non-insulin-dependent diabetes mellitus 
and related abnormalities. J Diabetes Complications 1997; 11: 69-76.
(3) Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Jarvinen H. Increased liver fat, 
impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. 
Gastroenterology 2008; 135: 122-130.
(4) Fride E, Foox A, Rosenberg E et al. Milk intake and survival in newborn cannabinoid CB1 receptor 
knockout mice: evidence for a “CB3” receptor. Eur J Pharmacol 2003; 461: 27-34.
(5) Flamment M, Gueguen N, Wetterwald C, Simard G, Malthiery Y, Ducluzeau PH. Effects of the 
cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat 
diet. Am J Physiol Endocrinol Metab 2009.
(6) Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more 
to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar 
rats. Endocrinology 2008; 149: 2557-2566.
(7) Kim JY, van de Wall E, Laplante M et al. Obesity-associated improvements in metabolic profile 
through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-2637.
(8) Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V. Effect of polyunsaturated fatty acids 
on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 
2008; 1781: 52-60.
(9) Banni S, Di Marzo V. Effect of dietary fat on endocannabinoids and related mediators: consequences 
on energy homeostasis, inflammation and mood. Mol Nutr Food Res 2010; 54: 82-92.
(10) Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of 
dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding 
N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 2001; 98: 6402-6406.
(11) Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the 
diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 
2005; 19: 1567-1569.
(12) Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid 
system in endocrine regulation and energy balance. Endocr Rev 2005.
(13) Tedesco L, Valerio A, Cervino C et al. Cannabinoid type 1 receptor blockade promotes mitochondrial 
biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 
2008; 57: 2028-2036.
(14) Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum 
Genet 1962; 14: 353-362.
(15) Benyshek DC, Watson JT. Exploring the thrifty genotype’s food-shortage assumptions: a cross-
cultural comparison of ethnographic accounts of food security among foraging and agricultural 
societies. Am J Phys Anthropol 2006; 131: 120-126.
(16) van Dijk G, Buwalda B. Neurobiology of the metabolic syndrome: an allostatic perspective. Eur J 
Pharmacol 2008; 585: 137-146.
(17) Matias I, Gonthier MP, Orlando P et al. Regulation, function, and dysregulation of endocannabinoids 
in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol 




(18) Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 
increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte 
cells. Mol Pharmacol 2003; 63: 908-914.
(19) Engeli S, Bohnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in 
human obesity. Diabetes 2005; 54: 2838-2843.
(20) Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 2008; 20 
Suppl 1: 110-115.
(21) Nunn AV, Guy GW, Bell JD. Endocannabinoids, FOXO and the metabolic syndrome: Redox, function 
and tipping point - The view from two systems. Immunobiology 2009.
(22) World Health Organization. 2006. Ref Type: Internet Communication
(23) Centraal buro voor de statistiek. 2009. Ref Type: Internet Communication
(24) de Kloet AD, Woods SC. Minireview: Endocannabinoids and their receptors as targets for obesity 
therapy. Endocrinology 2009; 150: 2531-2536.

APPENDICES









Obesitas ofwel ernstig overgewicht is een wereldwijd gezondheidsprobleem, niet 
alleen bij volwassenen maar in toenemende mate ook bij kinderen. Obesitas speelt 
een grote rol in het ontwikkelen van andere aandoeningen als suikerziekte en hart- en 
vaatziekten. Aan de basis van het ontstaan van de huidige epidemie van overgewicht 
ligt een overvloedige inname van nutriënten in combinatie met een minder actieve of 
passieve levensstijl. Hoewel deze gevolgtrekking op het eerste gezicht eenvoudig is, 
blijkt de werkelijke achtergrond van de obesitas-epidemie veel complexer te zijn en 
interacties tussen genetische, psychologische, pedagogische, socio-economische, dieet- 
en epigenetische factoren te omvatten. Opmerkelijk is dat individuen die ogenschijnlijk 
blootgesteld zijn aan dezelfde omgevingsfactoren een grote variatie kunnen vertonen 
in de ontwikkeling van overgewicht. Zowel vanuit fundamenteel als klinische oogpunt 
is het interessant om meer inzicht te verkrijgen in de intrinsieke regelmechanismen 
die deze variatie kunnen verklaren. Een veelbelovende kandidaat op dit vlak is het 
endocannabinoïd systeem (ECS). 
 De naam ‘endocannabinoïd systeem’ is afkomstig van cannabis. Cannabinoïd-
receptoren worden gestimuleerd door o.a. Δ9-THC, het belangrijkste psychoactieve 
bestanddeel van cannabis. Twee decennia geleden werden deze cannabinoïd 
receptoren geïdentificeerd, aanvankelijk in dieren maar later ook in mensen. Vervolgens 
werden lichaamseigen stoffen ontdekt die op deze receptoren aangrijpen: deze worden 
endocannabinoïden genoemd. Er zijn verschillende cannabinoïd-receptoren waarvan 
de cannabinoïd-1-receptor (CB
1
) en de cannabinoïd-2-receptor (CB
2
) het bekendst zijn. 
CB
1
-receptoren komen vooral voor in het centraal zenuwstelsel, maar ook buiten de 
hersenen, bijvoorbeeld in lever-, in spier- en in vetweefsel. CB
2
-receptoren komen 
vooral voor op cellen van het afweersysteem. De CB
2
-receptor valt buiten het bestek 
van dit proefschrift, aangezien het niet of nauwelijks betrokken is bij regulatie van de 
energiebalans. Opmerkelijk is dat endocannabinoïden gevormd worden uit langketen 
meervoudig onverzadigde vetzuren (LCPUFA, o.a. omega-3 en omega-6 vetzuren). Deze 
vetzuren komen veel voor in visolie. Verondersteld wordt dat de hoeveelheid omega-3 
en omega-6 vetzuren in het dieet van invloed is op de activiteit van het endocannabinoïd 
systeem.
 Van cannabis is al sinds de oudheid bekend dat het een stimulerend effect heeft 
op eetlust en tegenwoordig wordt Δ9-THC gebruikt om eetlust te stimuleren bij 
oncologische patiënten. Op grond van deze observatie is remming van de activiteit 
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van het endocannabinoïd systeem onderzocht als een mogelijk aangrijpingspunt voor 
het ontwikkelen van medicijnen voor de preventie en behandeling van obesitas. De 
eerste CB
1
-antagonist, rimonabant genaamd, bleek in studies bij zowel dieren als 
mensen gewichtstoename te voorkomen. Aanvankelijk werd verondersteld dat het 
gewichtsverminderende effect van blokkeren van de CB
1
-receptor een exclusief gevolg 
is van het remmen van eetlust. Echter, onafhankelijk van het effect op gewicht werden 
ook gunstige effecten van behandeling met rimonabant op andere risicofactoren 
van overgewicht gevonden zoals verlaging van plasmacholesterol en verbeterde 
insulinegevoeligheid. Ook bleek uit dierproeven dat wanneer ‘normale’ muizen (wild 







-/-) – de laatste minder dik worden dan WT 
muizen. Dit laat zien dat het ECS effecten heeft op energiebalans die onafhankelijk zijn 
van de effecten via de voedselinname. Hoewel rimonabant aanvankelijk veelbelovend 
leek in de behandeling van obesitas, is de registratie van rimonabant als medicijn voor 
obesitas opgeschort op grond van het optreden van ernstige bijwerkingen (depressie 
en verhoogd risico op suïcide). 
 Het doel van het onderzoek beschreven in dit proefschrift is inzicht verkrijgen in hoe 
het ECS betrokken is bij de regulatie van energie balans. Daarbij is tevens gekeken naar 
de interactie met visolie aangezien endocannabinoïden gevormd worden uit langketen 
meervoudig onverzadigde vetzuren die als zodanig de activiteit van het systeem zouden 
kunnen beïnvloeden.
 Een aantrekkelijk model om het endocannabinoïd systeem te bestuderen is de 
eerder genoemde CB
1
-/--muis. In hoofdstuk 2 wordt beschreven dat de CB
1
-receptor 
al vroeg in de ontwikkeling een rol speelt in de energiehuishouding. Eerder onderzoek 
bij muizen had aangetoond dat pups van CB
1
-/--moeders een lager lichaamsgewicht 
hebben dan pups van WT moeders. Uit deze eerdere studies kon echter niet worden 
geconcludeerd of dit het effect was van maternale factoren (bijvoorbeeld lactatie 
of zorg voor pups) dan wel van het ontbreken van de CB
1
-receptor in de pup. 
Voor de experimenten beschreven in hoofdstuk 2 zijn heterozygote CB
1
+/- muizen 
paartjes gekruist waarbij in overeenstemming met de verwachting op basis van 
erfelijkheidsprincipes ongeveer 25% van de pups CB
1
-/-, 25% WT en 50% heterozygoot 
bleek te zijn. Op deze manier konden, van dezelfde moeder, pups met en zonder de 
CB
1
-receptor met elkaar vergeleken worden. De gevonden significante verschillen in 
lichaamsgewicht en vetpercentage op de leeftijd van 3 weken tonen aan dat de CB
1
-
receptor een rol speelt in groei van jonge muizen en dat een effect op lichaamsgewicht 
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en vetgehalte dus onafhankelijk van het maternale genotype gevonden wordt. Uit de 
data beschreven in hoofdstuk 2 bleek verder dat het verschil tussen het CB
1
-/-- en WT 
genotype groter is in mannelijke pups dan in vrouwelijk pups. Resultaten beschreven in 
hoofdstuk 3, 4, 5 en 6 zijn gebaseerd op studies in mannelijke muizen.
 Een kerngedachte in dit onderzoek was dat metabole verandering door manipuleren 
van activiteit van het endocannabinoïd systeem met name gezocht moeten worden 
in specifieke effecten op het vetmetabolisme. Aangezien endocannabinoïden uit 
meervoudig onverzadigde vetzuren (PUFA) worden gevormd en aangezien bekend is 
dat deze vetzuren het vetmetabolisme beïnvloeden, zou kunnen worden aangenomen 
dat de hoeveelheid PUFA in het dieet van invloed is op effecten van blokkeren van 
CB
1
-activiteit. In hoofdstuk 3 zijn resultaten beschreven van studies in muizen die 
een van de volgende diëten kregen toegediend: 1) een standaard vezelrijk en vetarm 
dieet, 2) een hoog-vet dieet op basis van verzadigde vetzuren, of 3) een hoog-vet dieet 
waarbij een gedeelte van het vet afkomstig was uit visolie. Van elke dieetgroep werd 
de helft van de muizen behandeld met rimonabant. De rimonabant-behandelde dieet 
groepen namen significant minder toe in gewicht dan de controlegroepen. Opmerkelijk 
was dat deze relatieve gewichtsvermindering niet gepaard ging met een verminderde 
energie inname, noch met verminderde absorptie in de darm of een meetbaar verschil 
in energieverbruik. In overeenstemming met de verwachtingen lieten resultaten van 
hoofdstuk 3 leververvetting en dyslipidemie zien in de controlegroep op het hoog-vet 
dieet, terwijl dit niet werd gevonden in de controlegroep op het hoog-vet visolie dieet. 
Van het hoog-vet dieet is bekend dat het de vetzuuraanmaak in de lever verhoogd, 
terwijl van diëten rijk aan PUFA (zoals visolie) bekend is dat het de vetzuuraanmaak in 
de lever juist verminderd. Eerder was gesuggereerd dat het effect van blokkering van 
CB
1
-activiteit op het voorkomen van gewichtstoename een gevolg zou zijn van remming 
van de vetzuuraanmaak in de lever. Op basis van deze suggestie werd verwacht dat 
behandeling met rimonabant minder effect zou hebben op gewichtstoename van 
muizen die het hoog-vet visolie dieet kregen toegediend aangezien dit dieet de 
vetzuuraanmaak in de lever zelf al onderdrukt. Echter, de resultaten beschreven in 
hoofdstuk 3 laten het tegenovergestelde zien, namelijk dat het grootste effect van 
behandeling met rimonabant op gewichtstoename te vinden is in de hoog-vet visolie 
groep. Deze resultaten zijn dus in tegenspraak met een rol voor onderdrukking van 
de vetzuuraanmaak in het effect van behandeling met rimonabant op overgewicht. 
De studie beschreven in hoofdstuk 4 was opgezet om effecten van manipulatie van 
het endocannabinoïd systeem op vetzuuraanmaak in de lever nader te bepalen en 
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mogelijke mechanismen verantwoordelijk voor de ongevoeligheid van CB
1
-/--muizen 
voor leververvetting te evalueren. 
 In hoofdstuk 4, 5 en 6 is gekeken naar verschillen tussen jonge CB
1
-/--muizen en WT 
muizen afkomstig uit dezelfde nesten. Na verspenen kregen deze muizen gedurende 
6 weken één van de drie boven genoemde diëten toegediend. CB
1
-/--muizen op een 
hoog-vet dieet kregen geen leververvetting in tegenstelling tot WT muizen op hetzelfde 
dieet (hoofdstuk 4). De vetzuuraanmaak in de lever bleek echter niet te verschillen 
tussen CB
1
-/--muizen en WT muizen en ook de hoeveelheid vet die de lever verliet 
bleek niet te verschillen. Dit wijst op een verschil in aanvoer van vetzuren naar de 
lever (opname vanuit het bloed) dan wel een verschil in verbruik van vetzuren in de 
lever (vetzuuroxidatie). Ontwikkeling van het vetweefsel (adipogenese), aanmaak van 
vetzuren in het vetweefsel (lipogenese) en opname van vetzuren in het vetweefsel 
(lipolyse door LPL-activiteit) bleken niet beïnvloed door afwezigheid van de CB
1
-receptor 
(hoofdstuk 5). Wel bevestigden resultaten beschreven in hoofdstuk 5 dat CB
1
-/--muizen 
ongevoelig zijn voor het ontwikkeling van obesitas op een hoog-vet dieet en een 
verminderd vetgehalte hebben in vergelijking tot WT muizen uit dezelfde nesten. Tevens 
werden in CB
1
-/--muizen significant kleinere vetcellen gevonden vergeleken met die in 
WT muizen. Dit lijkt dus niet een gevolg te zijn van veranderingen in functioneren van 
het vetweefsel zelf maar eerder een gevolg van veranderingen in aanbod van vet voor 
opslag. Mogelijk speelt een verhoogd verbruik van vetzuren hierin een rol. Op chow en 
op hoog-vet dieet werd zowel in muizen behandeld met rimonabant (hoofdstuk 3) als in 
CB
1
-/--muizen (hoofdstuk 6) in vergelijking tot de respectievelijke controlegroepen, een 
significante verlaging van de respiratoire quotiënt (RQ) gevonden, hetgeen aansluit bij 
een toegenomen verbruik van vetzuren als energiebron (substraat). Hoofdstuk 6 gaat 
in op de vraag of een verhoogd vetzuurverbruik de stuwende kracht is achter verhoogd 
energieverbruik of – vice versa – dat verhoogd energieverbruik juist de oorzaak is van 
een verhoogd vetzuurverbruik. Het laatste lijkt het geval aangezien wel een verhoogd 
energieverbruik werd gevonden in CB
1
-/--muizen ten opzichte van WT muizen maar geen 
relatie in de tijd bleek te bestaan tussen toegenomen vetzuurverbruik (alleen overdag, 
dus in gevaste toestand) en verhoogd energieverbruik (hele dag).
 Concluderend bevestigen deze resultaten dat onderdrukking van activiteit van het 
endocannabinoïd systeem resulteert in gewichtsafname en een gunstiger metabool 
profiel (verlaagd vetgehalte, minder leververvetting, ‘minder ongunstige vetten in het 
bloed’). Deze effecten van blokkering van de CB
1
-receptor blijken niet gerelateerd te 
zijn aan veranderingen in het functioneren van het vetweefsel en er lijkt geen sprake 
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te zijn van onderdrukking van vetzuuraanmaak in de lever, noch in het vetweefsel. 
Mogelijk is sprake van een toegenomen energieverbruik m.n. door metabolisme van 
vetzuren. Interessant is daarbij ook de rol van efficiëntie in omgaan met beschikbare 
energie, hetgeen nader onderzoek verdient. Daarnaast verdient de rol van visolie in 
het dieet in bovengenoemde regulatiemechanismen extra aandacht, zeker gezien de 
bevindingen in dit proefschrift dat visolie suppletie in het dieet van muizen – naast 
gunstige metabole effecten – een ongewenste toename in vetgehalte en gewicht 
tot gevolg had. In hoeverre inzicht in de werking van het ECS uiteindelijk klinische 
toepasbaar is, is op dit punt moeilijk in te schatten. Aan de ene kant benadrukken de 
hier beschreven resultaten dat het ECS een veelbelovend aangrijpingspunt vormt voor 
preventie en behandeling van obesitas en comorbiditeit, echter de keerzijde is dat het 
ECS betrokken is bij de regulatie van uiteenlopende functies met name gerelateerd aan 
‘preventie van schade’ waarbij manipuleren van de activiteit van dit systeem dus een 
groot risico op bijwerkingen met zich mee zou kunnen brengen. Lange termijn studies 
zijn essentieel om alle laatstgenoemde negatieve effecten te evalueren tegenover de 

































FAAH fatty acid amide hydrolase
FAO fatty acid oxydation
FFA free fatty acids
FO fish oil
FTT failure to thrive
GLM general linear model
HF high-fat
HF/FO high-fat fish-oil enriched




MIDA mass isotopomer distribution analysis
NAFLD non-alcoholic fatty liver disease
NAPE-PLD  N-acyl phosphatidylethanolamine phospholipase D
PCRF percent relative cumulative frequency





VLDL very low-density lipoprotein(s)
WT wild type 
ZT Zeitgeber time
Abbreviations of genes
Gene  Official abbreviation
Acc1 acetyl-Co-enzyme A carboxylase alpha Acaca
Acc2 acetyl-Co-enzyme A carboxylase beta Acacb
Arcp30 adiponectin Adipoq
Aox acetyl-Co-enzyme A oxidase 1, palmitoyl Acox1
Ap2 fatty acid binding protein 4 Fabp4
Atgl/desnutrin adipose triglyceride lipase Pnpla2
B-actin actin, beta Actb
Cb1 cannabinoid receptor 1 Cnr1
Cd36 CD36 antigen (fatty acid translocase) Cd36
Cebpα CCAAT/enhancer binding protein α C/ebpα
Chrebp MLX interacting protein-like Mlxipl
Cpt1a carnitine palmitoyltransferase 1a, liver Cpt1a
Cyclophilin G peptidyl-prolyl isomerase G Ppig
Dgat2 diacylglycerol O-acyltransferase 2 Dgat2
Elovl6 ELOVL family member 6,  
 elongation of long chain fatty acids Elovl6
Faah fatty acid amide hydrolase Faah
Fas fatty acid synthase Fasn
Fatp4 solute carrier family 27  
 (fatty acid transporter), member 4 Slc27a4
Fatp5 solute carrier family 27 
 (fatty acid transporter), member 5 Slc27a5
Fxr farnesoid x receptor Nr1h4
HmgCoas 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2
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Hsl hormone sensitive lipase Lipe
Lcad acyl-Coenzyme A dehydrogenase, long chain Acadl
L-fabp fatty acid binding protein 1, liver Fabp1
Lpl lipoprotein lipase Lpl
Lxr liver x receptor Nr1h3
Nape-pld N-acyl phosphatidylethanolamine phospholipase D Napepld
Pparγ2 peroxisome proliferator activated receptor gamma, 
 isoform 2 Pparg
Pepck phosphoenolpyruvate carboxykinase 1 Pck1
Scd1 stearoyl-Coenzyme A desaturase 1 Scd1
Srebp1c sterol regulatory element binding transcription factor 1 Srebf1
Ucp-1 uncoupling protein 1 (mitochondrial, proton carrier) Ucp1





Primers and probes used for realtime PCR
Gene  Sequences (5’ to 3’) GenBankTM accession no.
Adiponectin Forward AGG ACA TCC TGG CCA CAA TG NM_009605
Reverse CTT AGG ACC AAG AAG ACC TGC AT
Probe CTC TCC AGG AGT GCC ATC TCT GCC A
Ap2 (Fabp4) Forward CAC CAT CCG GTC AGA GAG TAC TT NM_024406.1
Reverse TCT AGG GTT ATG ATG CTC TTC ACC T
Probe CAT CGA ATT CCA CGC CCA GTT TGA
Atgl/desnutrin Forward AGC ATC TGC CAG TAT CTG GTG AT NM_025802
Reverse CAC CTG CTC AGA CAG TCT GGA A
Probe ATG GTC ACC CAA TTT CCT CTT GGC CC
Cb1 Forward ACA AGC TTA TCA AGA CGG TGT TTG NM_007726.3
Reverse TGC TCC TCA GAG CAT AGA TGA TG
Probe CTC TGC CTG CTG AAC TCC ACC GTG
C/ebpα Forward CCA AGA AGT CGG TGG ACA AGA A NM_004364.2
Reverse AGG CGG TCA TTG TCA CTG GT
Probe CGC AAC AAC ATC GCG GTG CG
Cyclophilin G Forward CAG ATC GAG GGA TCG ATT CAG NM_001081086
Reverse TCA CCA CTT GAC ACC CTC ATT C
Probe CTC CTC CAC ATT GGA GAC AAG AGA TGC A
Faah Forward CAG AAG CTG TGC TCT TTA CCT ACC NM_010173.2
Reverse CAG ATA GGA GGT CAC ACA GTT GGT
Probe CTT TGT TCA CTT CCC AGG CCT TTC CC
Fatp4 Forward CCA GAC AAG GGT TTT ACA GAT AAG CT NM_011989
Reverse ACC TGC TGT GCA CCA CAA TG
Probe CGG GCA CCA CGG GGC TAC CC
Fatp5 Forward GTG CTG ATT GTG GAT CCA GAC NM_009512
Reverse GAA TGT TCT CAG CTA GCA GCT TG
Probe CCA GGA GAA CCT GGA AGA AGT CCT TCC
Hsl Forward GAG GCC TTT GAG ATG CCA CT NM_010719
Reverse AGA TGA GCC TGG CTA GCA CAG
Probe CCA TCT CAC CTC CCT TGG CAC ACA C
L-fabp Forward GAA CTT CTC CGG CAA GTA CCA A NM_017399
Reverse TGT CCT TCC CTT TCT GGA TGA G
Probe CCA TTC ATG AAG GCA ATA GGT CTG CCC
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Gene  Sequences (5’ to 3’) GenBankTM accession no.
Nape-pld Forward GGC CTT GGA GTC GAT TCT TCT NM_178728.3
Reverse GTA TTT CAT AAA CCA CCT TGG TTC AT
Probe
AGG TCA AAA GGA CCA AAC CTT TTT CCA 
ATC TC
Pparγ2 Forward CTA TGA GCA CTT CAC AAG AAA TTA CCA U09138.1
Reverse CAC AGA GCT GAT TCC GAA GTT G
Probe ACA CAG AGA TGC CAT TCT GGC CCA C
Supplemental Table 2
Fatty acid profiles of experimental diets in mg g-1
 chow (LF) HF HF/FO
C14:0 0,5 12,2 16,1
C16:0 8,4 92,5 79,5
C16:1 0,7 11,5 18,0
C18:0 3,7 76,3 50,5
C18:1 13,7 133,2 101,0
C18:2 16,9 11,5 9,7
C18:3 1,9 2,9 15,2
C20-22 0,4 4,0 53,3
C16 desaturation index 0,1 0,1 0,2
C18 desaturation index 3,7 1,7 2,0
ratio n-6/n-3 12,0 ND* 0,4
total dietary fat content 6% 36% 36%
Abbreviations: FO, fish oil; HF, high-fat; LF, low-fat; ND, not detectable.




Onderzoek doe je niet alleen en ik heb de afgelopen jaren dankbaar alle mogelijke 
hulp aanvaard. Zowel in Haren als in het Laboratorium Kindergeneeskunde hebben 
veel collega’s bijgedragen aan de totstandkoming van dit proefschrift. Niet alleen 
kwam ik volstrekt onwetend het lab ingewandeld in 2005, maar ook zijn de meeste 
experimenten beschreven in dit proefschrift simpelweg niet alleen uit te voeren. En dat 
is dan dus nog afgezien van het feit dat input van anderen onontbeerlijk is.
 Allereerst wil ik mijn promotores bedanken. Gertjan, jij bent met name betrokken 
geweest bij de dagelijkse gang van zaken, zoals de uitvoering van de experimenten 
en het oplossen van de daarbij onvermijdelijke problemen. Echter in jouw wereld zijn 
geen problemen maar uitdagingen en zie hier het uiteindelijke resultaat van zoveel 
enthousiasme. Altijd toegankelijk, geen zee te hoog, praktische/creatieve oplossingen, 
waarom niet ‘Science’ proberen!? Hartelijk dank! Folkert, goed tegenwicht, om 
explosies aan ideeën enigszins te beteugelen. Ruimte geboden, op de rails gehouden, 
er een punt aan weten te draaien, nuchtere kijk, “no nonsense”, “als je geen effect ziet 
is het er ook niet”, maar tot in de puntjes/komma’s redigeren. Hartelijk dank! Professor 
Sauer, toen ik nog dacht een oriënterend gesprek te gaan voeren over mogelijkheden 
om onderzoek te doen tijdens de specialisatie in het UMCG, had u Folkert al uitgenodigd 
om gelijk spijkers met koppen te kunnen slaan. Ik ben u dankbaar voor de mogelijkheid 
dit onderzoek te doen, voor het vertrouwen, maar met name ook voor de steun in de 
periode waarin combineren kliniek en onderzoek toch heel lastig bleek.
 Bijzonder belangrijk gedurende het hele traject bleken ook mijn kamergenoten, 
zowel in het UMCG als in Haren (Angelique, Izabella en Simon). Zij brachten mij de 
basisbeginselen van onderzoek doen, laboratoriumwerk en promoveren bij, maar 
relativeerden ook waar nodig en bleven vriendelijk ondanks frequente onvrijwillige 
opsluiting en andere warrige acties. Vincent de Noordeling (dat is een compliment ja), 
labgids, vraagbaak, “signifier”, literatuurleverancier, mooi dat ik de afgelopen jaren op 
je kon rekenen, die kussenslopen heb je nog te goed. Collega Mulder, rots in de branding 
bij onderzoeksleed, jij kan alles uitleggen en nog begrijpelijk ook, onwaarschijnlijk strak 
georganiseerde aanpak, op elk dekseltje kun je een verhaal kwijt, reversed pipetteren triplo, 
veelvuldig op jouw kennis geleund. Ook van jouw manier van werken heb ik geprobeerd 
te leren en de les “hoe bewaar ik monsters” heeft mij waarschijnlijk uiteindelijk veel 
ellende gescheeld. Ik blijf erbij, “Kool” was leuk geweest, en dan de volgende “Boer”, 
maar goed bij “Thomas” kan ik me neerleggen. 
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Theo, het is je vergeven dat je mijn mooie plekje ingepikt hebt. Volgens mij past 
F1.12 je als gegoten. Het heeft zeker ook geholpen om samen de laatste fase van het 
promoveren te doorstaan en ik hoop dat jij 26 mei een geweldige dag hebt. Nicolette 
en Janny, niet lang geduurd, maar wel gezellig. En dan de laatste aanwinst van F1.12: 
Maaike, en het is goed gekomen. Je was niet alleen kamergenoot maar vooral sister in 
crime. We hebben elkaar mooi op weten te jutten, maar waar nodig ook op de been 
weten te houden, kortom teamwerk (met cappuccino’s, champagne, koekjes en ijsjes). 
Jij gaat het in Zwitserland helemaal maken dat weet ik zeker en dan weer mooi terug 
naar Groningen want wat moet dit lab zonder Oosterveer. Die stukjes sturen we nog 
wel even weg…
 Ook in Haren heb ik dankbaar gebruik kunnen maken van de kennis en ervaring 
van mijn kamergenoten en bovendien een hele leuke tijd gehad. Angelique, gedreven, 
nuchtere, en gezellige collega, met veel meer onderzoekservaring zeker ten aanzien van 
dierexperimenten wat vooral in het eerste jaar zeer vaak broodnodig bleek. Izabella, 
always interested, always willing to help, even with less pleasant work like carcass 
analyses, always nice company.
 In mijn eerste jaren in Haren kreeg ik bovendien hulp van Kristin (indirecte 
calorimetry koningin), Rolinka (Science bleek toch net te hoog gegrepen, maar ik vond 
de poging zeer geslaagd, en ik denk oprecht dat het je nog weleens gaat lukken ook..
laat maar weten) en Mark Doornbos (waanzinnig veel werk verzet om materiaal van 
specifieke breinregio’s te verkrijgen en eveneens geholpen bij karkasanalyse).
 In 2008 moest het project in een hogere versnelling nadat veel tijd verloren was 
gegaan na ziek worden van de muizenfok. De gezamenlijke experimenten met Maaike, 
vanuit haar hoedanigheid als visolie-koningin en op grond van andere expertise en 
gewoon gezelligheid, bleken een ware marathon. Dit “Haren-avontuur” was alleen 
mogelijk dankzij de inzet van Trijnie (de rust zelf in alle hectiek, altijd gezellig en ja ik 
kom straks echt een keer langs in Friesland), Nanda (perfectionist, vuurdoop heet dat, 
veel van je gevraagd, maar hopelijk pluk je daar nu vruchten van!), Pieter (enthousiast 
in vitro werk en, waarschijnlijk iets minder enthousiast, genotyperen) en Rick (mooie 
tijden, mocht ik ooit een roddel willen verspreiden dan weet ik waar ik wezen moet).
 De verzorging van de dieren heeft altijd aandacht nodig maar was bij tijden 
een intensieve toestand. Auke, Jaap, Linda, Henk en Wanda bedankt voor jullie 




 Ook al houdt deel uit maken van twee verschillende laboratoria in dat je nergens 
voor 100% mee doet, dan nog heeft dit er niet toe geleid dat ik me niet thuis heb 
gevoeld in zowel het kindergeneeskunde lab van het UMCG als in Haren. Alle collega’s 
in het Laboratorium Kindergeneeskunde en in Haren wil ik bedanken voor de hulp (van 
praktische adviezen tot hulp bij experimenten) maar natuurlijk ook de gezelligheid: 
Marijke Schreurs (van eerste kennismaking met het lab tot eerste kennismaking 
met dierproeven tot alle mogelijke ondersteuning), Gretha (oftewel de Marijke van 
Haren), Anke (uitstapjes Haren, ware held), Juul (bijdrage aan experimenten, breinen 
verzamelen, muizenfokken en genotyperen voor gevorderden tot histologie), Esther 
(volgens die beslisdocumenten waren wij toch begin vorig jaar al gepromoveerd..), 
Henk (labvraagbaak: “in welk vat gooi ik dit dan weg”), Gerard en Paul (gedogen van 
mijn bom-calorimetrie-activiteiten op jullie territorium), Fjodor (primer en probe 
koning), Theo B, Ingrid (onontbeerlijke hulp bij vetzuurpiekjes), Albert (die proef met 
de orosboros komt nog wel), Renze (voorzitter bom-calorimetrie-genootschap), Frank 
Perton, Dirk-Jan, Jan Bruggink en Ramon (alle mogelijk ondersteuning in Haren), Jan 
Keijzer (meten van adipocyten en ander klein leed), Gerard Overkamp (onmisbare 
schakel in het indirecte calorimetrie gebeuren), Jan Strubbe, Hester (~visualiseren~), 
Aldo, Alinda, Anja, Annelies, Arne, Caroline, Deepa, Frans C, Frans S, Gemma, Girste, 
Harmen, Henriette, Hermi, Hilde, Jaana, Jan Freark, Janine, Jelske, Jurre, Karin, Klary 
Niezen, Leonie, Margot, Marije, Maxi, Niels, Pauline, Roelina, Riejanne, Robert, Sabina, 
Simon, Terry, Thierry, Thomas, Uwe, Wytse en Wytske. Anniek Werner, het heeft zeker 
mee aan jouw enthousiasme gelegen dat ik alsnog promotieonderzoek ben gaan doen 
en je praktische adviezen (dan geef je een slinger aan de snor) hebben me het eerste 
jaar goed op weg geholpen. Dank! Ik had graag je commentaar op dit boekje gehoord. 
En natuurlijk Stefano, jij neemt het stokje deels over, maar hebt ook al flink bijgedragen 
aan de laatste experimenten, zorg goed voor de CB
1
-tjes en ik ben benieuwd naar 
verdere resultaten.
 Veel dank ben ik ook verschuldigd aan degenen die wel grip weten te houden op 
regeldingen; Joke, Hilde, Gea, Han, Jannie, Marieke en Riekje Banus (GUIDE). Bedankt 
voor de ondersteuning en hier en daar het nodige geduld.
 Daarnaast kon ik in Leiden terecht om een uitstapje te maken naar mTOR, Dr. 
Margriet Ouwens en medewerkers van haar laboratorium, bedankt voor de gastvrijheid 
en de bereidheid om ook later nog opnieuw met mijn materiaal aan de slag te gaan.
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 Tevens wil ik de “GECKO raad van advies” bedanken voor hun inbreng, met name 
in het eerste deel van het project. Ook de andere GECKO-onderzoekers wil ik natuurlijk 
bedanken voor hun inbreng en natuurlijk voor de gezelligheid.
 Leden van de beoordelingscommissie, prof. dr. Bert Groen, prof. dr. Anton 
Scheurink en prof. dr. R.F. Witkamp, hartelijk dank voor uw bereidheid dit proefschrift 
te beoordelen. Anton, bedankt voor de belangstelling voor mijn project en de inbreng 
met name wat betreft het anorexia verhaal, maar natuurlijk ook voor de rondleiding in 
Stockholm! Bert, helaas niet op 9 juni, maar wellicht komt er een andere gelegenheid 
om te discussiëren over de beperkingen en mogelijkheden van indirecte calorimetrie.
 Hartelijk dank ook aan alle anderen die hebben bijgedragen aan de totstandkoming 
van dit proefschrift, in het bijzonder collega’s van de kindergeneeskunde, bedankt voor 
de belangstelling en het geduld ondanks eindeloos gezeur over die laatste loodjes. 
Joke, bedankt dat je me op het juiste moment weer op het juiste spoor wist te krijgen. 
 Degenen die de grootste offers hebben gebracht zijn niet collega’s maar vrienden 
en familie. Wat de vrienden aan gaat wil ik vooral zeggen: dit feestje is voor jullie en 
hopelijk is er nu eindelijk meer tijd. Wat betreft de familie kan ik ook kort zijn; zonder 
jullie geen proefschrift. Of het nu “data invoeren omdat je toch niks anders kan met 
gescheurde kniebanden”, “eerste hulp bij computerleed” of “begrip voor de zoveelste 
keer afhaken” was, uiteindelijk heeft jullie steun gemaakt dat ik dit project heb weten 
af te ronden. En Marijke, ik heb het goed begrepen je breekt mijn benen als ik nu gelijk 
weer aan een nieuw project begin… 
 Ton en Janny, de afgelopen jaren heb ik zeer frequent een beroep op jullie gedaan: 
hartelijk dank voor jullie bijdrage aan dit boekje!
 Pap, mam, ik wist al dat ik ten alle tijde op jullie alles omvattende ondersteuning 
kan rekenen en het was dan ook niet de bedoeling om dat nogmaals uit te testen, maar 
in praktijk hebben jullie je opnieuw in alle mogelijke bochten gedraaid om het voor ons 
makkelijker te maken. Voor Giel en Jort was dit zeker geen straf en ik hoop dat jullie 
uiteindelijk ook voornamelijk goede herinneringen over houden aan deze periode. 
Mochten Robert en ik denken dat we het druk hebben met twee kleine kinderen, jullie 
hebben het pas druk met vijf volwassen dochters. Dat Carolien en Marleen naast mij 
zullen staan als paranimfen maakt de cirkel wat mij betreft rond.
  Lieve Robert, bedankt.. maar dat weet je wel en op ons! Robert, Giel en Jort, dit 
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deels in het Researchlaboratorium Kindergeneeskunde van het UMCG en deels op in 
het Instituut voor Gedrag- en Neurowetenschappen, afdeling Neuroendocrinologie van 
het Biologisch Centrum Haren (promotores prof. dr. F. Kuipers, prof. dr. G. van Dijk en 
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